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Ac Acetyl 
Ac2O Acetic anhydride 
AcOH Acetic acid 
aq. Acqueous 
Arom. Aromatic 
b Broad 
Bn Bezyl 
BS(PEG)2 Bis-succinimidyl penta-ethylene glycol 
Bz Benzoly 
CSA Camphor-10-sulfonic acid 
Cbz Benzyloxycarbonil 
CPS Capsular polysaccharide 
CRM197 Cross-Reacting  Material 197 
d Doublet 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC N-N’-dicyclohexilcarbodiimide 
DCM dicholormethane 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
Eq Equivalent 
ELISA Enzyme-linked immunosorbent assay 
ESI Electrospray ionisation 
Fmoc Fluorenylmethyloxycarbonyl 
Hib Haemophilus influenzae type B 
HSA Human serum albumin 
IMH Imidazole 
J Coupling constant 
KHMDS Potassium bis(trimethylsilyl)amide 
KLH Keyhole Limpet Hemocyanin 
Lev Levulinic 
LPS Lipopolysaccharides 
MenA N.mengingitisis type A 
MALDI-TOF Matrix-Assisted Laser Desorption/ Ionization Time of Flight 
MS Mass spectroscopy/molecular sieves 
m/z Mass to charge ratio 
M.W. Molecular weight 
NAP 2-naphthylmethyl 
NMR Nuclear Magnetic Resonance 
NOEsy Nuclear Overhauser Effect Spectroscopy 
PAMP Pathogen-associated molecular patterns 
Piv Trimethlacetyl 
PTSA p-Toluenesulfonic acid 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Satd saturated 
t Triplet 
TBAI Tetra-n-butylammonium iodide 
TBAF Tetra-n-butylammonium fluoride 
TBDMS tert-butyldimethylsilyl 
TEAB Triethylammonium bicarbonate 
TDS Thexyldimethylsilyl 
Tf Trifluoromethanesulfonic 
THF Tetrahydrofuran 
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Synthesis of analogues of fragments of the capsular 
polysaccharide from Neisseria meningitidis Type A 
 
INTRODUCTION 
 
 
Carbohydrates and Immunology 
 
Together with proteins and nucleic acids, carbohydrates constitute one of 
the important classes of biomolecules. However, the carbohydrate compounds 
are the least exploited as potential therapeutic agents despite the crucial 
roles they play in numerous biological recognition processes (e.g., 
bacterial and viral infection, cancer metastasis and inflammatory reactions) 
[1]  
 
All cells are coated with thick layers of complex carbohydrates known as 
the glycocalyx, in which the glycan components are present in many 
different glycoforms, such as glycoproteins, proteoglycans, glycolipids and 
glycophosphatidylinositol-linked proteins. (Figure 1) Therefore, the cell 
glycocalyx is involved in cell differentiation, recognition, adhesion and 
many other important events, including pathological developments. The 
exposure of carbohydrates on cells’ surfaces enables them to interact with 
the immune system, acting as cell antigenic determinants. On the other hand, 
the dense surface distributions of often unique glycan structures on 
diverse pathogens and on malignant cells make carbohydrates attractive 
vaccine targets. 
Despite the important roles of carbohydrates in biological process, use of 
carbohydrates onto inducing immunity is still a relatively new strategy, 
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nevertheless the seminal finding that the pneumococcal antigens targeted by 
the immune system are polysaccharides dates back to 1923.[ 2]  
 
 
Figure 1. Cell membrane and carbohydrate 
 
 
The advent of chemotherapeutics and antibiotics dampened enthusiasm for the 
development of carbohydrate vaccines, but the emergence of multidrug 
resistance phenomena and their constant increase roused renewed interest. 
In 1983 PneumoVax (Merck and Co.), the first polysaccharide vaccine, was 
commercially launched. This vaccine was made up of unconjugated capsular 
polysaccharide isolated from 14 serotypes of the Streptococcus pneumoniae 
bacterium, whereas the current version includes 23 out of approximately 90 
known 
 
serotypes. In healthy adults, this vaccine induces good protection against 
most of the infections caused by these pathogens. [3] 
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Immune System  
 
The immune system is the body's defense against infectious organisms and 
other invaders. Through a series of steps called immune response, the 
immune system attacks organisms and substances that invade body systems and 
cause disease. 
The immune system is made up of a network of cells, tissues, and organs 
that work together to protect the body (Figure 2) 
 
 
 
Figure 2. Cells of the immune system 
 
 
Molecules which are perceived by the immune system as a foreign invader or 
simply as potentially dangerous for the host refer to antigen. The immune 
system responds to antigens by eliciting suitable immune response. More 
specifically, the integration of two distinct arms of the immune response, 
the innate and the adaptive (antigen-specific) responses, leads to 
protective immunity against pathogen exposure.  
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The innate immune is rapid and unspecific; it consists of soluble factors, 
such as complement proteins, and diverse cellular components including 
granulocytes (basophils, eosinophils and neutrophils), mast cells, 
macrophages, dendritic cells and natural killer cells; it functions as the 
first line of defense and responding to pathogen-associated molecular 
patterns (PAMPs). In contrast, the adaptive immune response is slower to 
develop, but manifests an increased antigenic specificity and memory. It 
consists of antibodies, B cells, and CD4+ and CD8+ T lymphocytes. Natural 
killer T cells and T cells are cytotoxic lymphocytes that straddle the 
interface of innate and adaptive immunity. The adaptive immune response is 
specific response such as production of antibodies against particular 
pathogen. [ 4 ]The adaptive response could occur during the lifetime of an 
individual as an adaptation to infection with the pathogen. An adaptive 
immune response confers lifelong protected immunity to reinfections with 
the same pathogen in many cases.  
 
 
 
Figure 3 Innate immune response and adaptive immune response 
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Both innate immunity and adaptive immune response rely on the activities of 
the white blood cell or leukocytes. Innate immune responses mainly involve 
granulocytes and macrophages while adaptive ones largely depend upon 
lymphocytes which provide the lifelong immunity that can follow exposure to 
disease or vaccination. The innate and adaptive immune system together 
could afford an effective defense system. Many infections are handled 
successfully by the innate system and cause no disease; others that cannot 
be resolved by innate immunity trigger an adaptive immune response and are 
then overcome; followed by lasting immunological memory.  
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Immunology of Polysaccharide antigens from bacterium 
 
As mentioned before, polysaccharides construct the major components on the 
bacterial surface. These can be in the form of capsules, glycoproteins or 
glycolipids. For examples, in Gram-negative bacteria, the lipopolysaccharide 
(LPS) covers up to 40% of the bacterial surface; the capsular polysaccharides 
(CPSs) are present in both Gram-negative bacteria such as N. meningitidis, 
Haemophilus influenzae, E. coli or Salmonella typhi and in Gram-positive such 
as Streptococci and Staphylococci (Figure 4).   
 
 
 
Figure 4. LPS and CPS in bacterial surface 
 
It has been well established that the surface polysaccharides could invoke the 
immune response confering protection against the disease since 1920s. [5]  The 
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introduction of antibiotics, however, put an effective stop for the next 
several decades to the development of vaccine based on either CPS or 
neoglycocojugates. Then in the 1970s, it was realized that the usage of 
antibiotics, although brought largely success, was not the ultimate solution to 
handle infection.   
 
Advances in immunology with delineation of B and T lymphocyte responses, and 
the role of T cell for the immunological memory functions, as well as the 
structural elucidation of surface polysaccharide made possible the development 
of new, polysaccharide-based vaccines. Today, several vaccines based on either 
purified CPSs or on neoglycoconjugates are available. In spite of the increased 
knowledge in polysaccharide immunology, there are several problems that remain 
to be considered and solved: 
 
1) Due to the structural differences in the surface polysaccharide and the 
serogrouping or serotyping system, the carbohydrate antigens exhibit 
large degree of antigenic variation. i.e. N.meningitidis with over 13 
[ 6 ]serogroups and Streptococcus pneumoniae involves over 90 different 
serotypes.  
 
2) Homology between carbohydrate structures present on bacterial surface 
and those of host cell membrane has to be taken into consideration. The 
mimicry of host-associated carbohydrate structures by bacterial 
polysaccharides could be a potential virulence and evasion factor[7].  
 
3) Polysaccharide antigens are mostly poor immunogens due to their T cell 
independent (TI) nature. Children below 2 years of age and elderly 
respond poorly to polysaccharide antigens.[8] 
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Neisseria Meningitidis  
 
Meningitis is an inflammation of the protective membranes covering the 
brain and spinal cord, known collectively as the meninges. The inflammation 
may be caused by infection with viruses, bacteria, or other microorganisms, 
and less commonly by certain drugs. Meningitis can be life-threatening 
because of the inflammation's proximity to the brain and spinal cord; 
therefore the condition is classified as a medical emergency.[9] (Figure 5) 
 
 
 
Figure 5. Meningitis 
 
Bacterial meningitis has still a profound impact on public health. Worldwide, 
approximately 1,200,000 cases (with more than 170,000 deaths) of bacterial 
meningitis are recorded annually, with at least a 5-10% of case fatality in 
industrialized countries and a 20% in the developing world. In addition, 
serious sequelae such as brain damage, hearing loss or a learning disability 
affect up to one third of survivors.[ 10 ] Several different microorganisms can 
cause meningitis. Especially, Streptococcus pneumoniae, Haemophilus influenzae 
type b (Hib) and Neisseria meningitides [11] are responsible for over 80% of all 
cases of bacterial meningitis.  
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Neisseria meningitidis is an encapsulated diplococcus bacterium. Its outer 
membrane is surrounded by a polysaccharide coat (Figure 6) which is 
essential for its pathogenicity, exerting a protective function against the 
host’s immune defense. Thirteen different serogroups of the Gram-negative 
bacterium N. meningitidis have been defined so far, although about 90% of 
meningitis infections are due to serogroups A, B, C, Y, W135 and X.[12] 
 
 
Figure 6. Structure of Neisseria meningitides 
 
 
All these serotypes can cause epidemics, but their relative incidences are 
strictly dependent on geographic area. Serogroup B and C are responsible 
for the majority of cases of meningococcal disease in developed countries, 
with more than 50% of causes due to serogroup B. Serogroup A however takes 
the main responsiblility of meningitis epidemics and outbreaks in 
developing countries, predominantly throughout what is known as the African 
meningitis belt. (Figure 7) In the African meningitis belt countries, the 
estimated incidence for the 20 year period 1970 -1992 was about 800000 
cases[13]  
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Figure 7. African meningitis belt  
 
The resistance to this type of infection is mediated by the production of 
specific antibodies against the bacterial capsular polysaccharides (CPSs), 
suggesting that a vaccine composed of purified CPSs as antigenic material 
can be effective for protection against meningococcal disease.  
 
Carba Analogues of Men A CPS – Introduction -  
 
15 
 
 
Carbohydrate based vaccine towards N. meningitidis  
 
Although polysaccharide-based vaccines were demonstrated highly effective 
in preventing disease in adults and older children, they possess several 
shortcomings. Owing to their T cell independent nature, polysaccharide 
antigens induce immune responses of relatively short duration, and no class 
switch from low affinity IgM to high affinity IgG antibodies occurs. 
Moreover, polysaccharides cause the maximum immune response after one dose, 
but do not induce immunological memory, i.e. they fail to induce a booster 
effect after revaccination. [14] As a consequence, plain polysaccharides do 
not mount a protective immune response in the immature immune system of 
infants and children under two years of age, and this holds true in elderly 
and immunocompromised patients.  
 
However, polysaccharides can be converted into T cell dependent immunogens 
by chemical conjugation to carrier proteins (typically, CRM197, tetanus or 
diphtheria toxoid, Protein D).[ 15 ] In this way, immunological memory is 
established, raising a strong, durable and protective immune response from 
early childhood. In 2005, a tetravalent meningococcal vaccine containing N. 
meningitidis serogroup A, C, Y and W-135 CPS conjugated individually to 
diphtheria toxoid was approved in the United States.[16 ] Recently, a second 
anti-meningococcal glycoconjugate vaccine, where meningococcal CPS 
oligosaccharides are covalently linked to CRM197, has been licensed.[17]  
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Capsular polysaccharide from Neisseria Meningitidis type A 
 
The structure of N. meningitidis serogroup A (Men A) consists of (1→6)-
linked 2-acetamido-2-deoxy-α-D-mannopyranosyl phosphate repeating units[18]. 
The presence of O-acetyl groups at the position C-3 is approximately 70% of 
the ManNAc residues. (Figure 8) The first effective anti-MenA vaccine was 
based on purified natural CPS and was licensed in the seventies in 
combination with other meningococcal CPSs.[19]  
 
OHO
RO
O
NHAc
P
O
O
O
nR=H or Ac  
Figure 8. Structure of the repeating unit of the CPS of N.meningitidis A.  
Structure heterogerogeneity derives from 3-O acetylation (R = H or R = Ac ) 
 
 
An additional feature of MenA CPS is the chemical lability in water, mainly 
due to the inherent instability of the anomeric glycosyl phosphodiesters.[20]  
Phosphodiesters are normally stable but when they are present at the 
anomeric position of a carbohydrate residue, the linkage become much more 
labile due to the possibility of the electron pair on the ring oxygen 
displacing the phosphate or phosphodiester. (Figure 9)  
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Figure 9 Mechanism for the phosphodiester cleavage 
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The chemical lability represents the main problem in the preparation and 
use of glycoconjugate vaccines against MenA, which are mainly intended for 
use in the “meningitis belt” countries. Thus, we became interested in the 
design and synthesis of novel and hydrolytically stable analogues of MenA 
CPS repeating unit. These could be incorporated into a saccharide chain in 
order to obtain oligomers endowed with enhanced shelf-life. On the other 
hand, their conjugation to a proper immunogenic protein carrier should 
elicit protective antibodies that will cross-react with the bacterial 
capsule.[21]  
 
Previously, our group developed a series of “C-phosphonate” analogues of 
MenA CPS repeating unit. (Figure 10) The presumption is that the carbon-
phosphorous bond is incapable of being hydrolyzed by the ordinary enzymes 
involved in the phosphonate cleavage.  Accordingly, we recently reported on 
the synthesis of phosphonoester-linked oligomers of MenA CPS[ 22 ] and their 
conjugation to gold nanoparticles, in order to be displayed in multivalent 
fashion for a stronger interaction with the target protein.[ 23 ] ELISA 
competitive assays showed that both the monovalent, non-conjugated antigens 
and the corresponding gold glyconanoparticles are recognized by a human 
polyclonal anti-MenA serum, confirming that the replacement of the anomeric 
oxygen atom with a methylene group does not prevent the antibody 
recognition and binding.[24]  
 
OHO
HO
NHAc
P
O
O
O
n  
Figure 10. C-phosphonate analogue of MenA CPS 
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Similar with the C-phosphonate analogues strategy, another stabilization of 
glycosyl 1-O-phosphates can also be achieved by using carbasugar analogues, 
where a methylene group replaces the pyranose oxygen atom.[ 25 ] (Figure 11) 
This structural modification leads to the loss of the acetalic character of 
the phosphodiester, that it is expected to gain improved stability towards 
hydrolysis.[26] 
  
HO
HO
O
NHAc
P
O
O
O
n  
Figure 11. Carba sugar analogue of MenA CPS 
 
 
In recent research of our group, carba-rhamnose was shown to be able to 
preserve the conformation and the biological activity -in terms of antibody 
affinity- of the natural rhamnopyranose when inserted into the 
Streptococcus pneumoniae type 19F CPS trisaccharide repeating unit.[ 27 ] 
Prompted by this result, we synthesized the monomer carba-N-
acetylmannosamine-1-O-phosphate and compared its geometrical and 
conformational properties with the naturally occurring N-acetylmannosamine-
1-O-phosphate, the MenA CPS repeating unit.[28] The results showed that they 
owned similar conformational behavior, so that the carba-N-
acetylmannosamine-1-O-phosphate can be regarded to as a potential mimic of 
MenA CPS repeating unit and be used in the construction of carba oligomers 
endowed with enhanced stability in comparison with the native polymer. 
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Therefore, the first subject of the PhD thesis is the synthesis of carba 
analogues of MenA CPS project. In particular, the research will be focused 
on the synthesis of designed monomer, dimer and trimer carba analogues of 
MenA CPS; A suitable strategy to prepare this kind of derivatives in 
relatively large amount in lab will be described; Preliminary immunological 
evaluation of the target molecules has been carried out based by 
competitive ELISA Assay; In addition, glyconcojugation of the synthesized 
oligosaccharides with carrier proteins will be accomplished; Last but not 
the least, several attemps using H-phosphonate polycondensation reaction to 
achieve oligosaccharides with higher number of repeating units will also be 
described.  
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CHEMSTRY PART 
1 Target Molecules 
 
The synthesis, preliminary biological evaluation and glycoconjugate of the 
carba analogues from Neisseria meningitides A capsular polysaccharide will be 
described in details in this part.[1] 
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Figure 1. Target molecules 
 
The designed target molecules 1,2 and 3 are all provided with a phosphodiester 
linked aminopropyl spacer at their reducing end to facilitate conjugation of 
the molecules to carrier protein (CRM197 and HSA) for further immunogenic 
studies (Figure 1). 
 
Our synthetic route towards compounds1-3 is outlined in Scheme 1, which is 
based on the H-phosphonate methodology [ 2 ] for the formation of the 
phosphodiester bridges. Therefore, both the introduction of the phosphodiester 
linked spacer at C-1 position of oligomers and also the elongation of oligomers 
are based on this method. 1, 2 and 3 can be achieved from the assembly between 
phosphonate alcohol 7 and the intermediates 4-6. Dimer 5 and trimer 6 can be 
afforded from monosaccharide building blocks 8 and 9, which are in turn 
obtained from the key precursor 4. The key intermediate 4 can be thus achieved 
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from commercially available compound 12 
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Scheme 1. Retrosynthetic approach 
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2 Synthesis of key precursor 4  
 
The first synthesis of carba sugar precursor 4 has been recently reported by 
our group [3]. The synthetic method however was proved to be not satisfied in 
large scale preparation. In this work, the first task is to synthesize the 
intermediate 4 on large scale. And also, based on the same synthetic route, an 
improved preparation of 4 has been developed which is more suitable for large 
scale synthesis. 
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Scheme 2.  Retrosynthectic analysis of 4 
 
 
The synthesis of precursor 4 will be divided into three parts: Coversion from 
commercially available glucal 12 to an alkene 11; from 11 to a carbocyclic ring 
10; finally from 10 to compound 4. (Scheme 2) 
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2.1 Synthesis of 11 
 
Firstly, the alkene 11 was synthesized in six steps from the commercially 
available 2,3,4-tri-O-acetyl-glucal 12. Treatment of 12 in typical Zemplén 
conditions by 1M solution of sodium methoxide in methanol afforded de-
acetylated compound 13. Regioselective 6-O-silylation of 13 was carried out 
with Chloro(dimethyl)thexylsilane (TDSCl), imidazole and tetrahydrofuran (THF), 
followed by benzylation of C-3 and C-4 hydroxyls with benzyl bromide, 
tetrabutylammonium iodide (TBAI), sodium hydride in THF, affording compound 15. 
Removal of the silyl ether of 15 in the presence of 1M tetra-n-butylammonium 
fluoride (TBAF) in THF, led to corresponding intermediate 16 in 67% overall 
yield in four steps.   
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Scheme 3. Synthesis of 11 
Carba Analogues of Men A CPS – Chemistry Section -  
27 
 
 
 
Previously, the primary hydroxyl in 16 was oxidized by pyridiniumdichromate 
(PDC) to result an aldehyde; after olefination of the aldehyde in the presence 
of methyltriphenylphosphonium iodide and sodium amide, alkene 11 could be 
obtained in a modest yield of 40 over two steps %[ 4 ]. In our synthesis, 2-
Iodoxybenzoic acid (IBX) was found to be a more efficient oxidant than PDC, the 
alcohol 16 could be converted completely to the desired aldehyde in the 
presence of IBX and Ethyl Acetate at reflux temperature. Next, potassium 
bis(trimethylsilyl)amide (KHMDS) was used as a base instead of the previously 
reported sodium amide during the Wittig reaction, furnishing 11 in a improved 
yield of 77% over two steps. The preparation of 11 could be scaled in multi 
gram scale.  (Scheme 3).  
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2.2 From Pyranose Ring to Carbocyclic Ring 
 
Conversion of alkene 11 to a carbocyclic compound 18 was achieved by applying 
heat-mediated Claisen rearrangement[ 5 ]. Heating 11 in a sealed tube in p-
dichlorobenzene at 240 ℃ could initiate the [3,3] sigmatropic rearrangement to 
form a new carbon-carbon bond, the resulting unstable intermediate 11-a was 
then reduced with sodium borohydride in ethanol and THF suspension leading to 
18 in 86% yield. (Scheme 4)  
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Scheme 4. Reaction mechanism for compound 18 formation 
 
Stereoselective OsO4-mediated syn-dihyroxylation of double bond in 18 produced 
less hindered α-face product 10 in 92% yield. The preparation of 10 could be 
scaled in multi gram scale. (Scheme 5) 
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 Scheme 5. Synthesis of 10 
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2.3 Preparation of Intermediate 4 
 
Then, the primary hydroxyl of triol 10 was selectively protected as TDS ether, 
leading to 19 in 93% yield. Since the C-1 axial hydroxyl of 19 has lost its 
anomeric character, intermediate 19 was able to undergo a regioselective 
acetylation at its C-1 position, which was carried out with trimethyl 
orthoacetate, and a catalytic amount of p-toluenesulfonic, followed by 80% HOAc, 
providing intermediate 20 in 91% yield. 
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Scheme 6. Synthesis of 4 
 
 
The C-2 hydroxyl group of 20 was then first activated as a triflate ester in 
the presence of triflic anhydride and pyridine, and the resulting intermediate 
was reacted with sodium azide instead of previously used tetrabutylammonium 
azide [3]to install the manno-congiguration, providing 21 in modest yield (50%). 
Interestingly, we found the reaction could be improved significantly by using a 
mixture of DMF and water. After several attemps (table 1), compound 21could be 
afforded in 79% yield. We envisaged that trace amount of water could better 
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dissolve the sodium azide, which accelerate the SN2 reaction. 
 
Entry Solvent NaN3 Equiv Time Temperature Yield 
1 DMF 15 12 hours 100℃ 41% 
2 DMF:H2O=9:1 10 4 hours 75℃ 72% 
3 DMF:H2O=4:1 5 6 hours 80℃ 63% 
4 DMF:H2O=19:1 5 4 hours 70℃ 74% 
5 Acetone 5 12 hours 70℃ 30% 
4 DMF:H2O=19:1 5 12 hours 40℃ 79% 
 
Table 1. Reaction conditions for preparing 21 
 
 
Eventually, reduction of the azide under Staudinger’s condition with 
triphenylphosphine and water, followed by N-acetylation with acetic anhydride 
gave the precursor 4 in 95% yield.( Scheme 6) Altogether, the key precursor 4 
was obtained in fourteen steps on multi gram scale in 26 % overall yield, to be 
compared with 8% reported in our previous synthesis [3].  
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3 Synthesis of building blocks 8, 9 and spacer 7 
 
After successfully accomplishing the preparation of key precursor 4, our 
attention was thus focused on the synthesis of phosphonate coupling building 
blocks 8 and 9 and spacer 7. Selective removal of protective groups of 
precursor 4 provided access either to 8 or to 9. C-6 hydroxyl free intermediate 
22 was afforded in the presence of TBAF in 91% yield. Treatment of 22 with a 
slight excess (1.2 equivalents) of 2-chloro-4H-1,3,2-benzodioxa phosphinin-4-
one (commonly named salicylchlorophosphite) in a mixture of acetonitrile and 
pyridine resulted in an H-phosphonate intermediate. After work up and 
purification by flash chromatography, the product was recovered as its 
triethylammonium salt 8 in quantitative yield (82%)  by washing a solution of 
the resulting compound in CHCl3 with 1M aquesous solution of Triethylammonium 
bicarbonate (TEAB) buffer. Building block 9 was furnished by the deacetylation 
of precursor 4 under Zemplén conditions in 84% yield. (Scheme 7) 
 
Following a similar procedure, commercially available benzyl N-(3-hydroxypropyl) 
carbamate 23 was activated as an H-phosphonate intermediate 7 (98% yield) [6] in 
order to be inserted at the reducing end of the oligomers. 
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Scheme 7. Synthesis of building blocks 8, 9 and spacer 7. 
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4 Synthesis of Monomer 1 
 
Having all the synthetic building blocks 7, 8 and 9 in hands, the stage was set 
for the synthesis of target molecules. The first synthetic oligomer is the 
monomer carba-analogue 1.  
 
First, according to a standard H-phosphonate protocol [2], H-phosphonate alcohol 
7 and compound 9 were condensed in the presence of trimethylacetyl (Pivaloyl) 
chloride in pyridine. The resulting H-phosphonate diester intermediate was 
oxidized in situ by iodine in a 19:1 mixture of pyridine and water to afford 
the glycosyl phosphodiester 24 in 81% yield. 
 
Global removal of the protecting group on 24 was accomplished in two steps. 
First, the TDS ether of 24 was removed by treatment with TBAF in THF, yielding 
25. Thereafter, the remaining protecting group (benzyls and benzyloxycarbonyl) 
were cleaved by hydrogenolysis over 10% palladium on carbon in a methanol-water 
mixture. Final purification was completed by elution of a water solution of the 
deprotected fragment over a column filled with Dowex 50W X8 resin (H+ form), 
followed by a second ion exchange on the same resin in Na+ form. Lyophilization 
of the eluted compounds provided oligomer 1 with its sodium salt in 95% yield 
in two steps. (Scheme 8). 
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scheme 8. Synthesis of monomer 1 
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5 Synthesis of Dimer 2 
 
Synthesis of carba analogue 2 started with building blocks 8 and 9. First, 
protected dimer 5 was achieved via the phosphonate condensation between H-
phosphonate 8 and 9, followed by iodine oxidation in 82% yield. Next, 5 was 
deacetylated under Zemplén conditions, generating compound 26. Then, the free 
hydroxyl of 26 was condensed with spacer H-phosphonate 7, and after the iodine 
oxidation, spacer bearing 27 was obtained in 45% yield. Interestingly, we found 
the yield of phosphonate coupling reaction could be significantly improved up 
to 85% by increasing the amount (5 equivalents) of the H-phosphonate 7. (Table 
2)  We envisaged that it might be due to the relative low reactivity of free 
hydroxyl of 26, which needed the presence of a large excess of H-phosphonte 
donor in the course of phosphonate condensation.  
 
 
Entry Equiv of 7 Temperature Condensation Time Yield 
1 1.2 Equiv 25 ℃ 45 min 45% 
2 1.5 Equiv 35 ℃ 120 min 42% 
3 2 Equiv 25 ℃ 45 min 50% 
34 5 Equiv 25 ℃ 45 min 85% 
Table 2. Reaction conditions for synthesis of 27 
 
 
After this, removal of the silyl group in TBAF and THF, followed by a 
palladium-mediated hydrogenolysis in methanol-water yielded the fully 
deprotected product.  After the ion exchange purification with Dowex 50W X8 
resin (H+ form and Na+ form) and the lyophilization, carba oligomer 2 was 
obtained in 77% yield as sodium salt. (Scheme 9) 
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Scheme 9.  Synthesis of Dimer 2 
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6 Synthesis of Trimer 3 
 
For the preparation of trimer carba analogue 3, first, similar phosphonate 
condensation reaction between 26 and H-phosphponate 8 and subsequent iodine 
oxidation afforded trimer intermediate 6 in 81% yield. The Zemplén 
deacetylation product 28 (from 6, 70% yield) was coupled with spacer alcohol 
phosphonate 7, and in situ oxidized, to be converted into the fully protected 
trimer precursor 23 in moderate yield of 57%. Increasing the amount of H-
phosphonate 7 did not remarkably improve the reaction yield (Table 3). Finally, 
after removal of all the protecting groups (TDS ether, benzyls and 
benzyloxycarbonyl), ion exchange purification (Dowex 50W X8 resin, H+ form and 
Na+ form ) and the lyophilization, oligomer 3 was provided as sodium salt. 
(Scheme 10)  
 
Entry Equiv of 7 Temperature Condensation Time Yield 
1 1.5 Equiv 25 ℃ 45 min 50% 
2 2 Equiv 25 ℃ 60min 52% 
3 5 Equiv 25 ℃ 45 min 57% 
Table 3. Reaction conditions for synthesis of 29 
 
 
The identity and purity of the target compounds (1, 2 and 3) was ascertained by 
1H, 13C, and 31P NMR spectroscopic analyses, including two-dimensional 
techniques. 
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Scheme 10.  Synthesis of Trimer 3 
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7. Preliminary Biological Evaluation  
 
Research work at Novartis Vaccine and Diagnostics Research Centre in 
Siena 
 
In collaboration with Novartis Vaccines & Diagnostics group, (Vaccine Chemistry 
Department, Novartis Italy), the relative immunogenicities of oligomers 1,2 and 
3 have been investigated. The abilities of increasing concentrations (from 0.5 
x 10-7 Mm to 0.5 mM) of the newly synthesized carba oligomers 1-3 to inhibit 
the binding between the MenA CPS, coated onto plates, and a polyclonal anti-
MenA serum were evaluated by competitive ELISA assay using native MenA CPS and 
native MenAavDP15 (MenA oligosaccharide with average polymerization degree 15) 
as positive controls, and Laminarin as negative control.  
 
The inhibition capacity of the synthetic compounds was determined in comparison 
with a native MenA oligosaccharide with average polymerization degree 3 (native 
MenAavDP3). The results showed that the best inhibition was given by native 
MenA CPS and by native MenAavDP15 (IC50 of 5.15 x 10-6 and 4.3 x 10-3 mM, 
respectively, and a 98% of inhibition of serum, Table 4 and Figure 2). Only 
dimer 2 was able to induce a 90% of serum inhibition with an IC50 of 0.16 – 
0.091 mM (Table 1). In contrast, compounds 1 and 3 were only poor competitors, 
with an inhibition around 30% of the antibody binding. Carba disaccharide 2 
showed a similar trend to nativeMenAavDP3 oligosaccharide, which reached 93% of 
serum inhibition with an IC50 of 4.3 x 10-2mM. 
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Figure 2. Competitive ELISA betweenthe native MenA CPS and oligosaccharide 
inhibitors for anti-MenA CPSpolyclonal serum. S1, S2 and S3 are the synthetic 
inhibitors compared with the native molecules MenA CPS, avDP15 and avDP3 
oligosaccharides. The non correlated polysaccharide Laminarin was used as 
negative control. 
 
 
 
Meningococcal 
A antigens 
1 2 3 Native 
MenA CPS 
Native 
avDP15 
Native 
avDP3 
IC50(mM) ---- 0.16 – 0.091 --- 5.15 x 10-
6 
4.3 x 
10-3 
4.3 x 10-2
Table 4. Competitive ELISA IC50Values (mM) 
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8. H-Phosphonate polycondensation 
 
In this PhD work, attempts to achieve longer chain carba oligomers were also 
carried out. Although the traditional solution and solid-phase techniques 
seemed feasible to construct oligomers with controlled numbers of repeating 
units, these strategies still own several problem like time consuming, lack of 
atom economy and unreliability in large scale preparation. Recently, several 
research groups have reported the one-step polycondensation reaction based on 
H-phosphonate chemistry to achieve poly (glycosyl phosphates) compounds in high 
yield, short number of steps and high reaction rate.   
 
For example, in their preparation of the first synthetic carbohydrate based 
vaccine, Verez-Bencomo and coworkers used the H-phosphonate polycondensation 
method to obtain their target oligosaccharide. After phosphonate condensation, 
in situ oxidation and size exclusion chromatography purification, the desired 
oligomers with an average of eight repeating units was obtained in 80% yield [7]. 
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Scheme 11 Example of H-Phosphonate polycondensation by Bencomo 
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Besides this, some other groups have also published the use of this strategy to 
quickly construct oligomers with high number of repeating units. [ 8 ] The high 
efficiency and high reaction rate of the H-phosphonate condensation reaction 
prompted us to investigate the possibility of applying this method onto our 
carba sugar intermediates to achieve longer chain oligomers.  
 
Therefore, following the same strategy described above for the synthesis of 
glycosyl phosphodiesters, monomer building blocks 35 and 25 were synthesized 
from intermediate 9 and 24. Treatment of 9 with salicylchlorophosphite gave 34, 
and removal of the sily ether from 34 delivered bifunctional H-phosphonate 
building block 35. 25 was the precursor for the synthesis of monomer 1. (Scheme 
12) 
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Scheme 12. Synthesis of monomer H-phosphonate building blocks  
 
 
However, the H-phosphonate condensation between 35 and 25 by using typical 
published procedure, after the ESI analysis, was shown to only provide cyclic 
dimer 36 instead of desired linear poly(glycosyl phosphate)as main product.  
Using high concentration (1 M of 35 in pyridine) of reaction which was supposed 
to favor the H-phosphonate polycondensation did not change the result. (Scheme 
13) 
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Scheme 13 Test for polycondensation 
 
 
We envisaged that using dimer H-phosphonate building blocks might be helpful to 
avoid the generation of cyclic dimer as it should in principle increase the 
molecule’s spacial distance to prevent the formation of the cyclic 
intermediates during the coupling course.  
 
Therefore, as shown in scheme 14, dimer H-phosphonate building block 37 was 
prepared from dimer precursor 26, which alcohol 38 was obtained  by 
desilylation of dimer 27. 
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Scheme 14. Synthesis of dimer H-phosphonate building blocks and test for 
polycondensation 
 
Then, as shown in the Scheme 15, compounds 37 and  38, were tested for 
polycondensation reaction. Disappointingly, the coupling between 37 and 38 
still generated dimer cyclic product 36.    
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Scheme 15. Test for polycondensation using dimer H-phosphonate building blocks 
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We thought the reason for the failure of H-phosphonate polycondensation might 
be due to the nature of carba sugar, which might be different from real 
olisaccharide at the molecular space. Although the real mechanism is still 
under the investigation, for the future work, due to the convenience of 
achieving oligosaccharides with higher number of repeating units, this method 
will be still explored.  
 
In short, we investigated the possibilities of applying polyconsation reaction 
on carba sugar analoues, wishing to achieve more advanced oligomers in one pot 
reaction. However, till now we have not found a suitable way to achieve this 
target. The corresponding monomer and dimer H-phosphonate building blocks only 
generated cyclic dimer product.  
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9. Protein conjugation 
Research work at Novartis Vaccine and Diagnostics Research Centre in 
Siena 
 
9.1 NEO-glycoconjuates for biological assays  
 
For the purpose of better the understanding immunogenical profile of the carba 
analogues of MenA CPS, and to investigate whether the carba oligomer 
glycoconjuates can compete with natural purified MenA CPS neo-glycoconjugates, 
a series of polysaccharide-protein glycoconjugates based on the carba analogues 
of MenA CPS fragments have been designed and synthesized. 
 
First of all, two different immunogenic proteins: CRM197 (Cross-Reacting 
Material 197 [ 9 ]) and HSA (Human Serum Albumin) were chosen to be conjugated 
with the carba oligomers.  
 
CRM197 first isolated in 1973, does not need chemical detoxification and could 
still maintain native three-dimensional structure during processing. CRM197 is 
commonly used as carrier protein in carbohydrate based vaccine, especially in 
routine childhood vaccines. [ 10 ] Currently licensed vaccine Menveo® (Novartis 
Vaccine,Switzerland ) is a tetravalent meningococcal CRM197-conjuate vaccine 
against meningococcal serogroup A, C, W-135 and Y. [11] 
 
Human serum albumin is the most abundant protein in human blood plasma. It is 
produced in the liver. Albumin constitutes about half of the blood serum 
protein. It is also a commonly used carrier protein. [12] 
 
In this research, neo-glycoconjugates obtained form carba oligomers conjugated 
with carrier protein CRM197 will be mainly used for mice immunization, while 
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those prepared from carba oligomers linked with HSA will be employed for 
further ELISA study. Lysine residues in CRM197 and HSA presented outwardly on 
the molecules can link with carba oligomers through suitable “linker 
molecule”. Furthermore, to investigate whether the “linker molecule” 
influences the immunological activities, two chemically different spacer will 
be used as molecular bridge, namely an Disuccinimidyl adipate for CRM197 and 
BS(PEG)5-based spacer for HSA.  
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9.2 Conjugation of carba oligomers to carrier protein CRM197 
 
First, using disuccinimidyl adipate linker chemistry (Scheme 16), [ 13 ] the 
synthesized carba oligomers 1, 2 and 3 were converted into activated monomer, 
dimer and trimer precursors 39, 40 and 41 respectively in DMSO, in the presence 
of TEA and disuccinimidyl adipate (known as SIDEA). After the purification 
(precipitation and centrifugation for several times, lyophilization), the 
freshly prepared activated oligomers 39, 40 and 41 were conjugated with CRM197 
in sodium phosphate buffer with one or two days’ incubation at room 
temperature.  
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Scheme 16. Synthesis of oligomers-CRM197 glycoconjugate 42, 43 and 44 
 
 
The fundamental parameters of the CRM197 conjugation is shown in Table 4. The 
sugar-loading was determined by MALDI spectra, while the SDS—PAGE allowed to 
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confirm the occurrence of the conjugation. All the neo-glycoconjugates 
contained at least ten oligomers.   
 
Product Activated 
Ester/Protein 
Loading 
(X) 
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration 
mg/ml 
42 40:1 18.5 67526 1.35 0.089 0.68 
43 50:1 12.3 68252 0.88 0.063 0.44 
44 50:1 10.5 69957 1.72 0.14 0.86 
Table 4. Data of CRM197 neo-glycoconjugates  
Carba Analogues of Men A CPS – Chemistry Section -  
50 
 
 
9.3 Conjugation of carba oligomers to carrier proteins HSA 
 
For the conjugation with carrier protein HSA, a similar approach to prepare the 
neo-glycoconjugates was employed. Only the bis-succinimidyl penta-ethylene-
glycol (called BS(PEG)5) was used instead of SIDEA for the purpose of 
investigating the influence of “linker molecules”.  
 
Thus, the activated monomer, dimer trimer precursors 45, 46 and 47 were 
prepared in DMSO, in the presence of TEA and BS(PEG)5. After purification, the 
activated oligomers were conjugated with HSA in sodium phosphate buffer 
solution with one or two days’ incubation, generating the neo-glycoconjugates 
48, 49 and 50. (Scheme 15, table 5) 
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Scheme 17. Synthesis of oligomers-HSA glycoconjugate 48, 49 and 50 
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As shown in table 5, the HSA glycolconjugation are similar to those of CRM197 
conjugation. The relatively lower oligomers loading on 50 (about eight sugar 
chains per protein molecule) might be mainly due to the steric hindrance of 
trimer carba analogue. 
 
Product Activated 
Ester/Protein 
Loading
X  
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration 
mg/ml 
48 40:1 14.6 74954 0.94 0.062 0.47 
49 50:1 14.5 76899 1.62 0.125 0.81 
50 50:1 7.9 73869 1.51 0.091 0.76 
Table 5. Data of HSA neo-glycoconjugates 
 
 
In short, the synthesized carba sugar compounds were all successfully 
conjugated with two kinds of carrier protein by two different linkers. The 
loading efficiency, as shown in Table 4 and Table 5, is satisfatory and will be 
helpful for the future immunological test. The biological evaluation of these 
neoglycoconjugates is still on the course in Novartis laboratory.    
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CONCLUSION 
 
Overall, we completed the synthesis and preliminary biological evaluation of 
the carba analogues of MenA CPS.  
 
For the synthesis work, a reliable procedure for preparing all the needed 
building blocks compounds has been established. The key intermediate 4 could be 
synthesized in lab in multi gram scale, which facilitates the synthesis of 
these derivatives. Based on the H-phosphonate coupling reactions, the oligomer 
elongation and phosphonate diester-linked spacer introduction were successfully 
achieved in high yield.  Also, the global deprotection and purification 
procedure proved to be efficient and are believed to be practical for preparing 
more complex derivatives. 
 
We have also carried out several trials employing H-phosphonate 
polycondensation reactions to achieve carba oligomers with higher number of 
repeating units. However, with current building blocks (monomer and dimer H-
phosphonates) and method, we only produced the undesired cyclic dimer. Further 
work will be focused on this part to find a feasible way to realize the H-
phosphonate polycondensation.  
  
The synthesized carba sugar compounds 1-3 were successfully conjugated with two 
kinds of carrier protein (CRM197 and HSA) by two different linkage molecules, 
which will be useful for the future immunological test for these analogues. The 
biological evaluation of the neoglycoconjugates is still on the course.    
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EXPERIMENTAL PART 
 
 
General:  Reagents were obtained from commercial sources and used as 
purchased. All the organic solvents were purchased anhydrous and used 
without further purification. Unless otherwise noted, all reactions were 
carried out at room temperature in oven-dried glassware with magnetic 
stirring. Molecular sieves were flame-dried under high vacuum prior to use. 
Organic solutions were concentrated under diminished pressure with bath 
temperatures <40℃.  NMR spectra were recorded on Bruker AC 300 and Bruker 
Avance 400 spectrometers at 298 K, unless otherwise reported. In 1H NMR 
spectra, multiplicities are quoted as singlet (s), broad singlet (br s), 
doublet (d), doublet of doublets (dd), triplet (t), or multiplet (m). In13C 
NMR spectra, signals corresponding to aromatic carbons are omitted. 
Chemical shifts are reported on the d (ppm) scale and in 31P spectra they 
are relative to H3PO4. Peak assignments were based on analysis of 2D 
spectra (H,H-COSY and HSQC or HMQC spectra). HRMS spectra were recorded in 
the negative or positive modes on Jeol AX-505 and Bruker Daltonics APEX 
TMII (FT-ICR) instruments. TOF MS analysis was performed operating in 
positive ion mode (Bruker model Ultraflex MALDI-TOF mass spectrometer). 
Optical rotations were measured at room temperature with a Perkin–Elmer 241 
polarimeter. TLC and HPTLC were carried out on Merck silica gel 60 F-254 
plates (0.25 mm and 0.2 mm thickness, respectively), and spots were viewed 
by spraying with a solution containing H2SO4 (31 mL), ammonium molybdate 
(21 g) and Ce(SO4)2 (1 g) in 500 mL water, followed by heating at 110 8C 
for 5 mins. Column chromatography was performed by the flash procedure on 
Merck silica gel 60 (230–400 mesh). Solvents were dried by standard 
procedures. 
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6-O-thexydimethylsilyl D-glucal 14 
 
 
O
OAc
AcO
AcO
O
OH
HO
HO
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OTDS
HO
HO
MeOH
MeONa
TDSCl, 
Imidazole
THF
12 13 14  
 
Synthetic Procedure: 
 
Synthesis of 13: 
 
3, 4, 6-Tri-O-Acetyl-D-Glucal 12 (25 g, 92 mmol) was dissolved in dry MeOH (150 
mL) under nitrogen atmosphere, NaOMe (1.5 g, 27.7 mmol) was added, the mixture 
was stirred at room temperature for 2 h, then the reaction mixture was 
neutralized to PH 7 with IR-120 resin, (H+ form, previously washed by MeOH), 
filtered, and concentrated, get a 16 g 13 as colorless oil. 
 
Synthesis of 14: 
 
To a solution of 13 (16 g, 92 mmol) and imidazole (14.6 g, 211 mmol) in THF 
(250 mL), was slowly added thexyldimethylsilyl chloride (35 mL, 164 mmol) at 
20℃. After stirring at room temperature for 24 hours, satd NaHCO3 (150 mL) was 
added to the reaction mixture, followed by extraction with CH2Cl2 (3 × 100 
mL). The organic phases were dried (Na2SO4), filtered, and concentrated. The 
crude materials was purified by flash chromatography (40% EtOAc/Hexane), 
afording 14 (22 g, 2 steps 83 %) as a clear oil.  
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Product characterization 13 
Formula C6H10O4 
Molecular Wright 146.14 
TLC conditions Rf: 0.3, CH2CL2 : MeOH = 9 : 1 
 
 
Product characterization 14 
Formula C14H28O4Si 
Molecular Wright 288.46 
TLC conditions Rf: 0.4, Hexane : ETOAc = 1 : 1 
 
The spectroscopic data were in agreement with the reported data [1] 
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3,4-di-O-Benzyl-D-glucal 16 
 
 
O
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BnBr, THF
TBAI,NaH
TBAF
THF
14 15 16  
 
Synthetic Procedure: 
 
Synthesis of 15: 
 
14 (22 g, 76 mmol) was dissolved in dry THF (150 mL). BnBr (19.5 mL, 164 mmol) 
was added at room temperature, then 60% NaH (6.11 g, 156 mmol) was added little 
by little, followed by TBAI (2.87 g, 8 mmol), the mixture was stirred under 
nitrogen atmosphere at room temperature for 2 hours. MeOH (100mL) was then 
added to quench the reaction, and another NH4Cl solution (250 ml) was added, 
followed by extraction with CH2Cl2 (3 × 100 mL). The organic phases were dried 
(Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (5% EtOAc/Hexane), providing 15 (34 g, 95 %) as a clear oil.  
 
Synthesis of 16: 
 
15 (34 g, 73 mmol) was dissolved in dry THF (150 mL), TBAF (1M solution in THF 
+ 5% H2O, 87 mL, 87 mmol) was added at 0℃, the solution was then stirred under 
nitrogen at room temperature. After 2 hours, satd NH4Cl solution (200 mL) was 
added and stirred for 10 min, CH2Cl2 (300 mL) was added for extraction, and the 
organic layer was washed with brine (200 mL), dried (Na2SO4), filtered, and 
concentrated. The crude material was purified by flash chromatography (40% 
EtOAc/Hexane), providing 16 (20.2 g, 85 %; 4 steps, 67 %) as a white solid.  
 
Product characterization 15 
Formula C28H40O4Si 
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Molecular Wright 468.7 
TLC conditions Rf: 0.5, Hexane : EtOAc = 19 : 1 
 
Product characterization 16 
Formula C20H22O4 
Molecular Wright 326.39 
TLC conditions Rf 0.35, Hexane : EtOAc = 3 : 1 
 
The spectroscopic data were in agreement with the reported data 
 
 
 
1H NMR spectrum of compound 16 
 
 
 
O
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1,5-Anhydro-di-O-benzyl-2,6,7-trideoxy-d-arabino-hept-1,6-dienitol, 11 
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O
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BnO
BnO
11
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Synthetic Procedure: 
 
Synthesis of 17 
 
To a solution of 16 (12.3 g, 38 mmol) in dry EtOAc (400 mL), freshly prepared 
2-iodoxybenzoic acid (89 g, 319 mmol, prepared from 2-iodobenzoic acid and 
Oxone [2]) was added, and the suspension was stirred under nitrogen at 75 ℃ for 
4 hours. The mixture was then cooling, filtered over a celite pad and 
concentrated. The crude was co-vaporated with toluene (3 × 50 mL) to obtain 
the aldehyde intermediate (12.3 g, 99%). NMR analysis showed the complete 
conversion from 17 to the aldehyde.   
 
Synthesis of 11 
 
Freshly prepared PPh3CH3I (23.3 g, 57 mmol) was dissolved in dry THF (40 mL), 
the solution was cooling to -78 ℃, then KHMDS (1M solution in THF, 57 mL, 57 
mmol) was added under nitrogen. The mixture was stirred at -78 ℃ for 30 
minutes, then another 1 hour at 0 ℃. The solution of the aldehyde 17 (12.3 g, 
38 mmol) in dry THF was added to the mixture at -78 ℃. The reaction mixture 
was then stirred at room temperature. After 3 hours, saturated aqueous solution 
of NH4Cl (200 mL) was added and stirred for 10 minutes, the mixture was diluted 
with CH2Cl2 (300 mL) and the organic layer was washed with brine, dried (Na2SO4), 
filtered, and concentrated. The crude was purified by flash chromatography (40% 
Toluene/Hexane) providing 11 (9.4 g, 77 %) as a clear oil.   
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Product characterization 17 
Formula C20H20O4 
Molecular Wright 324.37 
TLC conditions Rf 0.5, Hexane : EtOAc = 3 : 1  
 
Product characterization 11 
Formula C21H22O3 
Molecular Wright 322.4 
TLC conditions Rf 0.5, Hexane : EtOAc = 9 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [3] 
 
1H NMR spectrum of compound 11 
O
CH2
BnO
BnO
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(3R,4R,5R)-3,4-dibenzyloxy-5-(hydroxymethyl) cyclohexene, 18 
 
 
O
CH2
BnO
BnO
OH
BnO
BnO
1) 1,3 dichorobenzene,
11 18
2) NaBH4, EtOH/THF
 
  
Synthetic Procedure: 
 
Compound 11 (7.5 g, 23.3 mol) was dissolved in 1,6-dichlorobenzene (25 mL) in a 
sealed tube and heated at 240 ℃ for 2 h. After cooling down, the mixture was 
slowly poured into a suspension of NaBH4 (500 mg, 13 mmol) in THF (100mL) and 
EtOH (25 mL) and stirred for 15 minutes. Then water (200 mL) was added, and the 
mixture was extracted with CH2Cl2 (3×100 mL). The organic layer was washed 
with brine (200 mL), dried (Na2SO4), filtered, and concentrated. The crude was 
purified by flash chromatography (30% EtOAc/Hexane), providing 13 (6.5 g, 86 %) 
as a clear oil. 
 
Product characterization 18 
Formula C21H24O3 
Molecular Wright 324.41 
TLC conditions Rf 0.4 Hexane : EtOAc = 2 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [2] 
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1H NMR spectrum of compound 18 
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3,4-Di-O-benzyl-5a-carba-α-d-glucopyranose, 10 
 
 
OsO4
Me3NO 2H2O
Acetone/H2O
HO
BnO
BnO
OH OH10
OH
BnO
BnO
18  
 
Synthetic procedure: 
 
Compound 18 (6.5 g, 20.8 mmol) was dissolved in a mixture of acetone (75 mL) 
and H2O (25 mL), OsO4 (CAUTION!) solution (250 mg in 4.5 mL H2O and 18 mL 
acetone) was added at room temperature, followed by Me3NO (5.075 g, 46 mmol), 
and continued stirring for 48 h at room temperature. A saturated aqueous 
solution of Na2S2O3 (50 mL) was added and stirred for 30 minutes to reduce the 
OsO4, chloroform (300 mL) was added and the organic layer was washed with brine 
(200 mL), dried (Na2SO4), filtered, and concentrated. The crude was purified by 
flash chromatography (5% MeOH/CH2Cl2), providing 10 (6.23 g, 86.3%) as a white 
solid. 
 
 
Product characterization 10 
Formula C21H26O5 
Molecular Wright 358.43 
TLC conditions Rf 0.2, CH2Cl2 : MeOH = 19 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [4] 
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1H NMR spectrum of compound 10 
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3,4-di-O-benzyl-6-O-thexyldimethylsilyl-5a-carba-α-D-glucopyranose, 19 
 
HO
BnO
BnO
OH
OH
 TDSCl.IMH
TDSO
BnO
BnO
OH
OH
THF
10 19  
Synthetic Procedure 
 
To a solution of 10 (8.1 g, 22.6 mmol) and imidazole (4.6 g, 68 mmol) in THF 
(200 mL), thexyldimethylsilyl chloride (9.8 mL, 52 mmol) was added dropwise at 
15 ℃. The mixture was stirred at room temperature for 24 hours, then saturated 
aqueous solution of NaHCO3 (100 mL) was added, followed by extraction with 
EtOAc (3 × 150 mL). The organic phases were dried (Na2SO4), filtered, and 
concentrated. The crude was purified by flash chromatography (30% EtOAc/Hexane), 
yielding 19 (10.5 g, 93 %) as a colorless oil. 
 
Product characterization 19 
Formula C29H44O5Si 
Molecular Wright 500.74 
TLC conditions Rf 0.4, Hexane : EtOAc = 5 : 2 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [3] 
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1-O-Acetyl-3,4-di-O-benzyl-6-O-thexyldimethylsilyl-5a-carba-α-D-glucopyranose, 
20 
  
 
 (MeO)3CMe,
   PTSA
TDSO
BnO
BnO
OH
OH
AcOH
TDSO
BnO
BnO
OH
OAc19 20  
 
Synthetic Procedure 
 
Compound 19 was successively dissolved in dry acetonitrile (150 mL) under 
nitrogen. Trimethyl orthoacetate (6.25 mL, 50 mmol) was added at room 
temperature, followed by a catalytic amount of p-toluenesulfonic acid. After 15 
minutes, 80% aqueous solution of acetic acid (150 mL) was added and stirring 
was continued for 15 minutes. CH2Cl2 (200 mL) was added and the organic layer 
was washed with H2O (200 mL) and saturated aqueous solution of NaHCO3 (200 mL), 
dried (Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (25% EtOAc/Hexane), providing 20 (10.45 g, 91%) as a clear oil.  
 
Product characterization  20 
 
Formula C31H46O6Si 
Molecular Wright 542.78 
TLC conditions Rf 0.25, Hexane : EtOAc = 3 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [3] 
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1H NMR spectrum of compound 20 
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1-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-6-O-thexyldimethylsilyl-5a-carba-α-
D-mannopyranose, 21 
 
 
TDSO
BnO
BnO
N3
OAc
1) Tf2O,Py
2) DMF/H2O, NaN3
TDSO
BnO
BnO
OH
OAc20
21  
 
Synthetic Procedure 
 
20 (10.3 g, 19 mmol) was dissolved in a mixture of CH2Cl2-Pyridine (5:1, 360 
mL), then triflic anhydride (17 mL, 104 mmol) were added dropwise at -10 ℃. 
The mixture was stirred at 0℃ for 60 minutes. Then saturated aqueous solution 
of NaHCO3 (150 mL) was added, the organic layer was washed with brine (200 mL), 
dried (Na2SO4), filtered, and concentrated. The residue was then dissolved in a 
19:1 mixture of DMF-H2O (100 mL), and NaN3 (6.2 g, 95 mmol) was added. The 
reaction mixture was stirred overnight at 40 ℃, then the solvent was 
evaporated and the crude was purified by flash chromatography (2% 
EtOAc/Toluene), giving 21 (8.5 g, 79%) as an oil.  
 
Product characterization 21 
 
Formula C31H45N3O5Si 
Molecular Wright 567.79 
TLC conditions Rf 0.5, Toluene : EtOAc = 24 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [3] 
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2-Acetamido-1-O-acetyl-3,4-di-O-benzyl-2-deoxy-6-O-thexyldimethylsilyl-5a-carba-
α-D-mannopyranose ,4 
 
TDSO
BnO
BnO
N3
OAc
TDSO
BnO
BnO
NHAc
OAc
1) PPh3, H2O
2) MeOH, Ac2O
21 4  
 
 
Synthetic Procedure 
 
A mixture of 21 (9.1 g, 16 mmol) and PPh3 (12.6 g, 48 mmol) in dry THF (250 mL) 
was stirred overnight at 60 ℃ under nitrogen atmosphere. After addition of 
water (40 mL), the reaction was stirred for 24 h at the same temperature, then 
the solvent was evaporated. The residue was dissolved in MeOH (200 mL) and 
acetic anhydride (30 mL, 320 mmol) was added. After 24 h the solvent was 
evaporated and the crude material was purified by flash chromatography (30% 
EtOAc/Hexane), providing 4 (8.86 g, 95%) as an oil.  
 
Product characterization 4 
 
Formula C33H49NO6Si 
Molecular Wright 583.83 
TLC conditions Rf 0.3, Hexane : EtOAc = 3 : 1 
 
The optical rotation and the spectroscopic characterization data were in 
agreement with the reported data [3] 
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3-N-carbonbenzyloxy-propyl hydrogenphosphonate, triehtylammonium salt,7 
 
 
HO NHCbz
O NHCbzP
O
H
OHNEt3
23 7
CH3CN/Pyridine
O
PO Cl
O
 
Synthetic Procedure 
 
To a stirred solution of benzyl 3-hydroxypropylcarbamate 17 (13 mg, 0.06 mmol) 
in dry CH3CN (0.3) mL and pyridine (0.1 mL), a 0.4 M solution of 2-chloro-4H-
1,3,2-benzodioxaphosphinin -4-one in dry CH3CN was added (0.2 mL, 0.08 mmol ) 
at room temperature. The mixture was stirred at room temperature under nitrogen 
atmosphere for 45 minutes. Then a 1:1 mixture of pyridine-H2O (1mL) was added. 
TEAB (Triethylammonium bicarbonate buffer, 1M solution in H2O, 0.5 mL) was then 
added to the mixture, then the mixture was diluted with CHCl3 and concentrated 
without phase separation. The residue was purified by flash chromatography 
(5→10 % MeOH/CH2Cl2, 1% TEA), providing 7 (22 mg, 98%).  
 
Product characterization 7 
 
Formula C11H15NO5P 
Molecular Wright 272.21 
TLC conditions Rf 0.25 CH2Cl2 : MeOH = 14 : 1 
 
The spectroscopic characterization data was in agreement with the reported data 
[5] 
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2-Acetamido-1-O-acetyl-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranose, 22 
 
 
TDSO
BnO
BnO
NHAc
OAc
HO
BnO
BnO
NHAc
OAc
TBAF/THF
4 22  
 
Synthetic Procedure 
 
A stirred solution of 4 (1.05 g, 1.8 mmol) in dry THF (30 mL) was treated with 
TBAF (1M solution in THF + 5% H2O, 2.2 mL, 2.2 mmol), the mixture was stirred 
at room temperature under nitrogen atmosphere for 2 hours. The mixture was then 
diluted with CH2Cl2 (50 mL), the organic layer was washed with saturated 
aqueous solution of NH4Cl (50 mL), dried (Na2SO4), filtered, and concentrated. 
The crude was purified by flash chromatography (5% MeOH/CH2Cl2), affording 22 
(722 mg, 91%)   
 
Product characterization 22 
 
Formula C25H31NO6 
Molecular Wright 441.52 
TLC conditions Rf, 0.5, CH2Cl2 : MeOH = 19 : 1 
 
[α]D +32.3(c 1.0 in CHCl3) 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.51–7.20 (m, 10 H, HAr); 6.20 (d, J = 8.5 Hz, 1 H, 
NH); 5.2–5.1 (m, 1 H, H-1); 4.80–4.73 (d, J = 11.4 Hz, 1H, CHHPh); 4.62–4.58 (m, 
2 H, CH2Ph); 4.45 (m, 2 H, CHHPh, H-2); 3.98 (m, 1 H, H-3); 3.78 (m, 1 H, H-6 ); 
3.60–3.82 (m, 2 H, H-6’, H-4, ); 2.15 (m, 1 H, H-5); 2.03 (s, 3 H, OAc); 1.95 
(s, 3 H, NHAc); 1.92 (m, 1 H, H-5a’); 1.85 (m, 1 H, H-5a);  
 
13C  NMR (CDCl3 , 100.6 MHz) δ 172.6 (2 C=O); 138.1-127.9 (12 Ph); 78.9 (C-3); 
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76.7 (C-4); 72.9 72.8 (2CH2Ph); 68.3 (C-1); 63.6 (C-6); 50.7 (C-2); 39.8 (C-5); 
29.7 (C-thexyl); 27.2 (C-5a); 23.3 (NHAc); 21.1 (OAc);  
 
ES HRMS cacld for C25H31N1O6Na 464.20436, found 464.20417  
 
 
 
1H NMR spectrum of compound 22 
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13C NMR spectrum of compound 22 
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[6-O-(2-Acetamido-1-O-acetyl-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D- 
mannopyranosyl)] hydrogen phosphonate triehtylammonium salt, 8 
 
 
HO
BnO
BnO
NHAc
OAc
O
BnO
BnO
NHAc
OAc
P
H
O
O
HNEt3
822
CH3CN/Pyridine
O
PO Cl
O
 
 
Synthetic Procedure 
 
To a solution of 22 (70 mg, 0.16 mmol) in dry CH3CN (2 mL) and pyridine (0.7 
mL), 0.4 M solution of 2-chloro-4H-1,3,2-benzodioxaphosphinin-4-one in dry 
CH3CN (0.5 mL, 0.2 mmol) was added at room temperature. The mixture was stirred 
at room temperature under nitrogen atmosphere for 45 minutes. Then a 1:1 
mixture of pyridine-H2O (1:1, 1mL) solution was added and the mixture was 
diluted with CHCl3 (20 mL). The organic layer was washed with H2O (10 mL) and 1 
M TEAB(10 mL), dried (Na2SO4), filtered, and concentrated. The residue was 
purified by flash chromatography (5% MeOH/CH2Cl2, 1% TEA), providing a clean 
oil, the oil was diluted with CHCl3 (20 mL), then washed again by 0.5 M TEAB 
(10 mL), dried (Na2SO4), filtered, and concentrated get product 8 (80 mg, 82%) 
as a syrup.  
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Product characterization 8  
 
Formula C25H31NO8P 
Molecular Wright 504.49 
TLC conditions Rf 0.25 , CH2Cl2 : MeOH = 19 : 1   
 
The formation of the H-phosphonate intermediate was ascertained by 1H NMR 
analysis, which showed the diagnostic doublet at δ 6.03 (J H,P = 635 Hz ), 
compound 8 was used directly in the following coupling steps without further 
characterization.   
 
 
1H NMR spectrum of compound 8 
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31P NMR spectrum of compound 8 
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General Procedure A: Zemplén Deactylation 
 
 
A solution of precursor (4, 5 or 6) in dry MeOH was treated with 0.08 M NaOMe 
in MeOH and stirred under nitrogen atmosphere. After reaction completion, the 
mixture was diluted with MeOH, neutralized with Amberlite IR 120 (H+) resin, 
filtered, and concentrated. The crude was purified by flash chromatography, 
providing corresponding deacetylated product.  
 
 
 
General Procedure B: Phosphonate Coupling and Oxidation. 
 
The acceptor (9, 26 or 28) and the H-phosphonate (7 or 8) were coevaporated 
with pyridine for three times under high vacuum. The residue was then dissolved 
in the dry pyridine, and PivCl was added. The mixture was usually stirred under 
nitrogen atmosphere for 40 to 45 minutes. Then a freshly prepared solution of 
I2 in a 19:1 mixture of pyridine- H2O was added and the mixture was stirred for 
another 15 minutes. After this, CHCl3 was added to dilute, and the organic 
layer was washed with 1 M aqueous solution of Na2S2O3 and 0.5 M TEAB, dried 
(Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatograph, providing the phosphodiester derivatives. 
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General Procedure C: Global Removal of Protection Group (Desilylation, 
Hydrogenation and Ion exchange) 
 
The protected oligomer (24, 27or 29) was dissolved in dry THF and treated with 
a 1M solution of TBAF in THF under nitrogen atmosphere for 4 hours. The mixture 
was then diluted with CHCl3,and the organic layer was washed with asaturated 
aqueous solution of NH4Cl and 0.5 M TEAB, dried (Na2SO4), filtered, and 
concentrated. The crude residue was purified by flash chromatography, providing 
the correspondingdesilylated derivative. This intermediate was hydrogenolysed 
over Pd/C in a 1:1 mixture of MeOH and H2O at room temperature for 48 h. The 
mixture was filtered over a Celite pad and the filtrate was concentrated. Then 
the residue was dissolved in H2O and first eluted through a column filled with 
Dowex 50W-X8 resin (H+ form), and then through a column filled with the same 
resin in Na+ form. The eluate was concentrated and lyophilized to afford the 
target compound as sodium salt. 
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2-Acetamido-3,4-di-O-benzyl-2-deoxy-6-O-thexyldimethylsilyl-5a-carba-a-D-
mannopyranose, 9 
 
OTDS
BnO
BnO
NHAc
OAc
TDSO
BnO
BnO
NHAc
OH4 9
MeONa
MeOH
 
 
Synthetic Procedure 
 
Compound 4 (600mg, 1.02 mmol) was dissolved in MeOH (20 mL) and deactylated 
with 0.08 M NaOMe in MeOH (5mL) according to general procedure A. The crude was 
purified by flash chromatograph (5% MeOH/CH2Cl2), providing alcohol 9 (470 mg, 
84%) 
 
Product characterization 9 
 
Formula C31H47NO5Si 
Molecular Wright 541.79 
TLC conditions Rf 0.5, CH2Cl2 : MeOH = 19 : 1  
 
1H  NMR (CDCl3 , 400 MHz) δ 7.30–7.43 (m, 10H, HAr); 5.78 (d, J = 7.8 Hz, 1H, NH); 
4.73 (d, J = 11.6 Hz, 1H, CHHPh); 4.65–4.58 (AB system, 2 H, CH2Ph); 4.43 (d, J 
= 11.5 Hz, 1 H, CHHPh); 4.23 (m, 1 H, H-2,); 3.98 (m, 1 H, H-1); 3.88–3.77 (m, 
3 H, H-3, H-6’, H-4, ); 3.67 (dd, J = 5.6, 9.6 Hz, 1 H, H-6); 2.21 (d, J = 5.6 
Hz, 1 H, H-5); 1.92 (s, 3 H, NHAc); 1.84 (m, 1 H, H-5a’); 1.79 (m, 1 H, H-5a); 
1.66 (m, 1 H, CHthexyl); 0.92 (d, J = 6.8 Hz, 6 H, 2 CH3CHthexyl); 0.88 (s, 6 H, 2 
CH3thexyl); 0.09, 0.12 (2 s, 6 H, 2 CH3Si); 
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13C  NMR (CDCl3 , 100.6 MHz) δ 172.6 (2 C=O); 139.4-128.4 (12 Ph); 79.5 (C-3); 
74.5 (C-4); 72.4, 73.3(CH2Ph); 68.2 (C-1); 63.5 (C-6); 54.1 (C-2); 39.8 (C-5); 
34.5 (CHthexyl); 30.3 (C-5a); 25.3 (C-thexyl); 23.4 (NHAc); 20.4 (2CH3-thexyl); 18.7 
(2CH3CHthexyl); -3.6, -3.5 (CH3Si);  
(Found: C, 68.00; H, 8.42; N, 2.35. Calc. for C33H49NO6Si: C, 67.89; H, 8.46; N, 
2.40); 
 
ES HRMS cacld for C31H47N1O5SiNa 564.31157, found 564.31148  
 
1H NMR spectrum of compound 9 
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13C NMR spectrum of compound 9 
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3-N-carbobenyloxy-propyl-O-(2-acetamido-3,4-di-O-benzyl-6-O-thexyldimethylsilyl-
2-deoxy-5a-carba-α-D-mannopyranosyl) phosphate triethylammonium salt, 24 
 
 
1) Pyridine, PivCl,
2) I2, Pyridine/H2O
         81%
TDSO
BnO
BnO
NHAc
OH
O NHCbz
P
O
O
BnO
BnO
NHAc
O
TDSO
Et3NH
9
24
O NHCbzP
O
H
OHNEt3
7
 
 
Synthetic procedure 
 
Alcohol 9 (204 mg, 0.38 mmol) was condensed with H-phosphonate 7 (282 mg, 0.75 
mmol) in pyridine (5 mL) in the presence of PivCl (0.1 mL, 0.79 mmol), and in 
situ oxidized by solution of I2 (155 mg, 0.61 mmol) in pyridine-H2O (4 mL) 
according to general procedure B. to generate phosphodiester. The crude was 
purified by flash chromatograph (5% MeOH/CH2Cl2, 1% TEA), yielding compound 19 
(281 mg, 81%) as a colorless oil.   
 
Product characterization 24 
 
Formula C42H60N2O10PSi 
Molecular Wright 811.99 
TLC conditions Rf 0.2 , CH2Cl2 : MeOH = 19 : 1   
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[α]D +14.7 (c 1.0 in CHCl3) 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.40-7.23 (m, 15 H, HAr); 5.15-5.11 (m, 2 H, CH2Ph); 
4.78 (d, J = 11.4 Hz, 1 H, CHHPh);. 4.63-4.34 (m, 5 H, H-1, H-2, CH2Ph, CHHPh); 
4.17 (dd, J = 4.4, 6.4 Hz, 1 H, H-3); 4.07-3.91 (m, 2 H, OCH2CH2CH2N); 3.83 (m, 
1 H, H-6’); 3.65 (m, 1 H, H-4); 3.57 (m, 1 H, H-6); 3.45-3.27 (m, 2 H, 
OCH2CH2CH2N); 3.03 (q, 6 H, 3 CH2-Et); 2.11 (m, 1 H, H-5); 1.95 (s, 3 H, NHAc); 
1.87 (m, 2 H, H-5a, H-5a’); 1.79 (bt, 2 H, OCH2CH2CH2N); 1.62 (m, 1 H, CHtexyl); 
1.29 (t, J = 7.3 Hz, 9 H, 3 CH3-Et); 0.89 (d, J = 6.8 Hz, 6 H, 2 CH3CHtexyl); 0.84, 
0.83 (2 s, 6 H, 2 CH3-texyl); 0.07, 0.07 (2s, 6H, 2 CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 167.1 181.8 (2C=O); 133.5-116.0 (18 Ph); 78.2 (C-
3); 76.5 (C-4); 72.4, 72.5 (2 CH2Ph); 70.4 (C-1); 66.3 (CH2Ph); 62.7 
(OCH2CH2CH2N, C-6); 52.8 (C-2); 45.6 (CH2-Et); 40.0 (C-5); 37.2 (OCH2CH2CH2N); 
34.3 (CHtexyl); 30.4 (OCH2CH2CH2N); 29.6 (C-5a); 25.1 (C-thexyl); 23.3 (NHAc); 20.4 
(2CH3-thexyl); 18.6 (2CH3CHthexyl); 8.5 (CH3-Et); -3.5 -3.6  (2 CH3Si); 
 
31P NMR (CDCl3 , 162 MHz) δ 1.28. 
 
ES HRMS cacld for C42H60N2O10PSi 811.37603, found 811.37373 
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1H NMR spectrum of compound 24 
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13C NMR spectrum of compound 24 
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2-acetamido-1-O-acetyl-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranoside 6-
(2-acetamido-3,4-di-O-benzyl-6-O-thexyldimethylsilyl-2-deoxy-5a-carba-α-D-
mannopyranosyl phosphate), triethylammonium salt,5 
 
1) Pyridine, PivCl,
2) I2, Pyridine/H2O
TDSO
BnO
BnO
NHAc
OH9
TDSO
BnO
BnO
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O
BnO
BnO
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P
O
O
O
OAc
HNEt3
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O
BnO
BnO
NHAc
OAc
P
H
O
O
HNEt3
8
 
 
 
Alcohol 9 (80 mg, 0.0725 mmol) was condensed with H-phosphonate 8 (48 mg, 0.079 
mmol) in pyridine (2 mL) in the presence of PivCl (23 uL, 0.18, and in situ 
oxidized by solution of I2 (60 mg, 0.24 mmol) in pyridine-H2O (1.2 mL) 
according to general procedure B. to generate phosphodiester. The crude was 
purified by flash chromatograph (10% MeOH/CH2Cl2, 1% TEA), yielding compound 5 
(100 mg, 82%) as a colorless oil.  
 
Product characterization 5 
 
Formula C56H76N2O13PSi 
Molecular Wright 1044.27 
TLC conditions Rf 0.25 , CH2Cl2 : MeOH = 9 : 1   
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[α]D +17.3 (c 1.0 in CHCl3)  
 
1H  NMR (CDCl3 , 400 MHz) δ 8.03-6.91 (m, 20 H, HAr); 5.15 (m, 1 H, H-1); 4.81 (m, 
2 H, CH2Ph); 4.73-4.52 (m, 8 H, H-2’, H-2, 3 CH2Ph); 4.42-4.30 (m, 1 H, H-
6’(e)); 4.31-4.20 (m, 1 H, H-3’); 4.03-3.82 (m, 5 H, H-1’, H-3, H-6’(a); H-
6(e); H-4); 3.81-3.60 (m, 1 H, H-4’); 3.58 (m, 1 H, H-6(a)); 3.03 (q, 6 H, 3 CH2-
Et); 2.21-2.03 (m, 2 H, H-5’, H-5); 2.1 (s, 3 H, OAc); 1.95 (s, 6 H, 2NHAc); 
1.9-1.8 (m, 2 H, H-5a’(a); H-5a’(e)); 1.62 (m, 1 H, CHthexyl); 1.29 (t, 11 H, 3 
CH3-Et, H-5a(a); H-5a(e)); 0.89 (d, J = 6.8 Hz, 6 H, 2 CH3CHthexyl); 0.84, 0.83 (2 s, 
6 H, 2 CH3-thexyl); 0.07,0.06 (2 s, 6 H, 2 CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 170.5 170.3 170.0 (3 C=O); 138.9-122.9 (24 Ph); 
79.1 78.4 (C-3’, C-3); 75.8 75.2 (C-4’, C-4); 74.2 72.3 72.8 72.0 (4 CH2Ph); 
70.3 67.5 (C-1’, C-1); 65.2 62.7 (C-6’,C-6); 52.0 49.6 (C-2’, C-2); 45.3 (3 
CH2-Et); 39.7 38.3 (C-5’, C-5); 34.3 (CHthexyl); 29.7 (C-5a’, C-5a); 25.1 (C-
thexyl); 23.5 23.2 (2NHAc); 21.2 (CH3-C=O); 20.4 (2 CH3-thexyl); 18.7 (2 CH3CHthexyl); 
8.5 (3 CH3-Et); -3.5, -3.6 (2 CH3Si); 
 
31P NMR (CDCl3 , 162 MHz) δ 1.46.  
 
ES HRMS cacld for C56H74N2O13P Si 1043.48598, found 1043.48326 
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1H NMR spectrum of compound 5 
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13C NMR spectrum of compound 5  
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31P NMR spectrum of compound 5 
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2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranoside 6-(2-
acetamido-3,4-di-O-benzyl-6-O-thexyldimethylsilyl-2-deoxy-5a-carba-α-D-
mannopyranosyl phosphate), triethylammonium salt, 26 
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Synthetic procedure 
 
Compound 5 (200 mg, 0.17 mmol) dissolved in MeOH (5 mL) and deactylated with 
0.08 M NaOMe in MeOH (3.5mL) according to general procedure A. The crude was 
purified by flash chromatograph (20% MeOH/CH2Cl2, 1% TEA), providing 
corresponding deacetylated intermediate (166 mg, 87%). 
 
Product characterization 26 
 
Formula C54H74N2O12PSi 
Molecular Wright 1002.23 
TLC conditions Rf 0.3 , CH2Cl2 : MeOH = 4 : 1   
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3-(Benzyloxycarbonyl)aminopropyl1-O-[2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-
carba-α-D-mannopyranosyl phosphate 6-(2-acetamido-3,4-di-O-benzyl-2-deoxy-6- O-
thexyldimethylsilyl-5a-carba-α-D-mannopyranosyl phosphate)], bis-
triethylammonium salt, 27  
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1) Pyridine, PivCl,
2) I2, Pyridine/H2O
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Synthetic Procedure 
 
26 (48 mg, 0.043 mmol) was condensed with H-phosphonate 7 (80 mg, 0.215 mmol) 
in pyridine (2 mL) in the presence of PivCl (13 uL, 0.1 mmol), and in situ 
oxidized by solution of I2 (29 mg, 0.12 mmol) in pyridine-H2O (2 mL) according 
to general procedure B. to generate phosphodiester. The crude was purified by 
flash chromatograph (20% MeOH/CH2Cl2, 1% TEA), yielding compound 27 (281 mg, 
81%) as a colorless foam.  
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Product characterization 27 
 
Formula C65H87N3O17P2Si 
Molecular Wright 1272.43 
TLC conditions Rf 0.35 , CH2Cl2 : MeOH = 4 : 1   
 
[α]D  +7.9 (c 1.0 in CHCl3) 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.35-7.21 (m, 25 H, HAr); 5.05 (s, 2 H, CH2Ph); 4.78-
4.57 (m, 8 H, 4 CH2Ph); 4.55-4.49 (m, 4 H, H-1’, H-1, H-2’, H-2); 4.25 (m, 1 
H, H-6’(e)); 4.02-3.91 (m, 6 H, H-3’, H-3, H-6’(a); H-6(e); OCH2CH2); 3.90-3.69 
(m, 3 H, H-4, H-4’, H-6(a)); 3.25 (m, 2 H, CH2CH2N); 2.15 (m, 2H, H-5, H-5’); 
2.02-1.98 (2 s, 6 H, 2 CH3-C=O); 1.93-1.81 (m, 6 H, OCH2CH2, H-5a, H-5a’); 1.62 
(m, 1 H, CHthexyl); 0.92-0.90 (d, 6 H, 2CH3CHthexyl); 0.85 (2 s, 6H, 2CH3-thexyl); 
0.08-0.06 (2s, 6 H, 2CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 171.9 (3 C=O); 138.9-127.8 (30 Ph); 78.6 78.5 (C-
3’, C-3); 75.5 (C-4’, C-4); 71.7 (4 CH2Ph); 70.3 (C-1’, C-1); 65.9 (CH2Ph); 
65.5 63.1 (C-6’,C-6); 62.8 (OCH2CH2); 52.0 51.0 (C-2’, C-2); 39.5 38.5 (C-5’, 
C-5); 37.3 ( CH2CH2N); 34.2 (CHthexyl); 30.5 ( OCH2CH2); 29.3 28.6 (C-5a’, C-5a,); 
25.0 (C-thexyl); 21.8 21.4 (2 CH3-C=O); 19.7 (2 CH3-thexyl); 17.7 (2 CH3CHthexyl); -
4.45 (2 CH3Si);  
 
31P  NMR (CDCl3 , 162 MHz) δ 0.85, 0.33,.  
 
ES HRMS cacld for C65H87N3O17P2SiNa 1295.51832, found 1295.52018 
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1H NMR spectrum of compound 27 
 
 
 
13C NMR spectrum of compound 27 
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31P NMR spectrum of compound 27 
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1-O-Acetyl-2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranosyl 6-
[2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate 6-
(2-acetamido-3,4-di-O-benzyl-2-deoxy-6-O-thexyldimethylsilyl-5a-carba-α-D-
mannopyranosyl phosphate)], bis-triethylammonium salt (6) 
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Synthetic Procedure 
 
26 (80 mg, 0.073 mmol) was condensed with H-phosphonate 8 (48 mg, 0.079 mmol) 
in pyridine (2 mL) in the presence of PivCl (23 uL, 0.18, and in situ oxidized 
by solution of I2 (60 mg, 0.24 mmol) in pyridine-H2O (1.2 mL) according to 
general procedure B. to generate phosphodiester. The crude was purified by 
flash chromatograph (15% MeOH/CH2Cl2, 1% TEA), yielding compound 6 (100 mg, 81%) 
as a colorless oil. 
 
Product characterization 6 
 
Formula C79H103N3O20P2Si 
Molecular Wright 1504.7 
TLC conditions Rf 0.3 , CH2Cl2 : MeOH = 6 : 1   
 
 
[α]D +12.4 (c 1.0 in CHCl3)  
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1H  NMR (CDCl3 , 400 MHz) δ 7.37-7.21 (m, 30 H, HAr); 5.23 (m, 1 H, H-1); 4.82-
4.69 (m, 7 H, H-2’’, 6 OCHHPh); 4.64-4.45 (m, 10 H, H-2, 2’, H-1’, 1’’, 6 
OCHHPh); 4.32 (m, 1 H, H-6’’’(e)); 4.22 (m, 1 H, H-6’’(e)); 4.10-4.02 (m, 2 
H, H-3’’, H-6’’(a)); 3.95 (m, 1 H, H-6’’’(a)); 3.89-3.72 (m, 6 H, H-4, 4’, 
4’’, H-3, H-3’, H-6(e)); 3.67 (m, 1 H, H-6(a)); 3.15 (q, 12 H, 6 CH2-Et); 2.17 
(m, 3 H, H-5, 5’, 5’’); 2.01-1.95 (m, 18 H, 2H-5a’, 5a’’, 5a’’’, 
4OAc,); 1.62 (m, 1 H, CHthexyl); 1.31 (t, J = 7.6 Hz, 18 H, 6 CH3-Et); 0.90 (d, 6H, 
2 CH3CHthexyl); 0.85 (2 s, 6 H, 2 CH3-thexyl); 0.08, 0.06 (2 s, 6 H, 2 CH3Si);  
 
13C  NMR (CDCl3, 100.6 MHz) δ 172.0 171.8 171.6 170.3 (4 C=O); 139.2-126.8 (36 
Ph); 79.1 78.6 78.5 (C-3’’, C-3’, C-3); 75.8 (C-4’’, C-4, C-4); 73.8 71.9 
71.5 (6 CH2Ph); 70.0 (C-1’’, C-1’, C-1 ); 65.4 65.3 63.4 (C-6’’, C-6’, C-
6); 52.6 50.8 49.7 (C-2’’, C-2’,C-2); 40.2 38.6 38.2 (C-5’’, C-5’, C-5); 
47.6 (6 CH2-Et); 34.2 (CHthexyl); 29.6 28.8 26.7 (C-5a’’, C-5a’, C-5a); 24.5 
(C-thexyl); 21.5 21.4 21.3 (4 CH3-C=O);19.6 (2 CH3-thexyl,); 17.8 (2 CH3CHthexyl); 7.9 
(6 CH3-Et); -4.0 (2 CH3Si);  
 
31P  NMR (CDCl3 , 162 MHz) δ 0.77, 0.18.  
 
ES HRMS cacld for C79H104N3O20P2Si 1504.64632 found 1504.64788  
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1H NMR spectrum of compound 6   
 
 
5
.5
5
1
1
.9
5
5
.3
5
1
.0
2
1
7
.5
2
3
.3
0
2
.7
0
1
.0
3
1
.0
0
4
.8
9
0
.9
9
2
.9
7
0
.9
9
1
.0
0
1
0
.8
8
1
0
.5
2
1
.0
0
2
6
.7
6
 
 
13C NMR spectrum of compound 6 
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31P NMR spectrum of compound 6 
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2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranosyl 6-[2-acetamido-
3,4-di-O-benzyl-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate 6-(2-acetamido-
3,4-di-O-benzyl-2-deoxy-6-O-thexyldimethylsilyl-5a-carba-α-D-mannopyranosyl 
phosphate)], bis-triethylammonium salt, 28 
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Synthetic Procedure 
 
Compound 6 (100 mg, 0.059 mmol) dissolved in MeOH (5 mL) and deactylated with 
0.08 M NaOMe in MeOH (3 mL) according to general procedure A. The crude was 
purified by flash chromatograph (25% MeOH/CH2Cl2, 1% TEA), providing 
corresponding deacetylated intermediate (68 mg, 70%). 
 
Product characterization 6 
 
Formula C77H101N3O19P2Si 
Molecular Wright 1461.63 
TLC conditions Rf 0.25 , CH2Cl2 : MeOH = 3 : 1   
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3-(Benzyloxycarbonyl)aminopropyl1-O-{2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-
carba-α-D-mannopyranosyl phosphate 6-[2-acetamido-3,4-di-O-benzyl-2-deoxy-5a-
carba-α-D-mannopyranosyl phosphate 6-(2-acetamido-3,4-di-O-benzyl-2-deoxy-6-O-
thexyldimethylsilyl-5a-carba-α-D-mannopyranosyl phosphate)]}, tris-
triethylammonium salt, 29 
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Synthetic Procedure: 
 
28 (68 mg, 0.041 mmol) was condensed with H-phosphonate 7 (90 mg, 0.24 mmol) in 
pyridine (2 mL) in the presence of PivCl (17 uL, 0.13 mmol), and in situ 
oxidized by solution of I2(27 mg, 0.11 mmol) in pyridine-H2O (2 mL) according 
to general procedure A. to generate phosphodiester. The crude was purified by 
flash chromatograph (35% MeOH/CH2Cl2, 1% TEA), yielding compound 29 (47 mg, 57%) 
as a colorless oil. 
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Product characterization 29 
 
Formula C88H114N4O24P3Si 
Molecular Wright 1732.87 
TLC conditions Rf 0.3 , CH2Cl2 : MeOH = 2: 1   
 
[α]D +13 (c 1.0 in CHCl3)  
 
1H  NMR (CDCl3 , 400 MHz) δ 7.35-7.15 (m, 35 H, HAr); 5.05 (m, 2 H, CH2Ph); 4.83-
4.44 (m, 18 H, H-1, 1’, 1’’, H-2, 2’, 2’’, 6 CH2Ph); 4.28 (m, 2 H, 
OCH2CH2CH2N); 4.06-3.91 (m, 7 H, H-3, 3’, 3’’, H-6, 6’’); 3.88-3.79 (m, 4 H, 
H-4, 4’, 4’’, H-6’(e)); 3.71 (m, 1 H, H-6’(a)); 3.28 (t, J = 6.7 Hz, 2 H, 
OCH2CH2CH2N); 2.95 (q, J = 7.3 Hz, 18 H, 9 CH2-Et); 2.31 (m, 3 H, H-5, 5’, 
5’’); 2.21-1.98 (m, 13 H, H-5a, 5a’, 3 OAc); 1.82 (m, 2 H, OCH2CH2CH2N); 1.65 
(m, 1 H, CHthexyl); 1.37 (m, 2 H, H-5a’’(a); 5a’’(e)); 1.13 (t, J = 7.3 Hz, 27 
H, 9 CH3-Et); 0.92 (d, 6 H, 2 CH3CHthexyl); 0.85 (2 s, 6 H, 2 CH3-thexyl); 0.08, 0.06 
(2 s, 6 H, 2 CH3Si); 
 
13C  NMR (CDCl3, 100.6 MHz) 172.0 171.7 171.6 (4 C=O); 139.2-127.0 (42 Ph); 79.2 
79.0 78.5 (C-3’’, C-3’, C-3); 76.5 (C-4’’, C-4’, C-4); 71.4 (C-1’’, C-
1’, C-1 ); 71.9 (7 CH2Ph); 65.8 (OCH2CH2CH2N); 65.5 63.4 62.7 (C-6’’, C-6’, 
C-6); 52.2 52.1 50.5 (C-2’’, C-2’, C-2); 46.0 (9 CH2-Et); 39.9 39.7 38.2 (C-
5’’, C-5’, C-5); 37.2 (OCH2CH2CH2N); 34.2 (CHthexyl); 30.5 (OCH2CH2CH2N); 29.6 
29.3 28.9 (C-5a’’, C-5a’, C-5a); 25.1 (C-thexyl); 21.5 21.4 21.4 (3 CH3-C=O); 
19.6 (2 CH3-thexyl); 17.8 (2 CH3CHthexyl); 8.48 (9 CH3-Et); -4.48 (2 CH3Si); 
 
31P  NMR (CDCl3 , 162 MHz) δ 1.11, 0.68,0.5.  
 
ES HRMS cacld for C88H114N4O24P3SiNa2 1777.66060 found 1777.66337   
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1H NMR spectrum of compound 29 
 
 
 
13C NMR spectrum of compound 29 
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31P NMR spectrum of compound 29 
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3-Aminopropyl 1-O-(2-acetamido-2-deoxy-5a-carba-α-D-mannopyranosylphosphate), 
sodiumsalt, 1 
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Synthetic Procedure: 
 
Compound 24 (36 mg, 0.039mmol) was dissolved in THF (2 mL) and treated with 
TBAF in THF (0.4 mL, 0.4 mmol) according to general procedure C. The crude 
residue was purified by flash chromatography (25%, MeOH/CH2Cl2, 1% TEA), 
providing the desilylated compound 25.  
 
This intermediate (30 mg) was hydrogenolysed over Pd/C (60 mg) in 50% MeOH/H2O 
(4 mL) and subjected to ion exchange and lyophilization according to general 
procedure C, affording monomer 1 as a white solid (14 mg,95% over two steps):   
 
 
Product characterization 1 
 
Formula C11H22N2O7P 
Molecular Wright 325.28 
 
[α]D  +7.6 (c 1.0 in H2O) 
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1H  NMR (D2O , 400 MHz) δ 4.52 (bs, 1 H, H-2); 4.45 (bdd, 1 H, H-1); 4.26 (q, J 
= 6.1 Hz, 2 H, OCH2CH2CH2N); 4.12 (dd, J = 4.8, 9.7 Hz, 1 H, H-3); 3.90-3.64 (m, 
3 H, H-4, H-6, H-6’); 3.26-3.20 (m, 2 H, OCH2CH2CH2N); 2.16 (s, 3 H, NHAc); 
2.15-2.02 (m, 4 H, H-5, H-5a’, OCH2CH2CH2N); 1.77 (bt, 1 H, H-5a);  
  
13C  NMR (D2O, 100.6 MHz) δ 174.9 (C=O); 72.8 (C-1); 71.2 (C-3); 71.0 (C-4); 
63.7 (OCH2); 62.4 (C-6); 54.1 (C-2); 39.9 (C-5); 37.5 (CH2N); 28.4 (OCH2CH2CH2N); 
28.3 (C-5a); 22.2 (OAc);  
 
31P  NMR (D2O , 162 MHz) δ 1.10. 
 
ES HRMS cacld for C12H24N2O8P 355.12758, found 355.12727 
 
1H NMR spectrum of compound 1 
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13C NMR spectrum of compound 1 
 
 
31P NMR spectrum of compound 1  
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3-Aminopropyl 1-O-[2-acetamido-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate 6-
(2-acetamido-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate)],  disodium salt, 2 
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Synthetic Procedure: 
 
Compound 27 (53 mg, 0.040 mmol) was dissolved in THF (4 mL) and treated with 
TBAF in THF (0.60 mL, 0.60 mmol) according to general procedure B. The crude 
residue was purified by flash chromatography (30% MeOH/CH2Cl2, 1% TEA), 
providing the desilylated compound. 
 
This intermediate (38 mg) was hydrogenolysed over Pd/C (80 mg) in 50% MeOH/H2O 
(4 mL) and subjected to ion exchange and lyophilization according to general 
procedure B, affording dimer 2 as a white solid (21 mg, 77% over two steps) 
 
Product characterization 2 
 
Formula C21H39N3O15P2 
Molecular Wright 635.49 
 
 
[α]D +10.8 (c1.0 in H2O).  
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1H  NMR (D2O , 400 MHz) δ 4.58-4.52 (m, 2 H, H-2, H-2’); 4.46-4.44 (m, 2 H, H-1, 
H-1’); 4.23-4.18 (m, 1 H, H-6’(e)); 4.14-4.05 (m, 5 H, H-6(e); H-3, H-3’, 
OCH2CH2CH2N); 3.89-3.81 (m, 2 H, H-6(a); H-6’(a)); 3.75 (t, J = 10 Hz, 1 H, H-4); 
3.68 (t, J = 9.8 Hz, 1 H, H-4’); 3.26 (t, J = 7.2 Hz, 2 H, OCH2CH2CH2N); 2.15 
(s, 6 H, 2 NHAc); 2.17-2.05 (m, 6 H, H-5a(e); H-5a’(e); H-5, H-5’, OCH2CH2CH2N); 
1.89 (bt, J = 12.8 Hz,1 H, H-5a(a)); 1.77 (bt, 1 H, J = 14 Hz, H-5a’(a));  
 
13C  NMR (D2O , 100.6 MHz) δ 72.4 72.3 (C-1’, C-1); 70.9 (C-4’); 70.5 (C-3’, 
C-3); 69.5 (C-4); 66.0 (C-6); 63.6 (OCH2CH2CH2N); 62.4 (C-6’); 53.8 (C-2’, C-
2); 38.9 (C-5’); 37.9 (C-5); 37.5 (OCH2CH2CH2N); 28.3 (OCH2CH2CH2N); 28.1 (C-
5a’, C-5a); 22.3 (2 NHAc)  
 
31P  NMR (D2O , 162 MHz) δ 0.93, 0.61. 
 
ES HRMS cacld for C21H40N3O15P2 636.19401 found 636.19368  
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1H NMR spectrum of compound 2 
 
 
13C NMR spectrum of compound 2  
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31P NMR spectrum of compound 2 
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3-Aminopropyl 1-O-{2-acetamido-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate 6-
[2-acetamido-2-deoxy-5a-carba-α-D-mannopyranosyl phosphate 6-(2-acetamido-2-
deoxy-5a-carba-α-D-mannopyranosyl phosphate)]},trisodium salt,3  
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Synthetic Procedure: 
 
Compound 29 (45 mg, 0.022 mmol) was dissolved in THF (5 mL) and treated with 
TBAF in THF (0.45 mL, 0.45 mmol) according to general procedure B. The crude 
was purified by flash chromatography (50% MeOH/CH2Cl2, 1% TEA), providing the 
desilylated compound.  
 
This intermediate (32 mg) was hydrogenolysed over Pd/C (80 mg) in 50% MeOH/H2O 
(4 mL) and subjected to ion exchange and lyophilization according to general 
procedure B, affording trimer 3 as a white solid (17 mg, 78% over two steps) 
 
Product characterization 3 
 
Formula C30H54N4O22P3 
Molecular Wright 915.69 
 
 
 
[α]D  +8.2 (c 1.0 in H2O). 
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1H  NMR (D2O , 400 MHz) δ 4.58-4.51 (m, 3 H, H-2, 2’, 2’’); 4.47-4.44 (m, 3 H, 
H-1, 1’, 1’’); 4.29-4.01 (m, 8 H, H-4, 4’, H-6, 6’, OCH2CH2CH2N); 3.85 (m, 
2 H, H-6’’); 3.70-3.65 (m, 4 H, H-3, 3’, 3’’, H-4’’); 3.29 (t, J = 7.2 
Hz, 2 H, OCH2CH2CH2N); 2.15 (s, 9 H, 3Ac); 2.10-2.04 (m, 5 H, H-5, 5’, 5’’, 
OCH2CH2CH2N ); 1.97-1.77 (m, 6 H, H-5a, 5a’, 5a’’);  
 
 
13C  NMR (D2O , 100.6 MHz) δ 174.9 (3 C=O); 72.3 (C-1’’, C-1’, C-1); 70.5 70.5 
70.4 (C-4’’, C-4’, C-4); 69.5 69.4 69.3 (C-3’’, C-3’, C-3); 66.0 65.7 (C-
6’, C-6); 63.5 (OCH2CH2CH2N); 62.3 (C-6’’); 53.7 53.7 51.7 (C-2’’, C-2’, 
C-2); 38.9 38.9 37.8 (C-5’’, C-5’, C-5); 37.4 (OCH2CH2CH2N); 28.2 
(OCH2CH2CH2N); 26.8, 27.5, 27.8 (C-5a’’, C-5a’, C-5a); 22.2 (3 CH3-C=O);  
 
31P  NMR (D2O , 162 MHz) δ 0.95, 0.86, 0.60. 
 
ES HRMS cacld for C30H55N4O22P3Na 939.24240 found 939.24192  
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1H NMR spectrum of compound 3 (T = 40 °C) 
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13C NMR spectrum of compound 3 
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31P NMR spectrum of compound 3 
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H-phosphonate Polycondensation (monomer)  
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Synthetic Procedure for 34 and 35 and polycondensation 
 
To a solution of 9 (200 mg, 0.37 mmol) in dry CH3CN (4 mL) and pyridine (1.4 
mL), 0.4 M solution of 2-chloro-4H-1,3,2-benzodioxaphosphinin-4-one in dry 
CH3CN (1 mL, 0.4 mmol) was added at room temperature. The mixture was stirred 
at room temperature under nitrogen atmosphere for 45 minutes. Then a 1:1 
mixture of pyridine-H2O (1:1, 2 mL) solution was added and the mixture was 
diluted with CHCl3 (30 mL). The organic layer was washed with H2O (10 mL) and 1 
M TEAB (10 mL), dried (Na2SO4), filtered, and concentrated. The residue was 
purified by flash chromatography (5% MeOH/CH2Cl2, 1% TEA), providing a clean 
oil, the oil was diluted with CHCl3 (20 mL), then washed again by 0.5 M TEAB 
(10 mL), dried (Na2SO4), filtered, and concentrated get product 34 (205 mg, 82%) 
as a syrup.  
 
 
A stirred solution of 34 (205 mg, 0.29 mmol) in dry THF (10 mL) was treated 
with TBAF (1M solution in THF + 5% H2O, 1 mL, 1 mmol), the mixture was stirred 
at room temperature under nitrogen atmosphere for 8 hours. The mixture was then 
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diluted with CHCl3 (20 mL), the organic layer was washed with saturated aqueous 
solution of NH4Cl (20 mL) and 1 M TEAB (20 mL), dried (Na2SO4), filtered, and 
concentrated. The crude was purified by flash chromatography (10% MeOH/CH2Cl2), 
affording 35 (104 mg, 64%)  
 
Polycondensation  
 
The H-phosphonate compound 35 (104 mg, 0.18 mmol) and 25 (14 mg, 0.018 mmol) 
were dissolved in dry pyridine (1 mL) and the solvent evaporated under high 
vacuum. This procedure was repeated three times to remove traces of residual 
moisture. The dried compound was dissolved in a mixture of anhydrous pyridine 
and triethylamine (10:1, 200 uL), followed by dropwise addition of pivaloyl 
chloride (45 uL, 0.36 mmol). After 30 min, a fresh lot of pivaloyl chloride (30 
uL, 0.24mmol) was added. The reaction mixture was stirred at room temperature 
for 3 hours, a freshly prepared iodine solution (440 uL, 70 mg, 0.28 mmol in 
pyridine-water, 95:5) was added, and stirring was continued for another 2 
hours. Next the reaction was quenched by addition of CHCl3, and the organic 
layer washed with ice-cold solutions of Na2S2O3 (1 M) and TEAB buffer, dried 
over Na2SO4, and concentrated under high vacuum. The crude was purified by 
flash chromatography (20% MeOH/CH2Cl2), the affording product was analyzed by 
ESI mass spectrum and the 36 (922 m/z) was indicated as main product (70%)  
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Product characterization 34  
 
The formation of the H-phosphonate intermediates 34 was ascertained by 1H NMR 
analysis, which showed the diagnostic doublet at δ 6.10 (J H,P = 649 Hz), 
compound 34 was used directly in the following steps without further 
characterization.   
 
31P  NMR (CDCl3 , 162 MHz) δ 4.33  
 
 
Product characterization 35 
 
The formation of the H-phosphonate intermediates 35 was ascertained by 1H NMR 
analysis, which showed the diagnostic doublet at δ 6.06 (J H,P = 645 
Hz ),compound 35 was used directly in the following steps without further 
characterization.   
 
31P  NMR (CDCl3 , 162 MHz) δ 4.61 
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H-phosphonate Polycondensation (dimer)  
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Synthetic Procedure for 37 and polycondensation 
 
To a solution of 26 (250 mg, 0.23 mmol) in dry CH3CN (5 mL) and pyridine (1.7 
mL), 0.4 M solution of 2-chloro-4H-1,3,2-benzodioxaphosphinin-4-one in dry 
CH3CN (0.6 mL, 0.24 mmol) was added at room temperature. The mixture was 
stirred at room temperature under nitrogen atmosphere for 45 minutes. Then a 
1:1 mixture of pyridine-H2O (1:1, 2 mL) solution was added and the mixture was 
diluted with CHCl3 (30 mL). The organic layer was washed with H2O (5 mL) and 1 M 
TEAB (10 mL), dried (Na2SO4), filtered, and concentrated. The residue was 
purified by flash chromatography (10% MeOH/CH2Cl2, 1% TEA), providing a clean 
oil, the oil was diluted with CHCl3 (20 mL), then washed again by 0.5 M TEAB 
(10 mL), dried (Na2SO4), filtered, and concentrated get H-phosphonate product 
(174 mg, 60%) as a syrup.  
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A stirred solution of H-phosphonate product (174 mg, 0.14 mmol) in dry THF (10 
mL) was treated with TBAF (1M solution in THF + 5% H2O, 2 mL, 2 mmol), the 
mixture was stirred at room temperature under nitrogen atmosphere for 8 hours. 
The mixture was then diluted with CHCl3 (25 mL), the organic layer was washed 
with saturated aqueous solution of NH4Cl (20 mL) and 1 M TEAB (20 mL), dried 
(Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (10% MeOH/CH2Cl2), affording 37 (110 mg, 71%)  
 
 
Polycondensation  
 
The dimer H-phosphonate compound 37 (100 mg, 0.89 mmol) and 38 (intermediate 
from preparation of 2, 11 mg, 0.089 mmol) were dissolved in dry pyridine (1 mL) 
and the solvent evaporated under high vacuum. This procedure was repeated three 
times to remove traces of residual moisture. The dried compound was dissolved 
in a mixture of anhydrous pyridine and triethylamine (10:1, 150 uL), followed 
by dropwise addition of pivaloyl chloride (25 uL, 0.20 mmol). After 30 min, a 
fresh lot of pivaloyl chloride (12 uL, 0.1 mmol) was added. The reaction 
mixture was stirred at room temperature for 3 hours, a freshly prepared iodine 
solution (440 uL, 70 mg, 0.28 mmol in pyridine-water, 95:5) was added, and 
stirring was continued for another 2 hours. Next the reaction was quenched by 
addition of CHCl3, and the organic layer washed with ice-cold solutions of 
Na2S2O3 (1 M) and TEAB buffer, dried over Na2SO4, and concentrated under high 
vacuum. The crude was purified by flash chromatography (25% MeOH/CH2Cl2), the 
affording product was analyzed by ESI mass spectrum and the 36 (922 m/z) was 
indicated as main product (70%)  
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Product characterization 37  
 
The formation of the H-phosphonate intermediates 37 was ascertained by 1H NMR 
analysis, which showed the diagnostic doublet at δ 6.22 (J H,P = 655 Hz), 
compound 37 was used directly in the following steps without further 
characterization.   
 
31P  NMR (CDCl3 , 162 MHz) δ 2.99, 1.01  
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Monomer-Glycoconjugate (CRM197) 
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Synthetic Procedure 
 
Monomer 1 (3 mg, 7.9 umol) was dissolved in a solution of DMSO (0.2 mL) and TEA 
(0.02 mL), then the solution was dropped into a mixture of SIDEA (10 eq) in 
DMSO (0.15 mL), the reaction was stirred for 2 hours. After purification from 
the excess of bi-functional linker by precipitation (Ethyl Acetate, 3 mL), 
washing (Ethyl Acetate, 7 × 1 ml) and lyophilization, the activated 
oligosaccharides 37 (1.5 mg) was obtained . 
 
Compound 37 was reacted with 1.7 mg of protein (0.057 mL of 30 mg/mL of protein 
in NaPi 10 mM + 10% saccharosium, pH 7.2) in 100 uL of 100 mM NaPi buffer (pH 
7.2): the conjugation stoimetry was about 100:1 sugar/protein (mol/mol). The 
mixture was incubated for 24 hours at room temperature, mixing very gently with 
a magnetic stirrer. The glycoconjugate was purified from the excess of 
unconjugated carbohydrate precipitation by (NH4)2SO4. 
 
 
Carba Analogues of Men A CPS – Experimental part -  
 
121 
 
 
Product characterization 40 
 
MALDI-TOF mass spectrum of 40 was recorded: the found value for the 
glycoconjugate 40 was 67526m/z, corresponding to approximately 19 
oligosaccharide chains per CRM197 molecule (average m/z about 58400).  
 
Product Activated 
Ester/Protein 
Loading
(X) 
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
40 40:1 18.5 67526 1.35 0.089 0.68 
 
 
 
 
Carba Analogues of Men A CPS – Experimental part -  
 
122 
 
Dimer-Glycoconjugate (CRM197) 
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Synthetic Procedure 
 
Dimer 2 (4 mg, 6.3 umol) was dissolved in a solution of DMSO (0.55 mL) and TEA 
(0.04 mL), then the solution was dropped into a mixture of SIDEA (10 eq) in 
DMSO (0.25 mL), the reaction was stirred for 2 hours. After purification from 
the excess of bi-functional linker by precipitation (Ethyl Acetate, 3 mL), 
washing (Ethyl Acetate, 10 × 1.5 ml) and lyophilization, the activated 
oligosaccharides 38 (4.1 mg) was obtained . 
 
Compound 38 was reacted with 2 mg of protein (0.067 mL of 30 mg/mL of protein 
in NaPi 10 mM + 10% saccharosium, pH 7.2) in 100 uL of 100 mM NaPi buffer (pH 
7.2): the conjugation stoimetry was about 100:1 sugar/protein (mol/mol). The 
mixture was incubated for 24 hours at room temperature, mixing very gently with 
a magnetic stirrer. The glycoconjugate was purified from the excess of 
unconjugated carbohydrate precipitation by (NH4)2SO4. 
 
Carba Analogues of Men A CPS – Experimental part -  
 
123 
 
 
Product characterization 41 
 
MALDI-TOF mass spectrum of 41 was recorded: the found value for the 
glycoconjugate 41 was 68252 m/z, corresponding to approximately 12 
oligosaccharide chains per CRM197 molecule (average m/z about 58400). 
 
Product Activated 
Ester/Protein 
Loading
(X) 
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
41 50:1 12.3 68252 0.88 0.063 0.44 
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Trimer-Glycoconjugate (CRM197) 
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Synthetic Procedure 
 
Trimer 3 (4 mg, 4.7 umol) was dissolved in a solution of DMSO (0.55 mL), TEA 
(0.04 mL) and trace amount of water (15 uL) then the solution was dropped into 
a mixture of SIDEA (15 eq) in DMSO (0.25 mL), the reaction was stirred for 2 
hours. After purification from the excess of bi-functional linker by 
precipitation (Ethyl Acetate, 3 mL), washing (Ethyl Acetate, 10 × 1.5 ml) and 
lyophilization, the activated oligosaccharides 39 (4.0 mg) was obtained . 
 
Compound 39 was reacted with 2 mg of protein (0.067 mL of 30 mg/mL of protein 
in NaPi 10 mM + 10% saccharosium, pH 7.2) in 100 uL of 100 mM NaPi buffer (pH 
7.2): the conjugation stoimetry was about 100:1 sugar/protein (mol/mol). The 
mixture was incubated for 48 hours at room temperature, mixing very gently with 
a magnetic stirrer. The glycoconjugate was purified from the excess of 
unconjugated carbohydrate precipitation by (NH4)2SO4. 
 
Product characterization 42 
 
MALDI-TOF mass spectrum of 42 was recorded: the found value for the 
glycoconjugate 42 was 69957 m/z, corresponding to approximately 11 
oligosaccharide chains per CRM197 molecule (average m/z about 58400).  
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Product Activated 
Ester/Protein 
Loading
(X) 
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
42 50:1 10.5 69957 1.72 0.14 0.86 
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Monomer-Glycoconjugate (HSA, 46) 
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Synthetic Procedure: 
 
Monomer 1 (3 mg, 7.9 umol) was dissolved in a solution of DMSO (200 uL) and TEA 
(20 uL), then the solution was slowly dropped into a solution of BS(PEG)5 (10 
eq) in DMSO. After 3 hours of stirring, the activated oligosaccharides was 
purified from the excess of bi-functional linker by precipitation (Ethyl 
Acetate, 5 mL), washing (Ethyl Acetate, 10 × 1 ml) and lyophilization, 43 (2.5 
mg) was obtained. 
 
Compound 43 was then reacted with HSA (1.5 mg, 50 uL) in 100 uM NaPi buffer 7.2 
(20 uL), with a conjugation stoichiometry of 150:1 sugar/protein (mol/mol). 
After  
incubation for 24 hours at room temperature, mixing very gently with a magnetic 
stirrer, the glycoconjugate was purified from the excess of unconjugated 
carbohydrate precipitation by (NH4)2SO4. 
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Product characterization 46 
 
MALDI-TOF mass spectrum of 46 was recorded: the found value for the 
glycoconjugate 46 was 74954 m/z, corresponding to approximately 15 
oligosaccharide chains per HSA molecule (average m/z about 66504). 
  
Product Activated 
Ester/Protein 
Loading
X  
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
46 40:1 14.6 74954 0.94 0.062 0.47 
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Dimer-Glycoconjugate (HSA, 47) 
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Synthetic Procedure: 
 
Dimer 2 (4 mg, 6.3 umol) was dissolved in a solution of DMSO (500 uL) and TEA 
(40 uL), then the solution was slowly dropped into a solution of BS(PEG)5 (20 
eq) in DMSO. After 3 hours of stirring, the activated oligosaccharides was 
purified from the excess of bi-functional linker by precipitation (Ethyl 
Acetate, 5 mL), washing (Ethyl Acetate, 10 × 1 ml) and lyophilization, 44 (3.8 
mg) was obtained. 
 
Compound 44 was then reacted with HSA (2.2 mg, 50 uL) in 100 uM NaPi buffer 7.2 
(20 uL), with a conjugation stoichiometry of 150:1 sugar/protein (mol/mol). 
After  
incubation for 48 hours at room temperature, mixing very gently with a magnetic 
stirrer, the glycoconjugate was purified from the excess of unconjugated 
carbohydrate precipitation by (NH4)2SO4. 
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Product characterization 47 
 
MALDI-TOF mass spectrum of 47 was recorded: the found value for the 
glycoconjugate 47 was 76899 m/z, corresponding to approximately 14 
oligosaccharide chains per HSA molecule (average m/z about 66504). 
 
 
Product Activated 
Ester/Protein 
Loading
X  
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
47 50:1 14.5 76899 1.62 0.125 0.81 
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Trimer-Glycoconjugate (HSA, 48) 
 
HO
HO
HO
NHAc
O
HO
HO
NHAc
P ONa
O
O
2
O NH2
P
O
ONaO3
DMSO
TEA
HO
HO
HO
NHAc
O
HO
HO
NHAc
P ONa
O
O
2
O
H
N
P
O
ONaO
HSA
NaPi buffer
    PH 7
TG(HSA), 48
incubation 24-48 hours
45
O
O
N
O
O
NO
O
O O
O
5
BS(PEG)5
O
O
N O
O
O O
O
5
 
Synthetic Procedure: 
 
Trimer 3 (4 mg, 4.7 umol) was dissolved in a solution of DMSO (500 uL), TEA (40 
uL) and water (20 uL) then the solution was slowly dropped into a solution of 
BS(PEG)5 (20 eq) in DMSO. After 3 hours of stirring, the activated 
oligosaccharides was purified from the excess of bi-functional linker by 
precipitation (Ethyl Acetate, 5 mL), washing (Ethyl Acetate, 10 × 2 ml) and 
lyophilization, 45 (3.1 mg) was obtained. 
 
Compound 45 was then reacted with HSA (1.8 mg, 50 uL) in 100 uM NaPi buffer 7.2 
(20 uL), with a conjugation stoichiometry of 150:1 sugar/protein (mol/mol). 
After  
incubation for 48 hours at room temperature, mixing very gently with a magnetic 
stirrer, the glycoconjugate was purified from the excess of unconjugated 
carbohydrate precipitation by (NH4)2SO4. 
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Product characterization 48 
 
MALDI-TOF mass spectrum of 48 was recorded: the found value for the 
glycoconjugate 48 was 73869 m/z, corresponding to approximately 8 
oligosaccharide chains per HSA molecule (average m/z about 66504). 
 
Product Activated 
Ester/Protein 
Loading
X  
MW Protein 
Total 
Sugar 
Concentration 
mg/ml 
Protein 
Concentration
mg/ml 
48 50:1 7.9 73869 1.51 0.091 0.76 
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Design and Synthesis of 
Glycosylphosphatidylinositol (GPI) Anchors of 
Plasmodium falciparum 
 
INTRODUCTION 
 
Innate immunity and TLRs 
 
The innate immune system is an evolutionarily ancient system that detects the 
presence of microbial invaders and activates protective responses. It responds 
rapidly to pathogen associated molecular patterns (PAMP). Recognition of these 
PAMPs is mediated by sets of receptors, whose activation results in acute 
proinflammatory responses such as the production of a diverse set of cytokines 
and chemokines, direct local attack against the invading pathogen and 
initiation of responses that activate and regulate the adaptive component of 
the immune system.[1] 
 
 
 
Figure 1 Activation of TLRs by microbial molecules 
 
The discovery of Toll-like receptors (TLRs) has advanced the understanding of 
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early events in microbial recognition, subsequent host defense responses and 
the development of adaptive immune responses. Thirteen mammalian TLRs have been 
identified, each recognizing a discrete class of PAMP. For example, 
lipopolysaccharides (LPS) are recognized by TLR4, bacterial flagellin by TLR5, 
double-stranded RNA by TLR3, and bacterial DNA by TLR9. TLR2 recognizes 
structurally  the broadest range of microbial compounds including lipoproteins, 
lipopeptides, peptidoglycan, lipoarabinomannans, lipomannans, lipoteichoic 
acids and glycosylphosphatidylinositol (GPI). The promiscuity of TLR2 has been 
attributed to its ability to form heterodimers with TLR1 and TLR6. [2] (Figure 
1) 
 
TLRs are single transmembrane glycoproteins having an extracellular domain, 
a transmembrane domain and an intracellular signaling domain that is 
homologous to the cytoplasmic tail of the interleukin (IL-1) receptor (TIR 
domain). The TLRs detect pathogens by ligand-induced dimerization of the 
ectodomains leading to dimerization of cytoplasmic TIR domains, which then 
serves as a docking site for specific adaptor proteins. These adaptor 
proteins recruit kinases to initiate the activation of Mitogen activated 
protein (MAP) kinases and transcription factors. This leads to the 
upregulation of hundreds of genes including those directly responsible for 
destroying the invading pathogen, alerting neighboring cells to the 
presence of danger, and initiating effective adaptive immune responses. [3] 
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TLRs as therapeutic targeting of innate immune response 
 
Evidence is emerging that innate immune responses can be exploited for 
therapeutic purposes such as the development of adjuvants for vaccination and 
as immune modulators for the treatment of a wide range of diseases including 
asthma, rheumatoid arthritis, and cancer. [ 4 ] Toll-like receptors have many 
properties that make them attractive therapeutic targets such as overexpression 
in disease, knockout mice being resistant to disease, ligands exacerbating 
inflammation in disease models and genetic differences in TLRs or their 
signaling proteins correlate with risk of disease. [5] Several TLR agonists have 
been examined in clinical trials and for example the TLR4 agonist 
monophosphoryl lipid‐A (MPL) has been shown to possess favorable properties as 
adjuvant for vaccination [6] 
 
A concern of the use of TLR agonists is that they may over-activate the innate 
immune system leading to severe inflammation.  [ 7 ] Furthermore, TLR agonists 
induce a wide range of responses someone which might be beneficial whereas 
others harmful. Thus, the design of safe immune modulators requires a detailed 
knowledge of structure-activity relationships to harness beneficial effects 
without causing toxicity. This information is difficult to obtain by using 
isolated compounds due to structural heterogeneity and possible contaminations 
with other inflammatory components. The synthesis and immunological evaluation 
of panels of well-defined TLR ligands can address this deficiency.  
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Malaria and GPI 
 
Malaria is a mosquito-borne infectious disease of human and other animals 
caused by eukaryotic protist (a type of microorganism) of the genus plasmodium. 
The disease results from the multiplication of Plasmodium parasites within red 
blood cells, causing symptoms that typically include fever and headache, in 
severe cases progressing to coma or death. It is widespread in tropical and 
subtropical regions, including much of Sub-Saharan Africa, Asia and the 
Americas.  [8] (Figure 2) 
 
Figure 2 Countries with high risk of Malaria 
 
A particular form of malaria, referred to as pregnancy associated malaria, is 
especially distressing because it intervenes at the very beginning of human 
life causing maternal anemia, poor pregnancy outcomes and death. A mosquito 
infects a person by taking a blood meal. First, sporozoites enter the 
bloodstream, and migrate to the liver. They infect liver cells (hepatocytes), 
where they multiply into merozoites, rupture the liver cells, and escape back 
into the bloodstream. Then, the merozoites infect red blood cells, where they 
develop into ring forms, trophozoites and schizonts which in turn produce 
further merozoites. Sexual forms (gametocytes) are also produced, which, if 
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taken up by a mosquito, will infect the insect and continue the life cycle. 
(Figure 3) Among all the Malaria, infections caused by plasmodium falciparum 
take account for about 90% of the deaths. [9] 
  
 
Figure 3. Malaria life cycle 
 
During malaria infection, the host produces high levels of proinflammatory 
cytokines that have important roles in controlling parasite growth and govern 
the specificity and effectiveness of adaptive immunity. However, the 
proinflammatory mediators can be harmful when overproduced and population 
studies in malaria endemic areas and animal models indicate that excessive 
production of cytokines is associated with the pathology of malaria.[*9] 
Glycosylphosphatidylinositol (GPI) of P. falciparum is an important factor in 
the induction of proinflammatory responses and it has been shown to initiate 
such responses by interacting with TLR2. [10] 
 
GPI – Introduction -  
 
138 
 
 
Innate Immune responses elicited by CPI anchors of Plasmodium falciparum 
 
People in endemic areas have anti-GPI antibodies, which provide some protection 
against malaria symptoms. Research found that immunizations of mice with a 
synthetic glycan moiety of P. falciparum GPI could elicit anti-GPI antibodies, 
which prevent progression to cerebral malaria. [11] It has been suggested that 
inhibition of GPI-induced inflammatory responses will be a more effective 
approach for combating the pathology of malaria.[*10]  
 
GPIs, which are expressed ubiquitously by eukaryotes, are primarily involved in 
anchoring proteins to the cell surface. [ 12 ] The basic structure of GPIs 
comprises a conserved ethanolamine phosphate-substituted oligosaccharide moiety, 
(EtN-P-6Manα(1-2)Manα(1-6)Manα(1-4)GlcN) linked to phosphatidylinositol.[ 13 ] 
GPIs expressed by different organisms differ in the nature and composition of 
the lipids as well as in having additional sugars and/or ethanolamine-
phosphates attached to the conserved glycan. These variations confer broad 
structural diversity and may impart functional roles to GPIs. Characteristic 
features of parasite GPI include the presence of a saturated fatty-acyl moiety 
at the sn-1 position, an unsaturated fatty-acyl residue at Sn-2 of glycerol and 
a saturated fatty-acyl substituent at C-2 of inositol (Fig. 4).[14] 
 
The innate immune receptor TLR2 can be activated with GPI derived from the 
parasite P. falciparum, which is the causative agent of malaria, without 
responding to self GPIs. Although it is known that human and P. falciparum GPIs 
differ in some structural aspects, [15] specific features that are important for 
TLR2 binding and inducing proinflammatory response have not been established. 
Such information, however, is critical for understanding host-parasite 
interactions and for developing cell-based screening assays for indentifying 
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inhibitors of GPI-initiated cytokines production. 
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Figure 4 GPI anchors of Plasmodium falciparum 
 
Chemical Synthesis and innate properties of Plasmodium falciparum GPI anchors 
 
It has been proposed that inhibition of GPI-induced proinflammatory responses 
will provide an approach to combat the pathology of malaria [ 16 ]. Such a 
therapeutic strategy requires, however, a detailed knowledge of the structural 
features of GPI responsible for inducing proinflammatory responses. 
 
Therefore, the purpose of this work is to develop a reliable synthetic 
methodology that give easy access to a wide range of GPIs derivatives for 
structure activity relationship studies, and furthermore, rely on possible 
biological studies onto the synthesized molecules to define the structural 
features of GPI which are critical for TLR-mediated inflammatory responses.  
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P. falciparum GPI displays considerable structural heterogeneity and differs 
considerably from human GPI (Fig. 4). In particular, human GPI contains mainly 
alkyl substituents, which are longer in chain length and have a higher degree 
of unsaturation than those of parasites. It has been found that cleavage of GPI 
into oligosaccharide and phosphate inositol lipid abolishes proinflammatory 
responses, indicating that both lipid and carbohydrate are critical for 
activity. [17] Furthermore, enzymatic remodeling of GPI suggests that a compound 
containing a core tri-mannoside represents the minimum structure for activity. 
[18] 
 
Above all, for the purpose of establishing a reliable GPI synthesis strategy 
and preliminary structure activity relationship, three preliminary target 
molecules were designed (Figure 5), which represent : 1 ) different lipid chain 
saturation;  2) acyl vs. alkyl linked phosphonate lipids; 3) trisacchcaride and 
disaccharide.   
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Figure 5. Target molecules 1a, 1b and 2 
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Consideration of convergent approach for the synthesis of GPI anchors 
 
Several attractive strategies have been developed for the synthesis of GPI 
anchors. [19 ] In general, these approaches employ benzyl ethers as a permanent 
protecting group, and therefore cannot be used for the synthesis of compounds 
having unsaturated fatty acids. To address this problem, benzoyl esters have 
been used as permanent protecting group. However, their removal resulted in 
partial loss of fatty esters. [ 20 ] Guo and coworkers introduced a more 
attractive approach that employed p-methoxybenzyl (PMB) ethers for permanent 
protection.[ 21 ] PMB ethers can be removed by acid treatment or oxidation with 
DDQ and hence are compatible with the presence of alkenes. However, this 
approach did not use C-2 esters for controlling anomeric selectivities in 
glycosylations. Furthermore, PMB ethers are rather fragile in acid catalyzed 
glycosylation and can cause difficulties for the preparation of complex 
compounds. 
 
The methyl naphtyl (NAP) ether has been recently introduced as novel protecting 
group in carbohydrate synthesis, and can be easily removed in high yield by 
oxidation with DDQ [ 22 ]. In previous projects of Boons’ research group in 
University of Georgia, NAP ether has been used as a permanent protecting group, 
and could be removed as many as ten by using DDQ oxidation. [23] NAP ether is a 
more attractive permanent protecting group than the PMB ether because of its 
much higher acid stability [24]. Therefore, in this synthetic work towards GPI 
anchors, the NAP will be employed as a permanent protecting group. 
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Besides, Fmoc, Lev and TDS will be used as orthogonal protecting groups for 
parallel combinatorial synthesis of complex oligosaccharides. These protecting 
groups can be removed under mild conditions without affecting fatty acids of 
GPI final products. Furthermore, Lev and Fmoc will ensure neighboring group 
participation in glycosylations thereby controlling 1,2-trans selectivities, 
which will be convenient for the Building blocks assembly.  
 
 
Above all, the synthesis work towards target molecules 1a, 1b and 2 will be 
described in the following chemistry section .  
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GPI-CHEMISTRY SECTION 
 
1 Target Molecule and retrosynthetic analysis: 
 
The synthesis work of the designed GPI target molecules: disaccharides 1a and 
1b and trisaccharide 2 (Figure 1) will be described in this part. 
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21a: R1 = COC13H27,  R2 = COC13H27;  
1b: R1 =  CO(CH2)7CH=CH(CH2)7CH,  R2 =  C16H33  
 
Figure 1. Target molecules 
 
As discussed in the introduction part, the two disaccharides bear the same 
inositol acylation (COC13H17). However, for the purpose of research, they carry 
different phosphate lipid group (saturated lipid in 1a and unsaturated lipid in 
1b). The trisaccharide 2 shares the same lipid group with disaccharide 1a, and 
has an extra mannose moiety at its C-6 position.   
 
The retrosynthetic analysis of the target molecules is outlined in Scheme 1. 
Several protecting groups will be employed in this project like NAP, Lev and 
Fmoc (see the introduction part).  
 
Taki the trisaccharide 2 as an example, fatty acid acylation and 
phosphorylation onto the trisaccharide intermediate 3 could generate the fully 
protected precursor. Intermediate 3 could be obtained by the glycosylation 
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between pseudodisaccharide acceptor 5 and mannosyl donor 4, while 5 could be in 
turn achieved from conjugation between inositol 6 and a suitable glucosamine 
donor 7.    
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Scheme 1. Retrosynthetic approach 
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2. Building blocks synthesis 
The first part of the work is the preparation of the needed building blocks, 
namely the inositol 6, the gluocosamine donor 7 and the mannosyl donor 4. 
 
2.1 Synthesis of an optically pure myo-inositol derivative 6 
Recently, Fraser-Reid group developed a novel methodology for the preparation 
of an optically pure myo-inositol acceptor starting from commercially available 
methyl glucoside [ 1 ] (Scheme 2). The procedure relied on the discovery that 
enolesters could undergo the Ferrier reaction with excellent stereocontrol [2]. 
Among all the published GPI chemical synthesis work, this strategy represents 
the most efficient synthesis of myo-inositol. Therefore, our synthetic work 
towards this moiety was mainly carried out on the basis of this method.  
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Scheme 2. Synthesis of myo-inositol derivative by Fraser-Reid group. 
 
 
 
Thus, as shown in Scheme 3, C-6 hydroxyl group in glucoside 8 was selectively 
protected in the presence of tert-butyldimethylsilyl chloride (TBDMSCl), TEA, 
DMAP and DMF, to afford compound 9 in 86% yield. Then the remaining C-2, C-3 
and C-4 hydroxyl groups were all protected as NAP-ehters in condition of sodium 
hydride, 2-(naphthyl)methyl bromide (NAPBr), TBAI and DMF, to provide fully 
protected intermediate 10 in 90% yield. Removal of the C-6 silyl group using 
tetrabutylammonium fluoride delivered compound 11 in 90% yield. Then 11 was 
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converted into aldehyde 12 by using IBX oxidation, followed by enol acetylation 
to afford the enol acetate 13 in 2 steps in 72% yield. With higher oxidation 
efficiency and simpler work up (without column purification), the IBX oxidation 
proved to be more efficient than the previously published Moffat oxidation or 
Swern oxidation conditions [1]. 
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Scheme 3. Synthesis of 6 
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Then, on treatment with mercury(II) trifluoroacetate, the enol acetate 13 
underwent type II Ferrier rearrangement, and furnished cyclohexan-6-one 14 in 
62% yield. The reduction of the ketone 14 into intermediate 15 was successfully 
accomplished by using tetramethylammonium triacetoxy borohydride in 78% yield. 
The stereoselectivity in this reduction is likely a result of the axial 2-
position hydroxyl group coordinating to the reducing agent, leading to hydride 
delivery from the top face and therefore to the equatorial hydroxyl group at 
the 6-positon [3]. Removal of the acetyl protection of 15 afforded the triol 16 
in 94% yield. Finally, 1,2-O-cyclohexylidenation of the triol 16 in the 
presence of cylcohexanone, catalytic amount PTSA and trimethyl orthoformate by 
using acetonitrile as a solvent furnished the required 6-OH D-myo-inositol 
derivative 6 in 89% of yield.  
 
In short, synthesis of 6 from commercial starting material 8 was accomplished 
in nine steps in 20.2% yield in gram scale.  
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2.2 Synthesis of glucosamine building block 7 and 7a 
 
For the synthesis of glucosamine building block 7, as shown in Scheme 5, first, 
treatment of commercially available 17 under typical Zemplén conditions by 1M 
solution of sodium methoxide in methanol afforded de-acetylated compound 18. 
The methyl naphtyl acetal was then used to protect C-4 and C-6 hydroxyls by 
using 2-(dimethoxymethyl)naphthalene and  a catalytic amount of 
Camphorsulfonic acid (CSA), to provide 19 in two steps in 85% yield. Alkylation 
of C-3 hydroxyl by using sodium hydride, NAPBr, TBAI and THF led to compound 20 
in 92% yield. After this, the methyl naphtyl acetal was selectively opened in 
the presence of triethylsilane and TfOH to reveal the C-4 hydroxyl group, 
providing 21 in 86% yield. 
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Scheme 5. Synthesis of glucosamine building block 
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Installation of a Lev group at the C-4 hydroxyl on intermediate 21 was 
accomplished with levulinic acid, dicyclohexylcarbodiimide (DCC) and DMAP, and  
generated 22 in yield of 90%. The Lev group will allow to delivery of the C-4 
hydroxyl for the glycosylation with the mannosyl moiety in the synthesis of the 
trisaccharide. Then the anomeric silyl group of 22 was removed by using 
hydrogen fluoride in pyridine, to provide isomer 23 in 87% yield. Eventually, 
23 was turned into glycosyl trichloroacetimidate 7 (81%) with 
trichloroacetonitrile, DBU in DCM.   
 
Briefly, the preparation of building block 7 was achieved by seven steps in 
42.6% yield in multigram scale.   
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2.3 Synthesis of mannose building block 4 
 
Preparation of mannosyl donor 4 started with commercially available D-mannose 
31. After fully acetylation in pyridine and acetic anhydride; installation of 
the thiophenyl moiety at the anomeric position was achieved with thiophenol and 
boron trifluoride in ether; After Zemplén deacetylation with sodium methoxide 
and methanol, 34 was obtained in three steps in 65% yield [ 4 ].  C-4 and C-6 
hydroxyls of compound 34 were then protected by 2-(naphthyl) methylene acetal 
with 2-(dimethoxymethyl)naphthalene and CSA in DMF, affording 35 in 93% yield. 
Then the C-3 hydroxyl was selectively alkylated by NAP ether applying a Tin-
mediated method (Bu2SnO, NAPBr and TBAI) [ 5 ], leading intermediate 36 in 82% 
yield. 
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Scheme 6. Synthesis of mannose building block 
GPI- Chemistry Section- 
153 
 
 
 
Subsequently, C-2 hydroxy group of 36 was protected as Fmoc ether in pyridine 
with FmocCl (87%), to deliver product 37. Then the methyl naphtyl acetal of 37 
was selectively opened by using BH3/THF solution and a catalytic amount of 
copper(II) triflate to reveal the C-6 hydroxy group [ 6 ], affording 38 in 86% 
yield. Then, C-6 hydroxyl of 38 was protected by Lev group with levulinic acid, 
DCC and DMAP, giving compound  4 in 81% yield.( Scheme 6)  
 
Thus, synthesis of mannosyl building block 4 was carried out in eight steps in 
29.3% overall yield.  
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3.  Building blocks assembling 
 
With all the needed building blocks in hand, the next stage of the work is the 
oligosaccharides (disaccharide and trisaccharide) assembly. This part of the 
work included both the inositol 6 glycosylation with glucosamine donor 7 to 
construct disaccharide 5 and the mannose glycosylation reaction between 
disaccharide acceptor 40 and mannosyl donor 4 to achieve trisaccharide 41.  
 
3.1 Inositol glycosylation 
3.1 Using glysosyl trichloroactimidate donor 
 
For the synthesis of pseudodisaccharide precusor 5, TMSOTf-promoted 
glycosylation between acceptor 6 and glycosyl trichloroacetimidate donor 7 was 
expected to produce mainly the α-anomer product [ 7 ]. Therefore, the reaction 
was carried out under typical glycosylation condition by using catalytic amount 
of TMSOTf (Scheme 7).  
 
 
HO
O
ONAPO
ONAP
ONAP
6
NAPO
LevO
NAPO
N3
O
O
NH
CCl3
7
O
O
ONAPO
ONAP
ONAP
5
NAPO
LevO
NAPO
N3
O
0.05eq TMSOTf
 
 
Scheme 7. Inositol glycosylation using glysosyl trichloroactimidate donor 
 
 
GPI- Chemistry Section- 
155 
 
However, the result of the inositol glycosylation proved to be not satisfactory. 
Both the yield of reaction and the stereoselectivity of glycosylated product 
were quite low（table 1）. Using different solvent system and temperature did 
not help to improve the reaction.(Table 1) The main reason for this result is 
the relatively low reactivity of the C-6 hydroxyl of inositol [8]. Besides, the 
presence of C-2 azido group on glycosyl donor 7 increases the difficulty for 
glycosylation.  Although there are many reports dealing with the inositol 
glycosylation, the use of traditional glycosylation methods to afford inositol 
pseudodisaccharide still seems to be quite difficult.[9]  
 
 
 
Table 1 Conditions for Inositol glycosylation using glysosyl 
trichloroactimidate donor 
Entry Solvent Temp Time Yield α:β 
1 Et2O -20 ℃ 12 h 25% 1.5:1 
1 Toluene -40 ℃ to rt 12h trace  
1 THF  -40 ℃ to rt 6 h trace   
1 CH2Cl2 -40 ℃ to rt 6 h 30% 1:1 
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3.2 using glycosyl (N-phenyl)trifluoroacetimidates donor 
 
The recently published reports which relied on glycosyl (N-
phenyl)trifluoroacetimidates as glycosyl donors to construct efficiently α -
glucosamine products have drawn our attention [10]. Encouraged by these results, 
we therefore decided to test the glycosyl (N-phenyl)trifluoroacetimidate donor 
onto our inositol glycosylation.  
 
Thus, as shown in Scheme 8, hemiacetal 23 was transformed to donor 7b with 
cesium carbonate and 2,2,2-Trifluoro-N-phenylacetimidoyl Chloride in DCM in 83% 
yield. 
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Scheme 8. Inositol glycosylation using glycosyl (N-phenyl)trifluoroacetimidates 
donor 
 
Surprisingly, the glycosylation between 7b and 6, after several attemps (Table 
2), produced pseudodisaccharide precusor 5 in 69% yield  with exclusive α-
configuration at the newly formed glycosylation bond. This result, to the best 
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of our knowledge, represents the highest yield and best stereo-control ever 
described in GPI’s inositol glycosylation. Although the mechanism has still 
not been clarified yet, this method seems a reliable strategy for the inositol 
glycosylation, and the reaction could be scaled up to five hundreds milligram 
scale with stable yield.  
 
 
 
 
Table 2 Conditions for Inositol glycosylation using glycosyl (N-
phenyl)trifluoroacetimidate donor 
Entry Solvent Temp Time 7a : 6 yield 
1 CH2Cl2 -40 ℃ 2 h 1.5 : 1 52% 
1 CH2Cl2 -20 ℃  2 h 2 : 1 61% 
1 CH2Cl2  0 ℃  1 h  1.2 : 1 64% 
1 CH2Cl2 -10 ℃  1 h 1.5 : 1 69% 
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3.2 Mannose Installation 
 
After the synthesis of pseudodisaccharide 5, the next stage work is to assemble 
the α- mannose moiety onto C-4 hydroxyl group to establish trisaccharide. Thus, 
as shown in Scheme 9, C-4 O-Lev group of disaccharide 5 was first removed by 
using hydrazine actetate, delivered 40 in 70% yield. Then the glycosylation 
between thiophenyl mannosyl donor 4 and 40 was carried out in the in DCM with 
NIS/silver triflate as promoter system to provide trisaccharide 41 in 70% yield. 
As C-2 fmoc of donor 4 performed neighboring group participating effect during 
the glycosylation, exclusively α-product was generated.  
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Scheme 9. Synthesis of trisaccharide 
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4. Lipid Introduction (disaccharide) 
 
 
After the successful synthesis of the disaccharide and trisaccharide precursors, 
the next stage of the work was the lipid introduction. This part of the work 
included the selective acylation of inositol’s C-2 axial hydroxyl and the 
phosphorylation of inositol’s C-1 equatorial hydroxyl.   
 
4.1 Selective Acylation  
 
The selective acylation started with disaccharide 5. First, cyclohexylidene 
moiety of 5 was removed using 0.5 M Hydogen chloride in methanol to give diol 
44 in  80% yield. (Scheme 10) 
 
O
O
ONAPO
ONAP
ONAP
5
NAPO
LevO
NAPO
N3
O
C13H27CN
C13H27C M HCl/ Et2O
MeOH NH HCl
OMe C13H27C(OMe)3
MeOH
Et2O
42 43
O
HO
OHNAPO
ONAP
ONAP
44
NAPO
LevO
NAPO
N3
O
CH2Cl2 80%
MeOH/HCl
 
Scheme 10. Synthesis of diol 44 and trimethyl orthoester 43 
 
Studies by Frasier-Reid and coworker  have shown that the axial C-2 position of 
the resulting inositol diol can be selectively acylated by treatment with alkyl 
trimethyl orthoester to generate a cyclic orthoester intermediate, which upon 
treatment with Ytterbium(III) triflate will regioselectively open to the axial 
C-2 position to give the C-2 acylated compound [ 11 ]. Thus, following their 
strategy, freshly prepared trimethyl orthopalmitate 43 [12] was mixed with diol 
44 in acetonitrile in 40 ℃ with a catalytic amount of CSA to generate the 
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cyclic orthoester. Then, after simple work up (quenched with triethylamine and 
solvent evaporation), and treatment with 0.5 equiv of Ytterbium(III) triflate 
in DCM, the desired C-2 acylated compound 45 was obtained as a main product in 
73% yield with traces C-1 acetylated byproduct (Scheme 11).  
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Scheme 11. Acetylation of Inostol 
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4.2 Phosphorylation （Lipid） 
 
After the selective acylation of C-2, the last functionalizeation step is the 
installation of the phospholipid group at C-1 position. According to our 
previous experiences in the synthesis of phosphodiesters, we chose to rely on 
the H-phosphonate coupling strategy to achieve the C-1 phosphorylation.   
 
Therefore, for preparing the glycosyl H-phosphonate compound, a solution of 45 
in acetonitrile was added dropwise to the phosphorus trichloride- imidazole - 
triethylamine mixture reagent to generate the H-phosphonate intermediate. After 
work up and purification by flash chromatography column, the sugar H-
phosphonate  was recovered as its triethylammonium salt 46. [13]  
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Scheme 12. Synthesis of 48  
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Then, freshly prepared H-phosphonate 46 was coupled with alcohol 47 under 
typical reaction condition (using pivaloyl chloride as promoter, followed by in 
situ oxidation), providing protected disaccharide precursor 48 with saturated 
lipid chain over two steps in 64% yield. (Scheme 12) 
 
 
To prepare the protected precursor 50 containing unsaturated lipid chain, H-
phosphonate 46 was coupled with alcohol 49, which was synthesized as described 
in the literature [ 14 ]. After condensation and in situ oxidation, compound 50 
was obtained in two steps in 78% yield over two steps.  
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Scheme 12. Synthesis of 50  
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5. Global Deprotection 
 
The final part of the work is the removal of all the protecting groups, which 
involved azide-amine conversion, NAP ether removal and O-Lev and O-Fmoc 
cleavage.  
 
5.1 Synthesis of 1-a 
 
For the synthesis of 1-a, first, the azido group of 48 was transformed into 
amine by using 1,3-propanedithiol, pyridine and water in 82% yield, leading to 
52. Traditional Staudinger reduction and Zinc-mediated reduction only delivered 
the amine product in very low yield (<40%). Thereafter, the remaining NAP ether 
groups were cleaved by hydrogenolysis over 10% palladium on carbon in dioxane 
to generate 53 and the remaining O-Lev group of 53 was finally removed in the 
presence of hydrazine acetate in chloroform and methanol, affording 1-a in 65% 
yield in two steps. (Scheme 13) 
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Scheme 13. Synthesis of 1-a (Target molecular contains saturated lipid chain) 
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5.2 Synthesis of 1-b 
 
For disaccharide 1-b, the azide reduction under the same condition described 
above provided 55 in 95% yield. As the precursor 55 contained unsaturated lipid 
group, the removal of NAP ether groups was carried out using DDQ oxidation, 
which did not influence the lipid chain [ 15 ]. The purification of the crude 
product resulting from DDQ oxidation relied on preparative TLC to remove most 
of the DDQ byproduct, followed by C18 reverse phase column, generating 56. 
After the cleavage of the Lev group in 56 with hydrazine acetate, the target 
molecule 1-b was obtained in 80% over two stpes.   (Scheme 14) 
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Scheme 14. Synthesis of 1-b(Target molecular contains unsaturated lipid chain) 
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6.  Synthesis of 2 
 
  
The synthesis of trisaccharide 2 is still on the course, as outlined un Scheme 
15, the selective introduction of the fatty acid at C-2 position on inositol 
moiety of trisaccharide 41 will give intermediate 57; installation of 
phospholipid at C-1 position will generate protected precursor 58. After the 
global deprotection steps (azide reduction, hydrogenation and Fmoc, Lev 
cleavage), the target molecule 2 will be obtained.  
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Scheme 15. Synthesis of 2 (Trisaccharide target molecular) 
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CONCLUSION 
 
In summary, the design and synthesis of GPI anchors of plasmodium-falciparum 
have been described.  
 
The target molecules 1a and 1b and the protected trisaccharide precursor 41 
were synthesized. 
  
A convergent approach for preparing GPI molecules was established during the 
synthesis course. Several difficulties like selectively α -glycosylation on 
inositol moiety, selectively fatty acid acetylation at C-2 position of inositol 
and phosphonate lipid introduction have been addressed during the synthesis 
work.   
 
NAP ether was first employed as permanent protecting group as GPI synthesis, 
and was proved to be practical in synthesis work. Removal of NAP ether could be 
achieved by DDQ oxidation which does not affect the unsaturated phosphonate 
lipid moiety.  
 
Synthesis of trisaccharide 2 and more advanced oligosaccharides will be carried 
out in the future following the similar strategies. 
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EXPERIMENTAL PART 
 
General: Reagents were obtained from commercial sources and used as 
purchased. Dichloromethane was freshly distilled using standard procedures. 
Other organic solvents were purchased anhydrous and used without further 
purification. Unless otherwise noted, all reactions were carried out at 
room temperature in oven-dried glassware with magnetic stirring. Molecular 
sieves were flame-dried under high vacuum prior to use. Organic solutions 
were concentrated under diminished pressure with bath temperatures < 40 ℃. 
Flash column chromatography was carried out on silica gel G60 (Silicycle, 
60-200 μm, 60Å). Thin-layer chromatography was carried out on Silica gel 
60 F254 (EMD Chemicals Inc.) with detection by UV absorption (254 nm) were 
applicable, and by spraying with 20% sulfuric acid in ethanol followed by 
charring at 150℃ or by spraying with a solution of (NH4 )6Mo7O24 .H2O (25 
g/L) in 10% sulfuric acid in ethanol followed by charring at 150℃. 1H, 13C 
NMR and 31P spectra were recorded on a Varian Inova-400 (400/100 MHz) or a 
Varian Inova-500 (500/125 MHz), spectrometer equipped with Sun work 
stations. Multiplicities are quoted as singlet (s), broad singlet (br s), 
doublet (d), doublet of doublets (dd), triplet (t), or multiplet (m). 
Spectra were assigned using COSY, DEPT, and HSQC experiments. Mass spectra 
were recorded on an Applied Biosystems 4800 MALDI-TOF proteomics analyzer. 
The matrix used was 2,5-dihydroxybenzoic acid (DHB) as the internal 
standard. 
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6-O-tert-Butyldimethylsilyl-methyl-D-glucopyranoside, 9 
 
HO
HO
HO
OH
OMe
O
TBDMSO
HO
HO
OH
OMe
OTBDMSCl
DMF, Et3N, DMAP
8 9  
 
Synthetic Procedure: 
To a stirred solution of methyl-glucopyranoside 8 (10 g, 51 mmol), 
triethylamine (25 mL, 180 mmol), and DMAP (330 mg, 2.7 mmol) in DMF (100 mL) at 
0 ℃ was added TBDMSCl (8.5 g, 56 mmol). The reaction was then allowed to 
proceed at room temperature for 12 h. Upon reaction completion, the mixture was 
poured over ice-water (100 mL) and extracted with CH2Cl2 (250 mL), and the 
organic mixture was washed with saturated NH4Cl solution and brine (150 mL, 
each). The organic extract was then dried over Na2SO4 and stripped of solvent 
in vacuum, and the concentrated residue was purified by flash column 
chromatography (10% MeOH/ CH2Cl2) to afford 9 (14.98 g, 86% ) as a white solid 
 
Product characterization 8 
Formula C13H28O6Si 
Molecular Wright 308.44 
TLC conditions Rf: 0.35, CH2Cl2 : MeOH = 9 : 1 
The spectroscopic data were in agreement with the reported data [1] 
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6-O-tert-Butyldimethylsilyl-2,3,4-tri-O-naphthylmethyl-methyl-D-glucopyranoside, 
10 
 
 
TBDMSO
HO
HO
OH
OMe
O NAPBr, NaH
TBAI, DMF
9 10
TBDMSO
NAPO
NAPO
NAPO OMe
O
 
 
 
Synthetic Procedure 
 
To a stirred solution of 9 (1.9 g, 6.15 mmol) in DMF (23 mL), NAPBr (5.45 g, 
24.9 mmol) was added at room temperature. Then NaH (60%, 1 g, 24.96 mmol) and 
TBAI (227 mg, 0.6 mmol) were slowly added at 0℃. The reaction was then allowed 
to stir at room temperature for 2 h. Upon reaction completion, the mixture was 
quenched with methanol (5 mL) and diluted with ethyl acetate (30 mL). The 
organic mixture was washed with saturated NH4Cl solution (20 mL) and brine (10 
mL). The organic phases were dried (Na2SO4), filtered, and concentrated. The 
crude was purified by flash chromatography (5-10% EtOAc/Hexane), providing 10 
(4.06 g, 90 %) as a clear oil. 
 
 
Product characterization 10 
Formula C46H52O6Si 
Molecular Wright 728.99 
TLC conditions Rf: 0.5, Hexane : EtOAc = 9 : 1 
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1H  NMR (CDCl3 , 400 MHz) δ 7.87–7.23 (m,21 H, HAr); 5.21-4.80 (m, 6 H, 3 
CH2NAP); 4.58 (d, J = 12 Hz, 1 H, H-1); 4.20-4.02 (m, 1 H, H-2); 3.80-3.75 
(m, 2 H, H-4, H-6); 3.70-3.54 (m, 3 H, H-6’, H-3, H-5); 3.40 (m, 3 H, 
OMe);0.92 (s,9 H, 3 CH3Si); 0.08 (s, 3 H,  CH3Si); 0.07 (s, 3 H,  CH3Si);  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 751.9, found: 751.4 
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 2,3,4-tri-O-naphthylmethyl-methyl-D-glucopyranoside,11 
 
TBDMSO
NAPO
NAPO
NAPO OMe
O
HO
NAPO
NAPO
NAPO OMe
O
TBAF/THF
10 11   
 
Synthetic Procedure: 
To a stirred solution of 10 (3.98 g, 5.46 mmol) in THF (50 mL), 1 M TBAF (6 mL, 
6 mmol) was added at 0℃, and the reaction was then allowed to stir at room 
temperature for two hours. Upon reaction completion, CH2Cl2 (100 mL) was added, 
and washed with saturated NH4Cl solution (40 mL). The organic phases were dried 
(Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (33% EtOAc/Hexane), providing 11 (3.01 g, 90 %) as white solid. 
 
Product characterization 11 
Formula C40H38O6 
Molecular Wright 614.73 
TLC conditions Rf: 0.3, Hexane : EtOAc = 2 : 1 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.85–7.21 (m,21 H, HAr); 5.22-4.75 (m, 6 H, 3 
CH2NAP); 4.60 (d, J = 12 Hz, 1 H, H-1); 4.20-4.02 (m, 1 H, H-2); 3.80-3.45 
(m, 5 H, H-4, H-6, H-6’, H-3, H-5); 3.40 (m, 3 H, OMe);  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 637.7, found: 637.6 
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Methyl 6-O-acetyl-2,3,4-tri-O-naphthylmethyl-a-D-glucohex-5-enopyranoside,13 
 
 
HO
NAPO
NAPO
NAPO OMe
O
O
NAPO
NAPO
NAPO OMe
O Ac2O,TEA,DMAP
ClCH2CH2Cl
IBX
11 12
Acetone
OAc
NAPO
NAPO
NAPO OMe
O
13
 
 
Synthetic Procedure: 
 
From 11 to 12: 
 
11 (3.5 g, 5.7 mmol) was dissolved in dry acetone (150 mL), freshly prepared 
IBX (4.9 g, 17 mmol) was added to the solution. The reaction mixture was 
allowed to stir at 50℃ for 12 hours. Upon reaction completion, the suspension 
was cool down to room temperature and filtrated through a Celite pad.  The 
Celite pad was washed by CH2Cl2 (200 mL). The resulting solution was then 
concentrated and covapored with toluene for three times (50 mL * 3), affording 
crude of 12 4.2 g as a yellow oil. 
 
From 12 to 13  
 
To a solution of 12 (4.2 g) in ClCH2CH2Cl (100 mL), triethylamine (2.8 mL, 
20mmol), Acetic anhydride (1.9 mL, 20 mmol) were added, and the reaction 
mixture was stirred at 80℃ for 5 hours. After TLC analysis showed consumption 
of starting material, the mixture was cooled to room temperature and 
concentrated. The residue was purified by flash chromatography (20% 
EtOAc/Hexane), providing 11 (2.68 g, 72 %) as white wax. 
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Product characterization 12 
Formula C40H36O6 
Molecular Wright 612.71 
TLC conditions Rf: 0.25, Hexane : EtOAc = 3 : 1 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 635.7, found: 634.8 
 
 
Product characterization 13 
Formula C42H38O7 
Molecular Wright 654.75 
TLC conditions Rf: 0.25, Hexane : EtOAc = 5 : 1 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.85–7.21 (m,22 H, HAr, RC=CHOAc); 5.22-4.75 (m, 7 H, 
3 CH2NAP, H-1); 4.60 (d, J = 12 Hz, 1 H, H-1); 4.20-4.02 (m, 2 H, H-2, H-3); 
3.80-3.45 (m, 1 H, H-4); 3.40 (m, 3 H, OMe); 2.27, (s, 3 H, OAc) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 677.7, found: 677.3 
 
 
GPI – Experimental Part -  
176 
 
 2-hydroxy-3,4,5-tri-O-naphthylmethyl- 
6-oxocyclohexyl acetate 8 
 
 
NAPO
NAPO
NAPO OH
O
OAc
Hg(OOCCF3)2
Acetone: H2O
14
OAc
NAPO
NAPO
NAPO OMe
O
13  
 
Synthetic precedure: 
 
 
To a solution of 13 (1.9 g, 2.907 mmol) in acetone (80 mL) and water (20 mL) 
was added mercury(II) trifluoroacetate (1.41g, 3.49 mmol). The mixture was 
sttired at room temperature for 1 hours.  After TLC analysis indicating 
consumption of the 13, the suspension was diluted with brine (50 mL) and 
stiired for another 1 hour. Then CH2Cl2 was added to dilute the mixture and the 
organic phase was dried (Na2SO4), filtered, and concentrated. The crude was 
purified by flash chromatography (33% EtOAc/Hexane), providing 14 (1.27 g, 62 %) 
as white wax.  
 
Product characterization 14 
Formula C41H36O7 
Molecular Wright 640.72 
TLC conditions Rf: 0.25, Hexane : EtOAc = 5 : 1 
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1H  NMR (CDCl3 , 400 MHz) δ 7.85–7.21 (m,21 H, HAr); 5.25 (m, 1 H, H-1), 5.20-
4.66 (m, 6 H, 3 CH2NAP); 4.38 (brs,1 H, H-2); 4.32-4.18 (m, 2 H, H-4, H-5); 
3.85 (m, 1 H, H-3); ); 2.63 (brs, 1 H, OH); 2.27, (s, 3 H, OAc) 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 167.1 181.8 ((COCH3), C=O); 133.5-121.0 (C-Ph); 
83.2. (C-4); 82.8 (C-5); 80.5 (C-3); 78.8 (CH2Ph); 75.4 (C-1); 74.4 
(2CH2Ph); 70.1 (C-2) 23.3 (OAc)  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 663.7, found: 663.6 
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1-O-Acetyl-3,4,5-tri-O-naphthylmethyl-D-myo-inositol 15 
 
 
 
NAPO
NAPO
NAPO OH
O
OAc
CH3CN/AcOH
Me4NBH(OAc)3 NAPO
NAPO
NAPO OH
HO
OAc
14 15  
 
 
Synthetic Procedure: 
 
A mixture of acetic acid (12 mL) and acetonitrile (12 mL) was cooled to -40℃ 
and to this was added tetramethylammonium triacetoxyborohydride (3.07 g, 11.7 
mmol).After 10 mins, a solution of 14 (1.5 g , 2.34 mmol) in CH2Cl2 (15 mL) and 
CH3CN (15 mL) were added to the mixture, at -40℃. Then the reaction mixture 
was stiired at room temperature for 3 hours. After TLC analysis indicating 
consumption of the 14, the reaction was quenched by the addition of aqueous 
saturated Rochelle’s Salt solution (15 mL). Then the CH2Cl2 was added and 
washed with brine, the organic phase was dried (Na2SO4), filtered, and 
concentrated. The crude was purified by flash chromatography (60% EtOAc/Hexane), 
providing 15 (1.17 g, 78 %) as white wax.  
 
 
Product characterization 15 
Formula C41H38O7 
Molecular Wright 642.26 
TLC conditions Rf: 0.4, Hexane : EtOAc = 1 : 2 
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1H  NMR (CDCl3 , 400 MHz) δ 7.82–7.17 (m,21 H, HAr); 5.23 (m, 1 H, H-1), 5.17-
4.66 (m, 6 H, 3 CH2NAP); 4.45-4.37 (m,1 H, H-2); 4.37-4.18 (m, 3 H, H-4, H-5, 
H-6); 3.85 (m, 1 H, H-3); 2.67 (brs, 1 H, OH); 2.27, (s, 3 H, OAc); 1.78 (brs,1 
H OH) 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 167.1(COCH3); 133.3-121.3 (C-Ph); 83.4 (C-4); 
82.5 (C-5); 81.5 (C-3); 79.2 (CH2Ph); 74.9 (C-1); 74.1 (2CH2Ph); 70.6 (C-2), 
69.3 (C-6); 23.3 (OAc)  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 665.2, found: 665.8 
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3,4,5-tri-O-naphthylmethyl-D-myo-inositol, 16 
 
 
 
NAPO
NAPO
NAPO OH
HO
OAc
NAPO
NAPO
NAPO OH
HO
OHLiOH
CH2Cl2 / MeOH
15 16  
 
 
 
Synthetic Procedure 
 
 
15 (1.15 g, 1.79 mmol) was dissolved in a mixture of CH2Cl2 (30 mL) and MeOH 
(30 mL). To this solution was added lithium hydroxide (42 mg, 1.76 mmol), and 
the mixture was stirred at room temperature for 1 hour, After TLC analysis 
indicating consumption of the starting material, the reaction was quenched by 
the addition of saturated NH4Cl solution (5 mL). Then the reaction mixture was 
diluted by CHCl3 (50 mL), and washed with brine, the organic phase was dried 
(Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (5-10% MeOH/ CH2Cl2), providing 16 (1.01 g, 94 %) as white solid. 
 
 
Product characterization 16 
Formula C39H36O6 
Molecular Wright 600.7 
TLC conditions Rf: 0.5, CH2Cl2 : MeOH = 19 : 1 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 623.7, found: 623.4
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1,2-O-cylcohexylidine-3,4,5-tri-O-naphthylmethyl-D-myo-inositol, 16 
 
 
NAPO
NAPO
NAPO OH
HO
OH
HO
O
ONAPO
ONAP
ONAP
Cyclohexanone
16 6
CH3CN,PTSA
(MeO)3CMe
 
 
 
Synthetic Procedure: 
 
16 (2 g, 3.3 mmol), Trimethyl orthoformate (2 mL, 16.7 mmol) and PTSA (120 mg, 
0.63 mmol) was disolved in CH3CN and the reaction was stiired at room 
temperature for 10 mins. Then cyclohexanone (12 mL, 112 mmol) was added, and 
the mixture was stirred at room temperature for another 2 hours. After TLC 
anylysis showing consumption of the starting material, the reaction was 
quenched by the addition of saturated NaHCO3 solution (50 mL). After extraction 
with CH2Cl2 (50 mL * 3), the organic phase was dried (Na2SO4), filtered, and 
concentrated. The crude was purified by flash chromatography (20% EtOAc 
/Toluene), providing 6 (1.99 g, 89 %) as white solid. 
 
 
Product characterization 6 
 
Formula C45H44O6 
Molecular Wright 680.83 
TLC conditions Rf: 0.3, EtOAc : Toluene = 1 : 4 
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1H  NMR (CDCl3 , 400 MHz) δ 7.80–7.05 (m,21 H, HAr); , 5.01-4.64 (m, 6 H, 3 
CH2NAP); 4.28-4.21 (m,1 H, H-2); 3.97-3.65 (m, 4 H, H-4, H-5, H-1, H-3); 3.29-
3.23 (m, 1 H, H-6); 2.67 (brs, 1 H, C-6-OH);); 1.78-1.41 (m ,8 H, 4 CH2), 1.21 
(m, CH2) 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 132.2-125.6 (C-Ph); 81.4 (C-6); 80.8 (C-4); 
78.5 (C-5); 76.7 (C-3); 75.0 (2 CH2Ph); 74.7 (C-1); 74.4 (C-2), 74.0 
(CH2Ph); 39.3, 35.2, 31.1, 27.8, 24.7, 24.5 (6 CH2)  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 703.3, found: 703.8 
GPI – Experimental Part -  
183 
 
 
Thexyldimethylsilyl 2-azido-4,6-Naptylmethylene-β-D-glucopyranoside,19 
 
 
 
AcO
AcO
AcO
N3
O
OTDS
HO
HO
HO
N3
O
OTDS
O
O
HO
N3
O
OTDS
MeONa
MeOH CSA, CH3CN
17 18 19
CH(OMe)2
 
 
 
Synthetic procedure: 
 
For 18 
 
17 (1 g, 2.88 mmol) was dissolved in 1M MeONa/MeOH solution (50 mL) under 
nitrogen atmosphere, the mixture was stirred at room temperature for 2 h, then 
the reaction mixture was neutralized to PH 7 with IR-120 resin, (H+ form, 
previously washed by MeOH), filtered, and concentrated, get a crude of 18 (740 
mg) as colourless oil. 
 
For 19: 
 
Crude of 18 (740 mg) was dissolved in dry acetonirile (30 mL), then 
dimethoxymethyl naphthalene (600 mg, 2.97 mmol) was added to the solution, 
followed by CSA (40 mg, 0.2 mmol). The reaction mixture was stirred at room 
temperature for 12 hours. After TLC analysis showing the consumption of 18, the 
reaction was quenched by adding saturated NaHCO3 solution (30 mL). Then CH2Cl2 
(30 mL * 2) was added for extraction. The organic phase was dried (Na2SO4), 
filtered, and concentrated. The crude was purified by flash chromatography (17% 
EtOAc /Hexane), providing 19 (1.31 g, 85 %) as white solid. 
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Product characterization 19 
 
Formula C25H35N3O5Si 
Molecular Wright 485.65 
TLC conditions Rf: 0.3, EtOAc : Hexane = 1 : 5 
 
1H  NMR (CDCl3 , 400 MHz) δ 7.80–7.45 (m,7 H, HAr); 5.8 (s, 1 H, Hacetalic ), 4.61-
4.59 (d, 1 H, J = 9.6 Hz H-1); 4.34-4.31 (m,1 H, H-6a); 3.83-3.81 (m, 1 H, H-
6b,); 3.58-3.53 (m, 2 H, H-4, H-3); 3.41-3.36 (m, 2 H, H-5, H-2); 1.72 (m ,1 
H,CHthexyl);  0.88 (s, 12 H, 4 CH3thexyl); 0.09, 0.08 (2 s, 6 H, 2 CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 126.2-122.2 (C-Ph); 92.4 (Cacetalic); 89.8 (C-1); 
75.5 (C-3); 65.4 (C-4); 61.2 (C-2);, 60.8 (C-6); 59.8 (C-5);) 20.4 
(2CH3thexyl); 18.7 (2CH3CHthexyl); -3.6, -3.5 (CH3Si) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 508.8, found: 508.2 
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Thexyldimethylsilyl 2-azido-3-O-naphthylmethyl-4,6-Naptylmethylene-β-D-
glucopyranoside, 20 
 
 
O
O
HO
N3
O
OTDS
NAPBr, NaH
TBAI, THF
19 20
O
O
NAPO
N3
O
OTDS
 
 
 
Synthetic Procedure: 
 
19 (2.3 g, 4.74 mmol) was dissolved in THF (150 mL). At 0℃, NAPBr (1570 mg , 
7.1 mmol) was added to the mixture, followed by Sodium hydride (200 mg, 5 mmol) 
and TBAI (190 mg,  0.5 mmol). The reaction mixture was allowed to stir at room 
temperature for 2 hours. After TLC analysis showing the consumption of 19, the 
reaction was quenched by adding MeOH (20 mL) and saturated NH4Cl sooltion (100 
mL). CH2Cl2 (2 * 100 mL) was adding for extraction, and then the organic phase 
was dried (Na2SO4), filtered, and concentrated. The crude was purified by flash 
chromatography (5% EtOAc/Hexane), providing 20 (2.72 g, 92 %) as colorless oil. 
 
 
Product characterization 20 
Formula C36H43N3O5Si 
Molecular Wright 625.83 
TLC conditions Rf: 0.4, EtOAc : Hexane = 1 : 9 
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1H  NMR (CDCl3 , 400 MHz) δ 7.99–7.35 (m,14 H, HAr); 5.82 (s, 1 H, Hacetalic); 5.08 
(m, 2 H, CH2Ph); 4.60-4.57 (d, 1 H, J = 10 Hz , H-1); 4.33-4.31 (m,1 H, H-6a); 
3.79-3.77 (m, 2 H, H-6b, H-3); 3.72 (m, 1 H, H-4); 3.43 (m, 2 H, H-5, H-2); 
1.74 (m ,1 H,CHthexyl); 0.91 (s, 12 H, 4 CH3thexyl); 0.09, 0.08 (2 s, 6 H, 2 
CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 132.4-121.8 (C-Ph); 99.8 (Cacetalic); 95.8 (C-1); 
85.3 (C-3); 78.4 (C-4); 71.8 (CH2Ph); 74.2 (C-2); 69.8 (C-6); 67.8 (C-5); 
20.4 (2CH3thexyl); 18.7 (2CH3CHthexyl); -3.6, -3.5 (CH3Si) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 650.8, found: 650.3 
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Thexyldimethylsilyl 2-azido-3,6-O-di-naphthylmethyl-β-D-glucopyranoside, 21 
 
 
 
NAPO
HO
NAPO
N3
O
OTDS
Et3SiH, TfOH
20
21
CH2Cl2
O
O
NAPO
N3
O
OTDS
 
 
 
Synthetic Procedure: 
 
20 (1.2 g 1.92 mmol) was dissolved in CH2Cl2 (20 mL). Then the solution was 
cool down to -70℃, and triethylsilane (0.92 mL, 5.76 mmol) was slowly added to 
the reaction mixture, followed by TfOH (0.51 mL). The reaction mixture was then 
stirred at -40℃ for 30 minutes. The reaction was then cooled down to -70℃, 
and quenched by adding (10 mL), followed by triethylamine. The solvent was 
concentrated, and the resulting crude was purified by flash chromatography (20% 
EtOAc/Hexane), providing 21 (1.03 g, 86 %) as white solid. 
 
 
Product characterization 21 
Formula C36H45N3O5Si 
Molecular Wright 627.85 
TLC conditions Rf: 0.25, EtOAc : Hexane = 1 : 4 
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1H  NMR (CDCl3 , 400 MHz) δ 7.75–7.09 (m,14 H, HAr); 4.90-4.63 (m, 4 H, 2 CH2Ph); 
4.54-4.51 (d, 1 H, J = 12 Hz ); 4.33-4.31 (m,1 H, H-6a); 3.78-3.62 (m, 3 H, H-
6a, H-6b, H-4); 3.42-3.25 (m, 3 H, H-5, H-2, H-3); 2.17 (s, 1 H, C-6-OH); 1.74 
(m ,1 H,CHthexyl); 0.90 (s, 12 H, 4 CH3thexyl); 0.09, 0.08 (2 s, 6 H, 2 CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 131.0-124.8 (C-Ph); 100.3 (C-1); 86.2 (C-3); 
78.4 (C-4); 74.7 (C-5); 73.2, 72.9 (CH2Ph); 72.3 (C-4); 71.6 (C-6); 69.8 
(C-2); 23.2 (2CH3thexyl); 18.4 (2CH3CHthexyl); -3.6, -3.5 (CH3Si) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 650.8, found: 650.3 
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Thexyldimethylsilyl 2-azido-4- O-levulinoyl-3,6-O-di-naphthylmethyl-β-D-
glucopyranoside, 22 
 
 
NAPO
HO
NAPO
N3
O
OTDS
NAPO
LevO
NAPO
N3
O
OTDS
LevOH, DCC
DMAP, DCM
21 22  
 
 
Synthetic Procedure: 
 
21 (1.1 g 1.75 mmol) was dissolved in CH2Cl2 (50 mL), LeVOH (305 mg, 2.66 mmol), 
DCC (630 mg, 3.12 mmol) and DMAP (25 mg, 0.35 mmol) were added. The reaction 
mixture was stirred at room temperature for 2 hours. The solvent was 
concentrated and the resulting crude was purified by flash chromatography (30% 
EtOAc /Hexane), providing 22 (1.15 g, 90 %) as colorless oil. 
  
 
 
Product characterization 22 
Formula C41H51N3O7Si 
Molecular Wright 725.95 
TLC conditions Rf: 0.3, EtOAc: Hexane = 1 : 2 
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1H  NMR (CDCl3 , 400 MHz) δ 7.81–7.29 (m,14 H, HAr); 5.15-4.65 (m, 5 H, 2 CH2Ph, 
H-4); 4.56-4.53 (d, 1 H, J = 12 Hz ); 3.78-3.63 (m,3 H, H-6a, H-6b, H-5); 3.40-
3.22 (m, 2 H, H-3, H-2); 2.42-2.2 (m, 4 H, CH2Lev); 1.98 (s, 2 H, OAc); 1.75 
(m ,1 H,CHthexyl); 0.92 (s, 12 H, 4 CH3thexyl); 0.09, 0.08 (2 s, 6 H, 2 CH3Si); 
 
13C  NMR (CDCl3 , 100.6 MHz) δ 166.7 (CO), 129.3-126.8 (C-Ph); 99.9 (C-1); 
85.8 (C-3); 76.4, 75.8 (CH2Ph); 74.5 (C-5); 73.8 (C-4); 72.1 (C-6); 70.8 
(C-2); 38.8 (CH2LeV); 31.2 (OAclev); 28.7 (CH2Lev); 24.5 (2CH3thexyl); 18.3 
(2CH3CHthexyl); -3.6, -3.5 (CH3Si) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 748.9, found: 748.2
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2-azido-4- O-levulinoyl-3,6-O-di-naphthylmethyl-D-glucopyranoside, 23 
 
 
NAPO
LevO
NAPO
N3
O
OTDS
HF, Pyridine NAPO
LevO
NAPO
N3
O
OH
22 23  
 
 
Synthetic procedure: 
 
A solution of 22 (1.1 g, 1.52 mmol) in pyridine (10 mL) was slowly added in 40% 
HF/pyridine (20 mL) at -20 ℃ , the mixture was allowed to stir at room 
temperature for 2-3 hours. After TLC analysis showing consumption of 22, the 
reaction was quenched by saturated NaHCO3 solution (50 mL). CH2Cl2 (30 mL *3) 
was used for extraction, and then the organic phase was dried (Na2SO4), 
filtered, and concentrated. The crude was purified by flash chromatography (40% 
EtOAc /Hexane), providing 23 (770 mg, 87 %) as white solid. 
 
 
Product characterization 23 
Formula C41H51N3O7Si 
Molecular Wright 725.95 
TLC conditions Rf: 0.4-0.5, EtOAc : Hexane = 1 : 1 
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1H  NMR (CDCl3 , 400 MHz) δ Spectra for βisomer 7.78–7.39 (m,14 H, HAr); 5.21-
4.73 (m, 4 H, 2 CH2Ph,); 4.66 (m, H-4); 4.26-4.23 (m, 1 H, H-1β); 3.82-3.61 
(m,3 H, H-6a, H-6b, H-5); 3.45-3.27 (m, 2 H, H-3, H-2); 2.37 (s, 1 H, C-1-
OH)2.32-2.16 (m, 4 H, CH2Lev); 2.01 (s, 3 H, OAc);  
 
13C  NMR (CDCl3 , 100.6 MHz) δ Spectra for βisomer 170.7 (CO), 131.3-127.8 
(C-Ph); 88.3, (C-1); 84.1 (C-3); 78.4, 77.3 (CH2Ph); 73.5 (C-5); 72.9 (C-4); 
71.7 (C-6); 69.7 (C-2); 33.8 (CH2LeV); 27.2 (OAcLev); 26.6 (CH2Lev); 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 606.6, found: 606.2
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2-azido-4-O-levulinoyl-3,6-O-di-naphthylmethyl-D-glucopyranoside N-
Phenyltrifluoroacetimidate, 7 b 
 
 
NAPO
LevO
NAPO
N3
O
OH
23
NAPO
LevO
NAPO
N3
O
O
NPh
CF3
CS2CO3, CH2Cl2
7b
NPh
CF3Cl
 
 
 
Synthetic procedure: 
 
23 was disslolved in anhydrous CH2Cl2 (5 mL) and treated with F3CC(NPh)Cl (106 
mg, 0.513 mmol) and Cs2CO3 (167 mg, 0.513 mmol). The mixture was vigorously 
stirred for 3 h, diluted with cyclohexane (5 mL), and decanted to afford a 
cloudy solution, which was concentrated under reduced pressure. The resulting 
crude product was purified with flash chromatography (20% EtOAc/Hexane, 1% TEA) 
to yield N-phenyltrifluoroimidate 7b.  
 
 
Product characterization 7b 
Formula C41H37F3N4O7 
Molecular Wright 754.75 
TLC conditions Rf: 0.5, EtOAc : Hexane = 1 : 2 
 
MALDI-MS (negative mode, DHB): [M-H]-: m/z calcd.: 753.4, found: 754.0 
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S-Phenyl 1-thio-α-D-mannopyranoside, 34 
 
 
HO
HO
HO
OH
O
OH
AcO
AcO
AcO
OAc
O
OAc
AcO
AcO
AcO
OAc
O
SPh
HO
HO
HO
OH
O
SPh
Ac2O,Pyridine PhSH, BF3
MeONa.MeOH
3 steps 65%
31 32
33 34
Et2O
 
 
Synthetic procedure: 
For 32: 
D-mannose 31 (3.4 g, 18.3 mmol) was dissolved in pyridine (50 mL), and acetic 
anhydride (30 mL) was added at room temperature. The reaction mixture was 
allowed to stirred at room temperature for 5 hours. After TLC showing 
consumption of 31, CH2Cl2 (150 ml) was added to dilute the mixture, and 
extracted with H2O (200mL), saturated NaHCO3 (200 mL) and brine (100 mL). the 
organic phase was dried (Na2SO4), filtered, and concentrated. The crude was 
purified by flash chromatography (17% EtOAc/Hexane), providing 32 (6.5 g, 91 %) 
as white solid. 
 
For 33: 
 
A solution of pentaacetate 32 (6.50 g, 16.7 mmol) dissolved in CH2Cl2 (100 mL) 
was charged with thiophenol (2.3 mL, 22.4 mmol) under an argon atmosphere. 
Boron trifluoride ether (3.1 mL, 24.2 mmol) was added over a period of 10 
minutes. The reaction mixture was stirred for 14 hours at room temperature and 
then poured into an ice/water mixture, then neutralized with saturated NaHCO3 
solution. The organic phase was dried (Na2SO4), filtered, and concentrated. The 
crude was purified by flash chromatography (20% EtOAc/Hexane), providing 33 
(5.74 g, 78 %) as colorless oil. 
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For 34 
 
33 (5.74 g, 13.02 mmol) was dissolved in 1M MeONa/MeOH solution (50 mL) under 
nitrogen atmosphere, the mixture was stirred at room temperature for 2 h, then 
the reaction mixture was neutralized to PH 7 with IR-120 resin, (H+ form, 
previously washed by MeOH), filtered, and concentrated. The crude product was 
purified with flash chromatography (20% MeOH/ CH2Cl2) to yield 34 (3.36 g, 95%, 
3 steps 65%) as white solid. 
 
Product characterization 32 
Formula C16H22O11 
Molecular Wright 390.34 
TLC conditions Rf: 0.3, EtOAc : Hexane = 1: 5 
 
Product characterization 33 
Formula C20H24O9S 
Molecular Wright 440.46 
TLC conditions Rf: 0.25, EtOAc : Hexane = 1: 4 
 
Product characterization 34 
Formula C12H16O5S 
Molecular Wright 272.32 
TLC conditions Rf: 0.4, MeOH : CH2Cl2 = 1: 4 
 
 
The spectroscopic data were in agreement with the reported data [2]
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S-Phenyl 4,6-Naptylmethylene-1-thio-α-D-mannopyranoside, 35 
 
HO
HO
HO
OH
O
SPh
HO
OH
O
SPh
O
O
34 35
DMF,  PTSA
CH(OMe)2
 
 
 
Synthetic procedure: 
 
34 (1 g, 3.67 mmol) was dissolved in dry DMF (25 mL), then dimethoxymethyl 
naphthalene (917 mg, 4.41 mmol) was added to the solution, followed by PTSA (20 
mg, 0.1 mmol). The reaction mixture was stirred at room temperature for 24 
hours. After TLC analysis showing the consumption of 34, the reaction was 
quenched by adding saturated NaHCO3 solution (50 mL). Then CH2Cl2 (30 mL * 2) 
was added for extraction. The organic phase was dried (Na2SO4), filtered, and 
concentrated. The crude was purified by flash chromatography (5% MeOH/ CH2Cl2), 
providing 35 (1.4 g, 95.3 %) as white solid. 
 
Product characterization 35 
Formula C23H22O5S 
Molecular Wright 410.48 
TLC conditions Rf: 0.5, MeOH : CH2Cl2 = 1: 19 
 
1H  NMR (DMSO 400 MHz) δ 8.10–7.25 (m,12 H, HAr); 5.82 (s, 1 H, Hacetalic ), 5.52 
(d, 1 H, J = 1.2 Hz H-1); 4.25-4.15 (m, 2 H, H-5, H-6a); 4.11-4.02 (m, 2 H, H-2, 
H-4); 3.88-3.63 (m, 2 H, H-6b, H-3);  
13C  NMR (DMSO  100.6 MHz) δ 135.1-122.6 (C-Ph); 102.3 (Cacetalic); 89.9 (C-1); 
81.3 (C-4); 74.5 (C-2); 72.7 (C-3); 71.1 (C-6); 68.7 (C-5);  
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MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 410.2, found: 433.3
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S-Phenyl 3-O-Naptylmethyl-4,6-O-Naptylmethylene-1-thio-α-D-mannopyranoside, 
36 
 
HO
OH
O
SPh
O
O
Bu2SnO,Toluene
NAPBr,  TBAI
35
36
NAPO
OH
O
SPh
O
O
 
 
 
Synthetic procedure: 
 
n-Bu2SnO (486 mg, 1.65 mmol) was added to s solution of 35 (612 mg, 1.5 mmol) 
in Toluene (20 mL), and the resulting mixture was refluxed with removing water 
by using Dean Stark apparatus for 3 hours.  The reaction mixture was then 
cooled down, and NAPBr (400 mg, 1.8 mmol) and TBAI (111 mg, 0.33 mmol) were 
adding. The reaction mixture was allowed to stir overnight at room temperature. 
Saturated NH4Cl solution (40 mL) was used to quench the reaction. After 
extracted by CH2Cl2 (30 mL *2), the organic phase was dried (Na2SO4), filtered, 
and concentrated. The crude was purified by flash chromatography (33% EtOAc 
/Hexane), providing 36 (670 mg, 82.3 %) as white wax. 
  
 
Product characterization 36 
Formula C34H30O5S 
Molecular Wright 550.66 
TLC conditions Rf: 0.5, EtOAc: Hexane = 1: 2 
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1H  NMR (CDCl3 400 MHz) δ 8.10–7.25 (m,19 H, HAr); 5.80 (s, 1 H, Hacetalic ), 5.64 
(d, 1 H, J = 1.2 Hz H-1); 5.10-4.82 (m, 2 H, CH2Ph); 4.45-4.21 (m, 4 H, H-5, H-
4, H-2, H-6a); 4.17-4.04 (m, 2 H, H-3, H-6b); 3.02 (brs, 1 H, C-2-OH)  
 
13C  NMR (CDCl3 100.6 MHz) δ 136.4-126.2 (C-Ph); 104.1 (Cacetalic); 89.8 (C-1); 
80.8 (C-4); 76.3 (C-3); 73.8 (CH2Ph); 72.1 (C-2); 72.7 (C-3); 70.5 (C-6); 
66.2 (C-5);  
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 560.6, found: 583.9
GPI – Experimental Part -  
200 
 
 
S-Phenyl 2-O-(9-fluorenylmethoxycarbonyl)-3-O-Naptylmethyl-4,6-O-
Naptylmethylene-1-thio-α-D-mannopyranoside, 37 
 
 
Pyridine
FmocCl
36
NAPO
OH
O
SPh
O
O
NAPO
OFmoc
O
SPh
O
O
37
 
 
Synthetic Procedure: 
 
36 (120 mg, 0.22 mmol) was dissolved in 5 mL pyridine, and 170 mg FomocCl (170 
mg, 0.657 mmol) was added. The reaction mixture was allowed to stir at room 
temperature for 6 hours. After TLC analysis showing consumption of 36, CH2Cl2 
(10 mL) was added to dilute, and the solution was washed by saturated NaHCO3 
solution (10 mL) and brine (10 mL). The organic phase was dried (Na2SO4), 
filtered, and concentrated. The crude was purified by flash chromatography (17% 
Ether/Hexane), providing 37 (147 mg, 87 %) as colorless oil. 
 
 
Product characterization 37 
Formula C49H40O7S 
Molecular Wright 772.9 
TLC conditions Rf: 0.25, Ether: Hexane = 1: 5 
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1H  NMR (CDCl3 400 MHz) δ 8.10–7.25 (m,27 H, HAr); 5.91 (s, 1 H, Hacetalic ), 5.62 
(d, 1 H, J = 1.2 Hz H-1); 5.53-5.51 (m, 1 H, H-2); 5.05-4.93 (m, 2 H, CH2Ph); 
4.54-4.27 (6, 5 H, H-3, H-4, CH2Fomc, H-5, H-6a); 4.22-4.09 (m, 2 H, CH-fmoc, 
H-6b) 
 
13C  NMR (CDCl3 100.6 MHz) δ 135.4-120.2 (C-Ph); 104.2 (Cacetalic); 90.2 (C-1); 
82.2 (C-4); 79.8 (C-2); 76.7 (C-3); 74.1 (CH2Ph); 73.2 (CH2-Fmoc); 71.2 (C-
6); 67.6 (C-5); 50.2 (CH-Fmoc); 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 772.3, found: 795.2
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S-Phenyl 2-O-(9-fluorenylmethoxycarbonyl)-3,4-O-di-Naptylmethyl-1-thio-α-D-
mannopyranoside, 38 
 
 
NAPO
OFmoc
O
SPh
NAPO
HO
BH3/THF
Cu(OTf)2
37 38
NAPO
OFmoc
O
SPh
O
O
 
 
Synthetic procedure: 
 
37 (112 mg, 0.145 mmol) was dissolved in 1M BH3/THF solution (0.73 mL, 0.73 
mmol), the mixture was stirred for 10 minutes. At 0℃, Cu(OTf)2 (2.6 mg, 0.007 
mmol) was added and the suspension was allowed to stir at room temperature for 
3 hours. After TLC analysis showing consumption of 37, the reaction was 
quenched by adding MeOH (1 mL) and pyridine (1 mL) at -30℃. After concentrated 
under reduced pressure, the resulting crude product was purified with flash 
chromatography (25% EtOAc/Hexane) to yield 38 (95 mg, 84%).  
 
Product characterization 38 
Formula C49H42O7S 
Molecular Wright 774.92 
TLC conditions Rf: 0.2, EtOAc: Hexane = 1: 3 
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1H  NMR (CDCl3 400 MHz) δ 8.10–7.25 (m,27 H, HAr); 5.60 (d, 1 H, J = 1.6 Hz H-1); 
5.56-5.53 (m, 1 H, H-2); 5.18-4.78 (m, 4 H, 2 CH2Ph); 4.51-3.91 (m, 8 H CH2Fomc, 
H-5, CH-Fmoc, H-4, H-3, H-6a, H-6b); 3.03 (brs, 1 H, C-6-OH) 
 
13C  NMR (CDCl3  100.6 MHz) δ 135.2-120.6 (C-Ph); 88.7 (C-1); 81.8 (C-4); 
77.8 (CH2Ph); 76.9 (C-2); 76.7 (C-3); 75.8 (C-5); 74.5 (CH2Ph); 73.0 (CH2-
Fmoc); 71.0 (C-6); 47.6 (CH-Fmoc); 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 774.3, found: 797.7
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S-Phenyl 2-O-(9-fluorenylmethoxycarbonyl)-6-O-levulinoyl-3,4-O-di-
Naptylmethyl-1-thio-α-D-mannopyranoside, 4 
 
 
NAPO
OFmoc
O
SPh
NAPO
HO
LevOH, DCC
DCM
38 4
NAPO
OFmoc
O
SPh
NAPO
LevO
 
 
 
38 (90 mg 0.116 mmol) was dissolved in CH2Cl2 (50 mL), LeVOH (20 mg, 0.20 mmol), 
DCC (42 mg, 0.20 mmol) and DMAP (1 mg, 0.001 mmol) were added. The reaction 
mixture was stirred at room temperature for 2 hours. The solvent was 
concentrated and the resulting crude was purified by flash chromatography (30% 
EtOAc/Hexane), providing 4 (82 mg, 81 %) as colorless oil. 
 
Product characterization 38 
Formula C54H48O9S 
Molecular Wright 873.02 
TLC conditions Rf: 0.3, EtOAc: Hexane = 3: 7 
 
1H  NMR (CDCl3 400 MHz) δ 8.10–7.25 (m,27 H, HAr); 5.60 (d, 1 H, J = 1.6 Hz H-1); 
5.56-5.53 (m, 1 H, H-2); 5.18-4.76 (m, 6 H, 2 CH2Ph, H-6); 4.51-4.03 (m, 6 H 
CH2Fomc, H-5, CH-Fmoc, H-4, H-3); 2.43-2.24 (m, 4 H, CH2Lev); 1.98 (s, 2 H, OAc) 
 
13C  NMR (CDCl3  100.6 MHz) δ 135.3-122.4 (C-Ph); 88.9 (C-1); 85.4 (C-6); 
82.3 (C-4); 77.8 (CH2Ph); 77.2 (C-2); 76.9 (C-3); 74.9 (C-5); 74.1 (CH2Ph); 
73.0 (CH2-Fmoc); 47.6 (CH-Fmoc); 33.8 (CH2LeV); 27.2 (OAcLev); 26.6 (CH2Lev); 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 872.3, found: 895.7
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1,2-O-cylcohexylidine-3,4,5-tri-O-naphthylmethyl-6-O-(2-azido-4-O-levulinoyl-
3,6-O-di-naphthylmethyl-α-D-glucopyranosyl)-D-myo-inositol,5 
 
NAPO
LevO
NAPO
N3
O
O
NPh
CF3
7b
O
O
ONAPO
ONAP
ONAP
5
NAPO
LevO
NAPO
N3
O
CH2Cl2
HO
O
ONAPO
ONAP
ONAP
6
TMSOTf
 
 
Synthetic Procedure: 
 
Myo-inositol 6 (96 mg, 0.14 mmol) and glycosyl donor 7b (150 mg, 0.21 mmol) 
were dried together by covapored with anhydrous toluene (5 mL * 3) and left 
under vacuum for 4 h. Then molecular sieves (4 A, 10 mg) and anhydrous CH2Cl2 
(3 mL) were added under Argon atmosphere. The suspension were stirred at room 
temperature for 1 hour, and then cooled down to -10℃, TMSOTf (1.76 uL, 0.01 
mmol, diluted by 176 uL CH2Cl2) was added to the reaction mixture dropwisely, 
the reaction was allowed to stir at -10 ℃  for 1 hour. After TLC analysis 
showing consumption of donor 7b, the reaction was quenched by TEA (1 mL). The 
solvent was concentrated and the resulting crude was purified by flash 
chromatography (7% EtOAc/toluene), providing 5 (119 mg, 81 %) as colorless oil. 
 
Product characterization 5 
Formula C78H75N3O12 
Molecular Wright 1246.44 
TLC conditions Rf: 0.3, EtOAc: toluene = 1: 9 
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1H  NMR (CDCl3  500 MHz) δ 8.02–7.25 (m,35 H, HAr), 5.21-4.73 (m, 11 H, 5 CH2NAP, 
H-1, α isomer was confirmed by delata value of HSQC, 168.12); 4.65-4.57 (m,1 H, 
H-4); 4.54 (m, 1 H, H-2’), 4.18-3.99 (m, 3 H, H-6’, H-1’, H-4’); 3.87 (m, 1 
H, H-3’); 3.68-3.44 (m, 4 H, H-5’H-2, H-6a,CH H-6b); 3.40-3.21 (m ,2 H, H-5, 
H-3), 2.30-2.14 (m, 4 H, CH2Lev); 1.91 (s, 3 H, OAc) 
 
13C  NMR (CDCl3  100.6 MHz) δ 137.0-117.6 (C-Ph); 102.4 (C-1); 85.6 (C-5’); 
83.8 (C-3); 81.9 (C-4’); 81.5 (C-6’); 80.4 (C-1’); 79.7 (C-3’); 77.5 
(CH2Ph); 77.1 (CH2Ph); 76.8, 76.2, 76.0 (CH2Ph); 74.7 (C-4); 74.1 (C-2’); 
72.5 (C-5); 70.3 (C-6), 69.8 (C-2); 39.8-21.8 (CH2Lev, OAcLev, Carbons of 
cyclohexylidene) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 1246.45, found: 1268.5
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1,2-O-cylcohexylidine-3,4,5-tri-O-naphthylmethyl-6-O-(2-azido-3,6-O-di-
naphthylmethyl-α-D-glucopyranosyl)-D-myo-inositol,40 
 
 
O
O
ONAPO
ONAP
ONAP
5
NAPO
LevO
NAPO
N3
O
O
O
ONAPO
ONAP
ONAP
40
NAPO
HO
NAPO
N3
O
NH2NHOAc
CH2Cl2, MeOH
 
 
 
Synthetic Procedure: 
 
5 (75 mg, 0.06 mmol) was dissolved in a mixture of CH2Cl2 (5 mL) and MeOH (5 
mL), NH2NHOAc (60 mg, 0.65 mmol) was added at room temperature, the mixture was 
stirred at room temperature for 1 hour. After TLC analysis showing consumption 
of 5, the solvent was concentrated and the resulting crude was purified by 
flash chromatography (8% EtOAc/toluene), providing 40 (48 mg, 70 %) as 
colorless oil. 
 
Product characterization 40 
Formula C73H69N3O10 
Molecular Wright 1148.34 
TLC conditions Rf: 0.3, EtOAc: toluene = 1: 12 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 1148.3, found: 1172.0
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1,2-O-cylcohexylidine-3,4,5-tri-O-naphthylmethyl-6-O-(2-azido-3,6-O-di-
naphthylmethyl-4-O—(2-O-(9-fluorenylmethoxycarbonyl)-6-O-levulinoyl-3,4-O-di-
Naptylmethyl-α-D-mannopyranossyl)-α-D-glucopyranosyl)-D-myo-inositol,41 
 
 
O
O
ONAPO
ONAP
ONAP
40
NAPO
HO
NAPO
N3
O
NAPO
OFmoc
O
SPh
NAPO
LevO
4
O
O
ONAPO
ONAP
ONAP
41
ONAP
O
NAPO
N3
O
NAPO
OFmoc
ONAPO
LevO
NIS, Ag(OTf)2
CH2Cl2
 
 
 
Synthetic Procedure: 
 
40 (44 mg, 0.038 mmol) and mannose donor 4 (42 mg, 0.048 mmol) were dried 
together by covapored with anhydrous toluene (2 mL * 3) and left under vacuum 
for 4 h. Then molecular sieves (4 A, 10 mg) and anhydrous CH2Cl2 (3 mL) were 
added under Argon atmosphere. The suspension were stirred at room temperature 
for 1 hour, and then cooled down to -20℃, NIS (17 mg, 0.076 mmol) and Ag(OTf)2 
(19 mg, 0.076 mmol) were added to the reaction mixture, the reaction was 
allowed to stir at -20℃ for 1 hour and another 1 hour at room temperature. 
After TLC analysis showing consumption of donor 4, the reaction was quenched by 
adding pyridine (1 mL). The solvent was concentrated and the resulting crude 
was purified by flash chromatography (5% acetone/toluene), providing 41 (51 mg, 
70 %) as colorless oil. 
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Product characterization 40 
Formula C121H111N3O19 
Molecular Wright 1911.18 
TLC conditions Rf: 0.6, Acetone : toluene = 1: 9 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 1911.2, found: 1933.6
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3,4,5-tri-O-naphthylmethyl-6-O-(2-azido-4-O-levulinoyl-3,6-O-di-naphthylmethyl-
α-D-glucopyranosyl)-D-myo-inositol,44 
 
 
O
O
ONAPO
ONAP
ONAP
5
NAPO
LevO
NAPO
N3
O
O
HO
OHNAPO
ONAP
ONAP
44
NAPO
LevO
NAPO
N3
O
CH2Cl2
MeOH/HCl
 
 
 
Synthetic Procedure: 
 
5 (136 mg, 0.11 mmol) was dissolevd CH2Cl2 5 mL, 0.5 M HCl/MeOH (5 mL) was 
added to the mixture, the reaction mixture was allowed to stir at 40℃ for 2 
hours. After TLC analysis indicating consumption of 5, the reaction was 
quenched by adding TEA (3 mL). The solvent was concentrated and the resulting 
crude was purified by flash chromatography (5% MeOH/CH2Cl2), providing 44 (101 
mg, 80 %) as white wax. 
 
 
Product characterization 44 
Formula C72H67N3O12 
Molecular Wright 1166.32 
TLC conditions Rf: 0.5, MeOH : CH2Cl2 = 1: 19 
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1H  NMR (CDCl3  500 MHz) δ 7.90–7.21 (m,35 H, HAr), 5.25-4.68 (m, 10 H, 5 CH2NAP); 
4.61 (s,1 H, H-1); 4.54 (m, 1 H, H-2’), 4.36 (s, 1 H, H-4); 4.21 (m, 1 H, H-
2’); 4.15 (m, 1 H, H-6’); 3.78-3.57 (m ,7 H, H-1’, H-4’,H-3’, H-6a, H-6b, 
H-5’, H-2); 3.48-3.40 (m, 2 H, H-5, H-3); 3.23 (2 brs, C-1’-OH, C-2’-OH); 
2.44-2.22 (m, 4 H, CH2Lev); 1.95 (s, 3 H, OAc) 
 
13C  NMR (CDCl3  100.6 MHz) δ 130.0-125.1 (C-Ph); 102.3 (C-1); 84.4 (C-6’); 
83.9 (C-5’); 83.6 (C-2’); 81.8 (C-3); 80.9 (C-4’); 79.9-73.6 (CH2Ph);  
75.6 (C-3’); 73.4 (C-1’); 71.5 (C-4); 70.3 (C-6); 67.6 (C-2); 61.2 (C-5); 
38.5-32.3 (CH2Lev, OAcLev) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 1266.3, found: 1299.8
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3,4,5-tri-O-naphthylmethyl-2-O-tetradecanoyl-6-O-(2-azido-4-O-levulinoyl-3,6-O-
di-naphthylmethyl-α-D-glucopyranosyl)-D-myo-inositol,44 
 
 
1) CH3CN, CSA
C13H27C(OMe)3
43
O
HO
OHNAPO
ONAP
ONAP
44
NAPO
LevO
NAPO
N3
O
O
HO
OCOC13H27
NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
45
2) Yb(OTf)3, CH2Cl2
 
 
 
Synthetic procedure: 
 
44 (108 mg, 0.93 mmol) was dissolved in acetonitrile (5 mL), catalytic amount 
of CSA was added, the reaction mixture was stirred at 40℃ for 2 hours. After 
TLC analysis indicating consumption of 44, the reaction was quenched by adding 
TEA (1 mL). The solvent was concentrated and covapored with toluene for three 
times (2 mL * 3) to get a yellow crude. 
 
The crude intermediate was dissolved in anhydous CH2Cl2 (5 mL), and 5 mg of 
Yb(OTf)3 was added to the mixture. The reaction mixture was stirred at room 
temperature for 3 hours. After TLC analysis showing consumption of the starting 
materials, the reaction was quenched by TEA (1 mL). The solvent was 
concentrated and the resulting crude was purified by flash chromatography (17% 
ETOAc/toluene), providing 45 (101 mg, 73 %) as white wax. 
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Product characterization 45 
Formula C86H93N3O13 
Molecular Wright 1375.67 
TLC conditions Rf: 0.3, ETOAc : toluene = 1: 4 
  
1H  NMR (CDCl3  500 MHz) δ 7.77–7.35 (m,35 H, HAr), 5.82 (d, 1 H, J = 1.0 Hz H-
2’ ); 5.49-4.33 (m, 14 H, 5 CH2NAP, H-1, H-4, H-6a, H-6b); 4.24-4.08 (m, 2 H, 
H-4’, H-5’), 3.83-3.70 (m, 4 H, H-3’, H-6’, H-1’); 3.66-3.45 (m, 3 H, H-2, 
H-5, H-3);  2.40-2.16 (m, 4 H, CH2Lev); 2.02 (s, 3 H, OAc), 1.78-0.92(m, H of 
fatty acid)  
 
13C  NMR (CDCl3  100.6 MHz) δ 129.6-125.1 (C-Ph); 104.0 (C-1); 84.7 (C-3’); 
83.5 (C-5’); 83.1 (C-4’); 82.8 (C-3); 81.5-75.0 (CH2Ph); 79.9 (C-6’); 
74.1 (C-6); 73.2 (C-4); 71.5 (C-1’);69.7 (C-2’); 67.2 (C-2); 61.0 (C-5); 
38.2-15.5 (CH2Lev, OAcLev , Carbons of fatty acid) 
 
MALDI-MS (positive mode, DHB): [M + Na]+: m/z calcd.: 1375.3, found: 1398.1
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Triethylammonium (3,4,5-tri-O-naphthylmethyl-2-O-tetradecanoyl-6-O-(2-azido-4-O-
levulinoyl-3,6-O-di-naphthylmethyl-α-D-glucopyranosyl)- 1-O-(1, 2-di-O-
octadecanoyl-sn-glyceryl-phosphonato)-D-myo-inositol, 46 
 
 
O
HO
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
45
IMH, PCl3, Et3N
Py, H2O
46
O
O
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
PH O
OHNEt3
OCOC17H35
OCOC17H35
HO
47
PivCl, Pyridine
I2, Pyridine/H2O
2 steps 64%
OCOC17H35
OCOC17H35
O
O
O
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
48
PO
OHNEt3
46
O
O
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
PH O
OHNEt3
  
 
Synthetic procedure: 
 
For 46 
 
Imidazole (850 mg, 12.5 mmol) was co-evaporated with toluene (3 x 5 mL) and 
dried in vacum for 1 hour, and then dissolved in Toluene (10 mL). The solution 
was cooled to -10℃, followed by addition of PCl3 (235 mL, 2.7 mmol) in Toluene 
(3 mL) and Et3N (0.975 mL, 7 mmol). The reaction mixture was then allowed to 
stir for 30 min at 0℃. Meanwhile, 45 (200 mg, 0.17 mmol) was co-evaporated 
with Toluene (3 x 3 mL) and dried in vacuo and dissolved in a mixture of 
toluene (6 mL) and CH2Cl2 (6 mL). This solution was added dropwise to the 
reaction mixture over a period of 80 minutes. The mixture was then allowed to 
stir for further 40 minutes before being quenched by addition of water/pyridine 
(1:1, 15 mL). The aqueous layer was washed with CHCl3 (2 * 30 mL) and the 
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combined organic layers were further washed with 1M TEAB buffer (10 mL) and 
dried over Na2SO4. Evaporation in vacuo gave the crude residue, which was 
subjected to flash column chromatography with Et3N-deactivated silica gel 
(10% MeOH/ CH2Cl2) to afford H-phosphonate 46 (217 mg ,81%) as a white solid. 
 
For 48 
 
46 (80 mg, 0.052 mmol) and alcohol 47 (132 mg,0.26 mmol) were co-evaporated 
with anhydrous pyridine (3 x 3 mL) and dried under high vacuum overnight. 
The mixture was dissolved in anhydrous pyridine (5 mL) at room temperature, 
and pivaloyl chloride (30.2 uL, 0.24 mmol) was added and the mixture was 
stirred at room temperature for 3 h. Iodine (72 mg, 0.29 mmol) in a mixture 
of pyridine/water (19:1, 1 mL) was added for oxidation. The reaction 
mixture was further stirred 0.5 h at room temperature, and diluted with 
CHCl3 (25 mL), washed with saturated Na2S2O3 solution (10 mL), 1M TEAB 
buffer (10 mL) and dried over Na2SO4. Evaporation under reduced pressure 
gave the crude residue, which was subjected to flash column with Et3N-
deactivated silica gel ((12.5% MeOH/CH2Cl2) to give 48 (88 mg, 79%) as a 
white syrup. 
 
Product characterization 46 
Formula C86H93N3O15P 
Molecular Wright 1438.6 
TLC conditions Rf: 0.5, MeOH: CH2Cl2 = 1: 9 
 
The formation of the H-phosphonate 45 was ascertained by 1H NMR analysis, 
which showed the diagnostic doublet at δ 6.23 (J H,P = 653 Hz), compound 34 
was used directly in the following steps without further characterization.   
31P  NMR (CDCl3 , 162 MHz) δ 4.53  
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Product characterization 46 
Formula C125H167N3O20P 
Molecular Wright 2061.2 
TLC conditions Rf: 0.4, MeOH : CH2Cl2 = 1: 7 
 
1H  NMR (CDCl3  500 MHz) δ 7.80–7.32 (m,35 H, HAr), 5.88 (d, 1 H, J = 1.0 Hz H-
2’ ); 5.49-4.30 (m, 16 H, 5 CH2NAP, CH-glyceryl H-1, H-4, H-6a, H-6b, H-1’,); 
4.24-4.02 (m, 2 H, H-4’, H-5’), 3.91-3.68 (m, 6 H, H-3’, H-6’, 2 CH2-O); 
3.66-3.45 (m, 3 H, H-2, H-5, H-3); 2.98 (q, 6 H, 3 CH2-Et), 2.38-1.98 (m, 13 H, 
CH2Lev,, CH2Lipid, OAc), 1.81-1.10 (m, H of fatty acid, lipid , 3 CH3-Et)  
 
13C  NMR (CDCl3  100.6 MHz) δ 132.0-125.1 (C-Ph); 108.7 (C-2’); 102.3 (C-1); 
85.2 (C-3’); 81.2 (C-1’); 80.3 (C-4’); 79.8 (C-glyceryl); 79.1 (C-4); 
78.2-72.1 (CH2Ph); 75.2 (C-5’); 73.8 (C-3);; 72.4 (C-6); 71.7 (C-6’); 
70.4 (C-2); 68.0 (C-5); 63.0-61.8 (C-O on lipid); 47.1-11.0 (CH2Lev, OAc , 
CH2CH3 NEt3, Carbons of fatty acid, cabobons of lipid) 
 
31P  NMR (CDCl3 , 162 MHz) δ 2.11  
 
MALDI-MS (negative mode, DHB): [M-H]-: m/z calcd.: 2061.3, found: 2061.0 
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Triethylammonium (3,4,5-tri-O-naphthylmethyl-2-O-tetradecanoyl-6-O-(2-azido-4-O-
levulinoyl-3,6-O-di-naphthylmethyl-α-D-glucopyranosyl)- 1-O-(1-O-hexadecyl-sn-
glycerol-phosphonato)-D-myo-inositol, 50 
 
 
PivCl, Pyridine
I2, Pyridine/H2O
2 steps 78%
O
O
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
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PH O
OHNEt3
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OCO(CH2)7CH
OC16H33
CHC8H17
O
O
OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
N3
O
P OO
OHNEt3 OCO(CH2)7CH
OC16H33
CHC8H17
49 50  
 
 
Synthetic procedure: 
 
46 (80 mg, 0.052 mmol) and alcohol 49 (143 mg,0.26 mmol), which was 
prepared from reported method[3], were co-evaporated with anhydrous pyridine 
(3 x 3 mL) and dried under high vacuum overnight. The mixture was dissolved 
in anhydrous pyridine (5 mL) at room temperature, and pivaloyl chloride (45 
uL, 0.36 mmol) was added and the mixture was stirred at room temperature 
for 2 hours. Iodine (72 mg, 0.29 mmol) in a mixture of pyridine/water (19:1, 
1 mL) was added for oxidation. The reaction mixture was further stirred 0.5 
h at room temperature, and diluted with CHCl3 (25 mL), washed with 
saturated Na2S2O3 solution (10 mL), 1M TEAB buffer (10 mL) and dried over 
Na2SO4. Evaporation under reduced pressure gave the crude residue, which was 
subjected to flash column with Et3N-deactivated silica gel ((10% MeOH/ 
CH2Cl2) to give 50 (108 mg, 95%) as a white syrup. 
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Product characterization 50 
Formula C122H163N3O18P 
Molecular Wright 1989.2 
TLC conditions Rf: 0.5, MeOH: CH2Cl2 = 1: 9 
 
 
1H  NMR (CDCl3  500 MHz) δ 7.80–7.32 (m,35 H, HAr), 5.90 (s, H-2’); 5.57-4.11 (m, 
20 H, 5 CH2NAP, CH-glycery,l H-1, H-4, H-6a, H-6b, H-1’CH=CH, H-4’, H-5’), 
3.98-3.31 (m, 9 H, H-3’, H-6’, 2 CH2-O, H-2, H-5, H-3); 3.03(q, 6 H, 3 CH2-
NEt3), 2.31-0.98 (m, H of CH2Lev,, CH2Lipid, OAc, fatty acid, lipid and CH3-NEt3)  
 
13C  NMR (CDCl3  100.6 MHz) δ 131.0-125.7 (C-Ph); 118.7 (CH=CH); 105.2 (C-
2’); 102.2 (C-1); 88.7 (C-3’); 84.2 (C-1’); 83.1 (C-4’); 80.8 (C-4); 
78.2-73.1 (CH2Ph); 77.2 (C-5’); 76.8 (CH-glyceryl); 76.5 (C-3); 74.9 (C-
6’); 73.5 (C-6); 72.1 (C-2); 71.5 (C-O on lipid); 71.0 (C-5); 68.2 (C-O on 
lipid); 49.5-15.0 (Carbons of CH2Lev, OAc , CH2CH3NEt3, fatty acid, 
unsaturated lipid) 
 
31P  NMR (CDCl3 , 162 MHz) δ 2.35  
 
MALDI-MS (negative mode, DHB): [M-H]-: m/z calcd.: 2017.5, found: 2017.6 
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6-O-( 2-amino-2-deoxy-a-D-glucopyranosyl)-2-O-tetradecanoyl-1-O-(1, 2-di-O-
octadecanoyl-sn-glyceryl-phosphonato)-D-myo-inositol, 1 
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O
O
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O
O
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OCOC17H35
O
O
O
OCOC13H27HO
OH
OH
HO
LevO
HO
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O
53
PO
O
Dioxane
1,3-propanedithiol
CHCl3/MeOH
82%
2 steps 65%
 
 
Synthetic procedure: 
 
48 (50 mg, 0.024 moml) was dissolved in a solution of pyridine and water (5 
mL/1 mL). Then a 1,3-propanedithiol(50 uL, 0.5 mmol) and TEA (70 uL, 0.5 mmol) 
was added to the mixture and the reaction mixture was allowed to stir at room 
temperature for 2 hours. After the MALDI-TOF spectrum showed fully conversion 
of the amine, evaporation under reduced pressure gave the crude residue, which 
was subjected to flash column with (12.5 % MeOH/CH2Cl2) to give 52 (41 mg, 82%) 
as a colourless oil. 
 
Intermediate 52 (41 mg, 0.02mmol) was hydrogenolysed over Pd/C in dioxane (5 mL) 
for 24 hours at 40℃. After the MALDI-TOF spectrum showed completely removal of 
NAP ether, the mixture was filtered over a Celite pad and the filtrate was 
concentrated. Then the residue was purified through a C-18 reverse column 
(water, MeOH and dioxane as eluent) to give purified 53 18 mg. 
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53 was then dissolved in a solution of CHCl3 (2 mL) and MeOH (4 mL), and 
treated with hydrazine acetate (5 mg, 0.05 mmol), the reaction mixture was 
stirred at room temperature for 2 hours. After the MALDI-TOF spectrum 
indicated the comsuption of 53, the reaction mixture was evaporated under 
reduced pressure, and the resulting crude was purified through a C-18 
reverse column (water, MeOH and dioxane as eluent), further lyophilization gave 
the lipidated GPI anchor 1a as a white solid (16 mg, 2 steps for 65%). 
 
 
Product characterization 1a 
 
1H  NMR (CDCl3 : CD3OD : D2O = 3 : 3 : 1 500 MHz) δ, 5.63 (m, 1 H, H-2’ ); 5.45-
5.23 (m, 3 H, CH-glyceryl, H-1, H-1’); 4.89-3.45 (m, H of sugar, CH-O on 
lipid ), 2.57-0.81 (m, H of fatty acid, lipid)  
 
MALDI-MS (negative mode, DHB): calcd.for  C65H123NO18P [M-H]- m/z,.: 1236.85, 
found: 1236.75 
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6-O-( 2-amino-2-deoxy-a-D-glucopyranosyl)-2-O-tetradecanoyl-1-O-(1-O-hexadecyl-
sn-glycerol-phosphonato)-D-myo-inositol, 2 
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OCOC13H27NAPO
ONAP
ONAP
NAPO
LevO
NAPO
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O
P OO
OHNEt3 OCO(CH2)7CH
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1) 1,3-propanedithiol
Pyridine, H2O
2) DDQ, Dioxane
3)NH2NH2OAc
3 steps 76%
1-b  
 
Synthetic procedure: 
 
50 (50 mg, 0.025 moml) was dissolved in a solution of pyridine and water (5 
mL/1 mL). Then a 1,3-propanedithiol(50 uL, 0.5 mmol) and TEA (70 uL, 0.5 mmol) 
was added to the mixture and the reaction mixture was allowed to stir at room 
temperature for 2 hours. After the MALDI-TOF spectrum showed fully conversion 
of the amine, evaporation under reduced pressure gave the crude residue, which 
was subjected to flash column with (12.5% MeOH/CH2Cl2) to give amine 
intermediate (47 mg, 95%) as a colourless oil. 
 
Intermediate 52 (47 mg, 0.024 mmol) was dissolved in a mixture of CHCl3 (5 mL) 
and MeOH (5 mL), and DDQ (0.18 mmol) was added, and the reaction mixture was 
stirred at 40℃ for 24 hours. The the solvents system was changed to dioxane 
(10 mL), and another 40 mg DDQ was added and the reaction mixtiure was allowed 
to stir at 40℃ for another 24 hours over. After the MALDI-TOF spectrum showed 
completely removal of NAP ether, the mixture was filtered over a Celite pad and 
the filtrate was concentrated. The residue was first purfied by a prepartive 
TLC to remove most of the DDQ (Eluent: 50% MeOH/CH2Cl2), then was purified 
through a C-18 reverse column (water, MeOH and dioxane as eluent) to give 
purified intermediate. The resulting intermediate was dissolved in Dioxane and 
treated with hydrazine acetate (5 mg), after MALDI-TOF spectrum indicated fully 
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removal of Lev, the residue was purified through a C-18 reverse column (water, 
MeOH and dioxane as eluent), further lyophilization gave the lipidated GPI 
anchor 1b as a white solid (22 mg, 3 steps for 76%). 
 
 
Product characterization 1b 
 
1H  NMR (Dioxane-d6 500 MHz) δ, 5.60 (brs, 1 H, H-2’ ); 5.57-5.11 (m, 5 H, CH-
glyceryl,CH=CH, H-1, H-1’); 4.98-3.08 (m, H of sugar, CH-O on lipid ), 2.32-
0.65 (m, H of fatty acid, lipid)  
 
MALDI-MS (negative mode, DHB): calcd.for  C63H119NO17P [M-H]- m/z,.: 1192.82, 
found: 1192.93 
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